BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the molecular biology and genomics technology. More specifically, the present invention relates to microarrays for the investigation of skin neuro-endocrine-immune functions.
2. Description of the Related Art
As a biological barrier, the skin is continuously subjected to the environmental stresses such as ultraviolet radiation, pathogens and thermal and chemical insults (Slominski and Wortsman, 2000). To provide systemic protection, skin cells have numerous defense mechanisms, presumably evolving from a network of intracellular communications coordinated by messages from the local neuro-endocrine-immune system (Slominski and Wortsman, 2000).
This concept, of skin as a peripheral neuroendocrine organ, would imply that local homeostasis (and by inference systemic homeostasis) is regulated by the expression of hormones, neurotransmitters, neuropeptides, cytokines and their receptors. Accordingly, expression of the respective genes should be hierarchical, coordinated and organized into patterns defining functional pathways after exposure to environmental stressors and/or pathological events. The predominant environmental stressor for the skin is solar radiation, especially its UV wavelengths (200-320 nm) (Slominski and Pawelek, 1998). Primary responses to UV radiation (UVR) involve induction of melanin pigmentation and immunomodulation and endocrine activity represented by production of vitamin D and neuropeptides (Slominski and Pawelek, 1998; Slominski and Wortsman, 2000).
Chronic UVR exposure has potent carcinogenic and aging effects. However, the prior art is deficient in the development of a microarray assay to obtain further insight into the cutaneous stress response under chronic UVR exposure. The present invention fulfills this long-standing need and desire in the art by developing microarrays that could be used for simultaneous testing of transcriptional responses to cutaneous stressors in context of neuroendocrine-immune functions of the skin.
SUMMARY OF THE INVENTION
The present invention is directed to a microarray comprising a human molecular chip composed of approximately 700 genes developed to study peripheral response to stress. The chip was designed to evaluate hierarchical and coordinated gene expression patterns organized into functional pathways in response to environmental stress, dyshomeostatic stimuli or pathology. These human microarrays included oligonucleotides corresponding to genes encoding enzymes involved in hormonal production or degradation or neuropeptide processing, precursors to neuropeptide, cytokines, corresponding receptors, other immune markers. For completeness of such molecular chips, several structural genes governing melanogenesis (specific for melanocytes) or epidermal barrier formation by keratinocytes (different cytokeratins) were also included to allow evaluation of the neuroendocrine and immune pathways in relation to differentiated state of prevalent cells of the epidermal component. The oligonucleotides for genes in the microarray chip not limited to include the ones shown in Table 1.
This technology was then applied to the testing of transcriptional activity in keratinocytes exposed to UVR. Significant expression changes of genes arranged in patterns defining functional pathways were found. Thus, this chip could be used as an efficient molecular technology to study neuroendocrine and immune functions of the skin and other organs on a comprehensive molecular level in relation to external and internal stress or any dyshomeostatic signal. It would further allow shaping the modern concept of skin as a neuroendocrine organ requiring that local homeostasis and by inference systemic homeostasis is dependent on the regulated local expression of hormones, neurotransmitters, neuropeptides, cytokines and their receptors.
In one aspect of the present invention, there is provided a DNA microarray chip for measuring transcriptional responses to stress in a cell. The chip comprises 761 oligonucleotides for genes related to production and metabolism of hormones, neurotransmitters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes.
In another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell that comprises following steps. The cell is challenged with stress and nucleic acid samples are isolated from the cell. This is followed by measuring gene expression levels of a group of genes. Subsequently, the gene expression levels are analyzed statistically and compared to those without stress, where a statistically significant upregulation of the gene expression indicates transcriptional responses to stress.
In yet another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell that comprises the same steps of challenging, isolating nucleic acid and measuring gene expression levels. However, in this case the gene expression levels are analyzed statistically and compared to those without stress, where a statistically significant downregulation of the gene expression indicates transcriptional responses to stress.
Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiment of the invention. This embodiment is given for the purpose of disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features, advantages and objects of the invention as well as others which will become clear are attained and can be understood in detail, more particular descriptions and certain embodiments of the invention briefly summarized above are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
FIG. 1 shows detection of differentially expressed genes. Green dots represent genes with higher level of A546 labeled cDNA. Red dots represent genes with higher level of A647 labeled cDNA. Two green spots on the top are landing marks.
FIGS. 2A and 2B show relative expression of genes in UV-irradiated keratinocytes. FIG. 2A shows real-time RT-PCR results that were calculated by comparing UV-irradiated keratinocytes (incubated 12 hours after irradiation) against controls (no treatment). Data was normalized to GAPDH expression and represented mean ±SD (N=3). Ratios statistically significantly different from 1 (no difference) are denoted by asterisks (p<0.05). FIG. 2B shows RT-PCR of human gastrin. The samples were loaded as follows: immortalized keratinocytes (HaCaT; lane 1); epidermal keratinocytes (HeKa; lane 2); epidermal fibroblasts (lane 3); different melanomas (lanes 4-9); melanocytes (lane 10). M denotes molecular marker.
DETAILED DESCRIPTION OF THE INVENTION
The following abbreviations are used herein: AQP, aquaporin; CYP4F8, cytochrome P450, subfamily IVF, polypeptide 8; COX-2, prostaglandin-endoperoxide synthase 2; IL-6, interleukin 6; IL-1, interleukin 1; IL-2, interleukin 2; IL-8, interleukin 8; TNFSF9, tumor necrosis factor superfamily member 9; BMP3, bone morphogenetic protein 3; IGFBP6, insulin-like growth factor binding protein 6; VGEF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; KGF, keratinocyte growth factor; KGFR, keratinocyte growth factor receptor; TNFSF10 (TRAIL), tumor necrosis factor superfamily member 10; MMPs, metalloproteinases; CRF-R2, corticotropin releasing factor receptor type 2.
The present invention used microarray technology to detect several genes with changed expression levels (up- or down-regulated) in a time-dependent manner afetr exposure to UVR. Although the affected genes were mostly involved in water and salt balance and prostaglandin metabolism, they also included interleukins and growth factors, metalloproteinases, markers of keratinocyte differentiation and genes involved in stress response. Functional assessment revealed that majority of the detected genes represented defense mechanisms against malignant transformation. Thus, activation of interleukins, of keratinocyte differentiation markers and down-regulation of EGFR, KGF and KGFR may all represent anti-cancer defense mechanisms. In contrast, the stimulation of metalloproteinases, the enzymes responsible for the extracellular matrix rearrangement or the down-regulation of TRAIL might promote tumor progression in the human skin. Among all the genes that were analyzed, stimulation of COX-2, TNFSF9 and down-regulation of KGF and KGFR were the most interesting observation. Many of the gene expression changes induced by UVR have been already described. Thus, confirming the results obtained by using the microarray chip of the present invention with that already known made the data more reliable. The data was also verified independently using real-time PCR and sequencing. Thus, the microarray chip can be reliably used for the simultaneous assessment of the effect of different agents on the expression of a large set of endocrine-related genes.
In one aspect of the present invention, there is provided a DNA microarray chip for measuring transcriptional responses to stress in a cell. The chip comprises 761 oligonucleotides for genes related to production and metabolism of hormones, neurotransmitters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes. The oligonucleotides for genes in the DNA microarray chip have SEQ ID Nos. shown in SEQ ID No. 25-785.
In another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell, comprising the steps of: challenging the cell with stress; isolating nucleic acid samples from the cell; measuring gene expression levels of a group of genes; and analyzing the gene expression levels statistically as compared to those without stress, wherein a statistically significant upregulation of the gene expression indicates transcriptional responses to stress. The gene expression is measured by DNA microarray and further verified by RT-PCR. Representative examples of the stress are ultraviolet radiation, thermal stress, chemical stress, or immune stress. The preferred cell is epidermal keratinocyte, melanocyte, fibroblast, or immune cell. Representative examples of the statistical analysis that can be performed are one-way analysis of variance, post-hoc test or student t test. The statistically significant upregulation is atleast a 1.5-fold increase of expression of the genes. The group of genes not limited to include genes involved in water and salt balance, genes involved in prostaglandin metabolism, interleukin genes, growth factor genes, markers of keratinocyte differentiation genes, metalloproteinases genes, and stress response genes. The upregulated genes not limited to include the genes selected from the group of genes encoding for gastrin, vasopressin, aquaporin, prostaglandin-endoperoxide synthase 2, CYP4F8, IL-1, IL-2, IL-6, IL-8, tumor necrosis factor superfamily member 9, bone morphogenetic protein 3, insulin-like growth factor binding protein 6, vascular endothelial growth factor B, stromelysins 1 and 2, corticotropin releasing factor receptor type 1 and 2, and aldo-keto reductase.
In yet another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell that comprises the same steps of challenging, isolating nucleic acid samples, measuring gene expression levels and statistical analysis of the gene expression levels as compared to those without stress as described supra. However in this case, a statistically significant downregulation of the gene expression indicates transcriptional responses to stress. All other aspects regarding the assay to measure gene expression and to verify its expression, the types of stress, type of cell and the genes whose expression is measured is the same as described supra. The down-regulated genes not limited to include genes selected from the group of genes encoding for epidermal growth factor receptor, keratinocyte growth factor, keratinocyte growth factor receptor, activin A receptor type I, and tumor necrosis factor superfamily member 10.
The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the cells and methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.
EXAMPLE 1
Cell Lines and Cell Culture
Human adult epidermal keratinocytes and melanocytes were purchased from Cascade Biologics and cultured according to the company's protocol (Cascade Bio, Portland, Oreg.). Melanocytes were grown in Medium 154 and keratinocytes in EpiLife medium supplemented with appropriate growth factors and antibiotics. For co-cultivation experiments, keratinocytes and melanocytes were mixed in the ratio 20:1 and incubated in Medium 154 supplemented with HKGS (Cascade Bio, Portland, Oreg.).
EXAMPLE 2
Ultraviolet Light Treatment
Ultraviolet irradiation of cells was performed as previously described (Pisarchik and Slominski, 2001). Briefly, cells were cultured in 75 cm2 flasks at 85% confluency. The flasks were placed on the UV transilluminator 2000 (BioRad) and irradiated with 50 mJ/cm2 UVB (Pisarchik and Slominski, 2001). Time of exposure, corresponding doses and UV spectrum had been established previously; after UV exposure (50 mJ/cm2) the morphology of the cells did not change significantly (Pisarchik and Slominski, 2001). Irradiated cells were further incubated in culture media for 4, 12 and 24 hours, detached and processed for RNA isolation.
EXAMPLE 3
Microarray Slides
Oligonucleotides for genes related to production and metabolism of hormones, neurotransmiters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes were designed (http://www.utmem.edu/pathology/molecular-endocrinology.htm). The location of the oligos for each gene was chosen according to the structure of the corresponding gene obtained from the GeneBank. Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, Iowa) and printed on superamine slides (TeleChem, Sunnyvale, Calif.) at the University of Tennessee Molecular Resource Center.
EXAMPLE 4
RNA extraction, cDNA Preparation and Fluorescent Labeling
Total RNA was extracted using Trizol isolation kit (Gibco-BRL, Gaithersburg, Md.). The cDNA was synthesized, hybridized and labeled with Genisphere Array 50 kit according to the manufacturer protocol (Genisphere, Hatfield, Pa.).
EXAMPLE 5
Hybridization Protocol
Slides were washed by 0.2% SDS (2 min), water (two times, 2 min), dipped in absolute ethanol (1 min), dried by centrifugation (300×g, 2 min) followed by the injection of 100 μl of the hybridization mixture under the cover slip (LifterSlip cover glass, Erie Scientific Company, Portsmouth, N.H.). Slide hybridization and washing were done according to the protocol of the Genisphere Array 50 kit manufacture (Genisphere, Hatfield, Pa.). Slides were incubated overnight at 53° C. in the dark.
EXAMPLE 6
Data Acquisition and Analysis
At least four arrays were used in every experiment (every time-point). Fluorescence corresponding to A546 and A647 dyes was measured by Axon scanner at The University of Tennessee Molecular Resource Center. Program Fine PixPro 4.0 was used to identify spots and subtract background. Data was normalized by LOWES method (intensity-dependent) using the BRB-Array Tools 2.1 program written by Dr. Richard Simon (Biometrics Research Branch, National Cancer Institute) and Amy Peng (EMMES Corporation). The output Excel spreadsheet contained normalized logarithms (base 2) of ratios for each gene on the slide.
For easy interpretation, logarithms were recalculated into ratios. The factor of 1.5 was chosen as the cut-off for increase/decrease of gene expression, instead of the generally-used factor of 2. This was done because some genes that did show statistically significant stimulation of expression did not attain the 2-fold difference. To avoid false positives, only those genes that were consistently up- or down-regulated on several slides including dye-flip slides as presented on FIG. 1 were selected. Table 2 lists the average ratios for these genes. It is apparent from the table that the majority of selected genes were stimulated or inhibited at least 2 fold.
EXAMPLE 7
RT-PCR and Real-Time RT-PCR
Total RNA (10 μg) was treated with DNAse (Invitrogen), purified by Rneasy MinElute Cleanup kit (Quigen, Valencia, Calif.) and reverse transcribed by Superscript First-Strand Synthesis System (Invitrogen). The resulting cDNA was diluted 100 times in water and aliquots were subjected to quantitative real-time PCR in an iCycler (BioRad). The PCR mixture (25 μl) contained 5 μl of the diluted cDNA, 2.5 μl of each primer (0.04 μM) and 12.5 μl of SYBR Green (Applied Biosystems, Warrington, UK). Each sample was amplified in triplicate. Reactions were performed with initial hot start incubation at 95° C. for 10 min, followed by 40 cycles of denaturation at 95° C. for 10 sec and 60° C. for 1 min. The mixture was then incubated at 60° C. for 10 min, heated gradually in 0.4 increments and the melting curve was then analyzed. Relative gene expression was recalculated by ΔΔCt method. Briefly, the difference (ΔCt) between the Ct values of the target and the house-keeping gene (GAPDH or β-actin) were calculated:
ΔCt=Ct(target)−Ct(GAPDH)
ΔΔCt is the difference between UV-irradiated and control samples:
ΔΔCt=ΔCt(UV)−ΔCt(control)
The fold-time stimulation of gene expression is calculated as =2ΔΔCt
Primers used for the PCR were as follows: prostaglandin-endoperoxide synthase 2 (COX-2) P898 (ATGAGTGTGGGATTTGACCAG, forward, SEQ ID No. 1) and P899 (TTCCGGTGTTGAGCAGTTTTC, reverse, SEQ ID No. 2); TNRSF9 P900 (AGCTACAAAGAGGACACGAAG, forward, SEQ ID No. 3) and P901 (CGCAGCTCTAGTTGAAAGAAG, reverse, SEQ ID No. 4); Keratinocyte growth factor receptor P904 (GATGGTGCGGAAGATTTTGTC, forward, SEQ ID No. 5) and P905 (GCCGCTTTTCCATCTTTTCTG, reverse, SEQ ID No. 6); stromelysin 2 P908 (ATTTTGGCCCTCTCTTCCATC, forward, SEQ ID No. 7) and P909 (TGATGGCCCAGAACTCATTTC, reverse, SEQ ID No. 8); stromelysin 1 P910 (GGAAATCAATTCTGGGCCATC, forward, SEQ ID No. 9) and P911 (CATCGATTTTCCTCACGGTTG, reverse, SEQ ID No. 10); aquaporin 3 P912 (TTTGGCTTTGCTGTCACTCTG, forward, SEQ ID No. 11) and P913 (AAGCACATGGCAAAGGTCAC, reverse, SEQ ID No. 12); aquaporin 9 P916 (TTTGCTGGTGGAAAACTGCTG, forward, SEQ ID No. 13) and P917 (AAATGCGTTCGCCAGAGATAG, reverse, SEQ ID No. 14); keratin 1 K1-L (TGACCAAGGTGGACCTTCAG, forward, SEQ ID No. 15) and K1-R (ATGATGCTGTCCAGGTCGAG, reverse, SEQ ID No. 16); involucrin IVL-L (TCAGCCTTACTGTGAGTCTGG, forward, SEQ ID No. 17) and IVL-R (AGTCTTGAGGAGCTCCTGAC, reverse, SEQ ID No. 18); GAPDH G-L (TGATGACATCAAGAAGGTGGTGAAG, forward, SEQ ID No. 19) and G-R (TCCTTGGAGGCCATGTAGGCCAT, reverse, SEQ ID No. 20); β-actin BA-L (GCCCTGGCACCCAGCACAAT, forward, SEQ ID No. 21) and BA-R (TCATAGTCCGCCTAGAAGCA, reverse, SEQ ID No. 22).
The 283 bp long band corresponding to human Gastrin was amplified by primers P432 (TGCAGACGAGATGCAGCGAC, SEQ ID No. 23) and P433 (GTCCATCCATCCATAGGCTTC, SEQ ID No. 24). The reaction mixture (25 μl) contained 2.0 mM MgCl2, 0.25 of each dNTP, 0.4 μM of each primer, 75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween 20 and 1.25 u of Taq polymerase (Promega). The mixture was heated to 94° C. for 2.5 minutes and then amplified for 25 cycles: 94° C. for 10 seconds (denaturation), 55° C. for 10 seconds (annealing) and 72° C. for 30 seconds (extension). Amplification products were separated by agarose electrophoresis and visualized by ethidium bromide staining. The identified PCR products were excised from the agarose gel and purified using a GFX PCR DNA and gel band purification kit (Amersham-Pharmacia-Biotech). Sequencing was performed at the Molecular Resource Center at the University of Tennessee HSC (Memphis) using Applied Biosystems 3100 Genetic Analyzer and BigDye™ Terminator Kit.
EXAMPLE 8
Statistical Analysis
Data was analyzed using one-way analysis of variance and appropriate post-hoc test or by Student t test using Prism 4.00 software (GraphPad Software, San Diego, Calif.).
EXAMPLE 9
Technological Considerations
Exposure to sunlight is the leading cause of skin cancer due to its UV component (Ichihashi et al., 2003). A number of genes have been reported to be involved in the response to UVR including those coding for the cytokines IL-1β, IL-6, IL-10 (Kimbauer et al., 1991; Grewe et al., 1995). These data, generated by conventional approach were, however, concentrated on a limited number of well-known genes and consequently limited in scope. To overcome such constraints, DNA microarrays searching for a range of genes that might be differentially expressed in human keratinocytes in response to UV irradiation were developed. The known limitation of this technology was the small number of experimental samples that could be tested simultaneously versus the large number of variables (probes); thus statistically significant effects could reflect experimental biasing while lack thereof might reflect low sensitivity, rather than absence of biological effect. To minimize possible bias, detected effects were verified by RT-PCR.
Another important aspect of microarray technology is data normalization; for which there are several approaches (Bilban et al., 2002). The most widely accepted method was used herein: LOWES normalization (intensity dependent). The strongest factors affecting data reliability were the technical quality of the slides and intrinsic precision and consistency of the individual techniques. Sometimes it might be impossible to eliminate false positives due to nonspecific dye binding, but this could be solved by dye-flip experiments, as presented in FIG. 1. Briefly, if the dot is green on the first slide it should be red on the second with the opposite dye combination. This was exemplified in FIG. 1 where both dye combinations showed identical changes of gene expression (up- or down-regulation).
DNA microarray with 761 probes was specifically designed herein to investigate neuroendocrine functions in the skin, including probes for the barrier function (Slominski and Wortsman, 2000). Genes were chosen to reflect functional pathways activated in response to environmental stressors or pathological events; e.g. carbohydrate metabolism-related hormones; pituitary and thyroid hormones; steroidogenic enzyme receptors. Genes coding for neurotransmitters, catecholamines, growth factors, cytokines, housekeeping genes and others involved in the protective function of the skin were also added. The full list of the genes as well as oligonucleotide sequences are listed on Table 1.
The oligonucleotide design approach used herein was a modification of the commonly used technique of searching for oligos with desired melting temperature, preferably at the 3′ end of the gene. Instead the oligos were placed on the borders between different exons to avoid unspecific labeling of DNA impurities. It is well known that human introns contain a wide range of simple repetitive sequences of which polyA sequences are most common. Hence, the use of total RNA and poly(dT) sequence to synthesize cDNA for microarray experiments may result in some unspecific labeling since poly(dT) sequence may hybridize to introns. This concept was tested by hybridizing cDNA synthesized from total and polyA RNA of HaCaT cell line (data not shown). The polyA RNA sample showed lower signal but, when normalized the conditions showed identical results.
TABLE 1
|
|
DNA Microarray Chips for Neuroendocrine Functions in the Skin
ShortFull
PrimergenegeneAccession
namenamenamenumberPrimer sequenceComments
|
M001GCGGlucagonNM_002054TTCAAGACACAGAGGAGAAATC
50 bp; e2-3
AGATCATTCTCAGCTTCCCAGG![text missing or illegible when filed]()
GAC
(SEQ ID NO: 25)
|
M002GCGRglucagonNM_000160TGGTACCTGCCTTGGCACCACAA
50 bp; e4-5
receptorGTGCAACACCGCTTCGTGTTCAA![text missing or illegible when filed]()
AG
(SEQ ID NO: 26)
|
M003CRH-R1GTGCCAGGAGATCCTCAATGAG
50 bp; e4-5
AGAAAAAAAGCAAGGTGCACTA![text missing or illegible when filed]()
CATG
(SEQ ID NO: 27)
|
M004AGGAGATCCTCAATGAGGAGAA
40 bp; e4-5
AAAAGCAAGGTGCACTA
(SEQ ID NO: 28)
|
M005ATCCTCAATGAGGAGAAAAAAA
30 bp; e4-5
CAAGGTG
(SEQ ID NO: 29)
|
M006GTGCCAGGAGATCCTCAATGAG
50 bp, 62% GC,
AGGAGCCTGGGACTCAGGCACA
e4-cryptic;
CCTGdetects CRF-R1h
(SEQ ID NO: 30)
|
M007AGGAGATCCTCAATGAGGAGGA
40 bp, 62% GC
CCTGGGACTCAGGCACAe4-cryptic;
(SEQ ID NO: 31)detects CRF-R1h
|
M008ATCCTCAATGAGGAGGAGCCTG
30 bp, 62% GC
GACTCAGe4-cryptic;
(SEQ ID NO: 32)detects CRF-R1h
|
M009GTTCTACTGTTTCCTCAATAGTG
50 bp; e13-14;
GGTCCGTTCTGCCATCCGGAAGA![text missing or illegible when filed]()
GT
(SEQ ID NO: 33)
|
M010ACTGTTTCCTCAATAGTGAGGT
40 bp; e13-14;
GTTCTGCCATCCGGAA
(SEQ ID NO: 34)
|
M011CAACTCCTTCCTGGAATCCTTCC
50 bp; e13-15;
GGTCCGTTCTGCCATCCGGAAGA
detects deletion
GTof exon 13
(SEQ ID NO: 35)
|
M012CCTTCCTGGAATCCTTCCAGGT
40 bp; e13-15;
GTTCTGCCATCCGGAAdetects deletion
(SEQ ID NO: 36)of exon 13
|
M0135HTR2BSerotoninXM002541ATTGCCCTCTTGACAATAATGTT
50 bp, e1-2;
receptor 2BGAGGCTATGTGGCCCCTCCCACT
full-length
GT
(SEQ ID NO: 37)
|
M014CCTCTTGACAATAATGTTTGAG
40 bp, e1-2;
TATGTGGCCCCTCCCAfull-length
(SEQ ID NO: 38)
|
M015TGACAATAATGTTTGAGGCTAT
30 bp, e1-2;
GGCCCCfull-length
(SEQ ID NO: 39)
|
M016ATTGCCCTCTTGACAATAATGTT
50 bp, e1-3;
GGCATTGCCATTCCAGTCCCTAT
5HTR2
detects
AAdeletion of exon 2
(SEQ ID NO: 40)
|
M017CCTCTTGACAATAATGTTTGGCA
40 bp, e1-3; 5HTR2![text missing or illegible when filed]()
TGCCATTCCAGTCCCTdetects deletion of
(SEQ ID NO: 41)exon 2
|
M018TGACAATAATGTTTGGCATTGC
30 bp, e1-3; 5HTR2![text missing or illegible when filed]()
TTCCAGdetects deletion of
(SEQ ID NO: 42)exon 2
|
M0195HTR7SerotoninXM015676CCCTGTGCGTGATCAGCATTGA
50 bp, e1-2; 58% GC
receptor 7GGTACCTTGGGATCACAAGGCC![text missing or illegible when filed]()
TC
(SEQ ID NO: 43)
|
M020TGCGTGATCAGCATTGACAGGTA
40 bp, e1-2; 58% GC
CTTGGGATCACAAGGC
(SEQ ID NO: 44)
|
M021GATCAGCATTGACAGGTACCTT
30 bp, e1-2; 58% GC
GATCAC
(SEQ ID NO: 45)
|
M022CRF-R2CACCCCTGGACCCCGAGGGTCC
40 bp; e4-5; 65% GC;
alphaACTCCTACTGCAACACdetects alpha isoform
(SEQ ID NO: 46)
|
M023CRF-R2CATGACCCTCACCAACCTCTCA
50 bp; e2-5; 65% GC;
betaTCCCTACTCCTACTGCAACACGA
detects beta isoform
CT
(SEQ ID NO: 47)
|
M024CRF-R2CCCTCACCAACCTCTCAGGTCC
40 bp; e2-5; 65% GC;
betaACTCCTACTGCAACACdetects beta isoform
(SEQ ID NO: 48)
|
M025CRF-R2CTTTCCTCAGCTCTTCTGCCAAG
50 bp; e3-5; 54% GC;
gammaTCCCTACTCCTACTGCAACACGA
detects gamma isoform
CT
(SEQ ID NO: 49)
|
M026CRFCorticotropinCGAGCAGTTAGCACAGCAAGCT
50 bp
releasingACAGCAACAGGAAACTCATGGA![text missing or illegible when filed]()
factorATTA
(SEQ ID NO: 50)
|
M027UroUrocortinCTTCTCTGTCCATTGACCTCACC
50 bp
TCACCTGCTGCGGACCCTGCTG![text missing or illegible when filed]()
G
(SEQ ID NO: 51)
|
M028CRFBPCorticotropinATAAAGACAGACCCCAACCTCT
50 bp; est E1-2
releasingCCTTGCAATGTCATTTCTCAGA![text missing or illegible when filed]()
factorCC
binding(SEQ ID NO: 52)
protein
|
M029FSHFollicleNM_000510TGTGCTGGCTACTGCTACACCA
49 bp, e2-3, 55% GC
betastimulatingGATCTGGTGTATAAGGACCCAG![text missing or illegible when filed]()
hormone,A
p-p b
(SEQ ID NO: 53)
|
M030FSHRFollicleNM_000145GAACCTTCCCAACCTTCAATAT
50 bp, e3-4, 38% GC
stimulatingGTTAATATCCAACACAGGTATTA![text missing or illegible when filed]()
hormoneGC
receptor(SEQ ID NO: 54)
|
M031CGBchorionicNM_000737CACCAAGGATGGAGATGTTCCA
48 bp, e1-2, 58% GC;
gona
GGGCTGCTGCTGTTGCTGCTGCT
It should also detect
tropin, betaACGB7, CGB8, proba![text missing or illegible when filed]()
polypeptide(SEQ ID NO: 55)also CGB1, CGB5,
CGB6
|
M032GLYCAglycoproteinAH007338CTCCATTCCGCTCCTGATGTGCA
50 bp, e2-3, 56% GC;
alpha subunitGATTGCCCAGAATGCACGCTAC![text missing or illegible when filed]()
GGA
(SEQ ID NO: 56)
|
M033CTGTGTAGCTAAATCATATAACA
50 bp, e3-4, 42% GC;
GGTCACAGTAATGGGGGGTTTC![text missing or illegible when filed]()
AAG
(SEQ ID NO: 57)
|
M034LHBLuteinizingNM_000894TGTGCCGGCTACTGCCCCACCAT
47 bp, e1-2, 67% GC;
hormone betaATGCGCGTGCTGCAGGCGGTCC
high homology to C![text missing or illegible when filed]()
p-p(SEQ ID NO: 58)
|
M035LHCGRLuteinizingNM_000233TCAATGGGACGACACTGACTTCA
50 bp, e6-7, 46% GC;
hormoneTGGAGCTAAAGGAAAACGTACA![text missing or illegible when filed]()
receptorCTG
(SEQ ID NO: 59)
|
M036GNRH1Gonadotropin-NM_000825CCTCCGAGACCTGAAAGGAGCT
50 bp, e2-3, 50% GC;
releasingGGAAAGTCTGATTGAAGAGGAA![text missing or illegible when filed]()
hormoneCTG
(SEQ ID NO: 60)
|
M037GNRH2Gonadotropin-NM_001501CCCAGAATGCCCTTAGGCCCCCA
47 bp, e2-3, 67% GC;
releasingGAAGGGCCCTGGACACTGCAGC![text missing or illegible when filed]()
hormone(SEQ ID NO: 61)
|
M038GNRHRgonadotropin-NM_000406CGGGTCCTTCATCAGGACCCCCA
50 bp, e2-3, 52% GC;
releasingGAACTACAACTGAATCAGTCCA
hormoneGAA
(SEQ ID NO: 62)
|
M039GNRH2gonadotropin-NM_057163TAGTTTCCTGCTTGCCTTCCCCC
50 bp, e2-3, 56% GC;
releasingGCTGTTCCTGTTCCACACGGTCC![text missing or illegible when filed]()
horomoneCT
type 2(SEQ ID NO: 63)
|
M040GH2growthTTCCAACAGGGTGAAAACGCAG
50 bp, e3-43, 50% GC![text missing or illegible when filed]()
horomoneAGAAATCTAACCTAGAGCTGCT
more specific for GH![text missing or illegible when filed]()
GCAthan GH1, but can
(SEQ ID NO: 64)detect all GH, CSH
|
M041GH1growthNM_000515CAGGGAGGAAACACAACAGAAA
50 bp, e3-4, 54% GC,
horomoneCCAACCTAGAGCTGCTCCGCAT
will also detect CSH![text missing or illegible when filed]()
CCCCSH2, GH2
(SEQ ID NO: 65)
|
M042AGCCTGGTGTACGGCGCCTCTGA
47 bp, e4, more speci![text missing or illegible when filed]()
AGCAACGTCTATGACCTCCTAAA
for GH1 than to CSH
(SEQ ID NO: 66)
|
M043GHRgrowthNM_000163AAGTGTTTCTCTGTTGATGAAAT
50 bp, e4-5, 44% GC;
horomoneGTGCAACCAGATCCACCCATTG![text missing or illegible when filed]()
receptorCT
(SEQ ID NO: 67)
|
M044GHRHgrowthNM_021081CCACCTCCCCCTTTGACCCTCAG
47 bp, e1-2, 62% GC;
horomoneATGCGGCGGTATGCAGATGCCA![text missing or illegible when filed]()
releasing(SEQ ID NO: 68)
horomone
|
M045GHRHRgrowthNM_000823TTCTCTCACTTCAGCTCAGAGTC
50 bp, e3-4, 48% GC;
horomoneGGGGCTGTGAAACGGGATTGTA![text missing or illegible when filed]()
releasingTAT
horomone(SEQ ID NO: 69)
receptor
|
M046ghrelinghrelinAB029434GAGCCCTGAACACCAGAGAGTC
50 bp, e1-2, 56% GC;
AGCAGAGAAAGGAGTCGAAGAA
homol to motilin
CCAC(the same?)
(SEQ ID NO: 70)
|
M047MC1RmelanocortinXM_047456AACCTCTTTCTCGCCCTCATCAT
50 bp, only 1 exon,
1 receptorGCAATGCCATCATCGACCCCCT
52% GC; specific for
TMC1R
(SEQ ID NO: 71)
|
M048MC2RmelanocortinNM_000529GATCGTCCTGCTGGCTGTGTTCA
50 bp, only 1 exon,
2 receptorGAATAAGAATCTCCAGGCACCC
50% GC; specific for
TGTMC2R
(SEQ ID NO: 72)
|
M049POMCproopiomelano
NM_000939CTCACCACGGAAAGCAACCTGC
46 bp, e2-3, 63% GC;
tinGGAGTGCATCCGGGCCTGCAAG![text missing or illegible when filed]()
(SEQ ID NO: 73)
|
M050TCAGAGAGCAGCCTCCCGAGAC
46 bp, e1-2, 60% GC;
GAGCCTCAGCCTGCCTGGAAGA![text missing or illegible when filed]()
(SEQ ID NO: 74)
|
M051LOC5105preproprolactinNM_015893ACTCCATGGAGATCCGCACCCCT
48 bp, e1-2, 58% GC;
releasingACATCAATCCTGCCTGGTACGC
palindrom at 5′ end
peptide(SEQ ID NO: 75)
|
M052PrRPRprolactinAB048946TGCTGCTGGTCACCTACCTGCTC
49 bp, only 1 exon,
releasingCTCTGCTGGTCATCCTCCTGTCT
57% GC;
peptide(SEQ ID NO: 76)
receptor
|
M053PRLprolactinXM_033558GGGCATGGAGCTGATAGTCAGC
50 bp, e4-5, 48% GC;
AGGTTCATCCTGAAACCAAAGA
may detect peptides
AATGsimilar to prolactin
(SEQ ID NO: 77)
|
M054PRLRprolactinNM_000949GGATTTGATGCTCATCTGTTGGA
50 bp, e9-10, 46% GC![text missing or illegible when filed]()
receptorAAGGGCAAGTCTGAAGAACTA
should be absent whe![text missing or illegible when filed]()
GAGis alternatively
(SEQ ID NO: 78)spliced in cancer
(PRLR1b)
|
M055SSTsomatostatinNM_001048TGGCTGCTGCCGCGGGGAAGCA
47 bp, e1-2, 62% GC;
GAACTGGCCAAGTACTTCTTGG
have a palindron
(SEQ ID NO: 79)
|
M056SSTR1somatostatinNM_001049CCTCTATGGCTTTCTCTCAGACA
50 bp, only 1 exon,
receptor 1CTTCAAGCGCTCTTTCCAACGCA
50% GC; specific for
CCSSTR1
(SEQ ID NO: 80)
|
M057SSTR2somatostatinXM_085745GGCTATCCATTCCATTTGACCTC
50 bp, only 1 exon,
receptor 2ATGGCTCTGTGGTGTCAACCAA
50% GC; specific for
CCSSTR2
(SEQ ID NO: 81)
|
M058TCAATCAGTTCACCAGCATCTT
50 bp, only 1 exon,
GCCTGACAGTCATGAGCATCGA
50% GC; less specific
GAmay also detect SST![text missing or illegible when filed]()
(SEQ ID NO: 82)3, 5 genes
|
M059SSTR3somatostatinNM_001051CGCTCTTCGTGCTCTGCTGGATG
50 bp, only 1 exon,
receptor 3CCTTCTACGTGCTCAACATCGTC
56% GC; specific for
ACSSTR3
(SEQ ID NO: 83)
|
M060SSTR4somatostatinXM_009594GTCTTCGTGGTCTACACTTTCCT
47 bp, only 1 exon,
receptor 4CTGGGCTTCCTGCTGCCCGTGCT
59% GC; may also
(SEQ ID NO: 84)detect SSTR1
|
M061SSTR5somatostatinNM_001053TCACCAACATCTACATTCTCAA
50 bp, only 1 exon,
receptor 5TGGCAGTGGCCGACGTCCTGTA
59% GC; may also
TGdetect SSTR2, 3, 4
(SEQ ID NO: 85)
|
M062TRHthyrotropin-XM_002795AAGGGGACCAGGGTGAGCACT
48 bp, e2-3, 56% GC;
releasingGCGTCCCAGATCTITTCAATCTGA![text missing or illegible when filed]()
horomoneT
(SEQ ID NO: 86)
|
M063TRHRthyrotropin-XM_017795CAGCACAGTATCTTCAAGGAAG
50 bp, e1-2, 52% GC;
releasingAGGTCACCAAGATGCTGGCAGT![text missing or illegible when filed]()
horomoneGTTG
receptor(SEQ ID NO: 87)
|
M064TSHbThyroid stimu-NM_000549CTGTGCTGGATATTGTATGACA
50 bp, e1-2, 42% GC;
lating hormon,GGATATCAATGGCAAACTGTTT![text missing or illegible when filed]()
beta subunitTC
(SEQ ID NO: 88)
|
M065TSHRThyroid stimu-NM_000369GCTTACCGCCCAGTACGCAGACT
50 bp, e1-2, 52% GC;
lating hormonTGAAGCTTATTGAGACTCACCT![text missing or illegible when filed]()
receptorGA
(SEQ ID NO: 89)
|
M066DIO1type I 5′S48220TGCAACATTTGGGAGTTTATGCA
50 bp, e1-2, 42% GC;
iodothyronineGGTAATAGGCCACTGGTGCTGA![text missing or illegible when filed]()
deiodinaseTT
(SEQ ID NO: 90)
|
M067DIO2type 2 5′NM_000793CTGGAAGAGCTTCCTCCTCGAT
50 bp, e2-3, 52% GC;
iodothyronineCTACAAACAGGTGAAATTGGGT![text missing or illegible when filed]()
deiodinase v2AGG
(SEQ ID NO: 91)
|
M068DIO3type 3 5′NM_001362GCTACCAGGTCTCTGAGCTGCG
50 bp, only 1 exon
iodothyronineCTTGGTTGGAACGCTATGATGA
54% GC;
deiodinaseAA
(SEQ ID NO: 92)
|
M069SLC26A4IodineNM_000441AGAGCACTGGAGGAAAGACACA
50 bp, e9-10, 52% GC![text missing or illegible when filed]()
transportGTTGCTGGCATCATCTCTGCTG![text missing or illegible when filed]()
ATT
(SEQ ID NO: 93)
|
M070THRAthyroidXM_008585ACTTGTGAGGGCTGCAAGGGCT
50 bp, e4-5, 54% GC;
horomoneTTTCGCCGCACAATCCAGAAGAA![text missing or illegible when filed]()
receptor,CT
alpha(SEQ ID NO: 94)
|
M071THRBthyroidNM_000461ATCTATGTTGGCATGGCAACAGA
50 bp, e6-7, 48% GC;
hormoneTTGGTGCTGGATGACAGCAAGA![text missing or illegible when filed]()
receptor, betGCT
(SEQ ID NO: 95)
|
M072TGthyroglobulinNM_003235TAGGGAAGCCCAAGAAATGCCC
50 bp, e9-10 (the
ACGCCCTGTCAAUACAGGCTGA
biggest), 54% GC;
CAA
(SEQ ID NO: 96)
|
M073CAAGGGCGGGAACTGGCTGAGA
50 bp, e7-8 (Assuming
AGGTTTGGAGTTGTTACTGGAT
that it can also be
AATshorter protein),
(SEQ ID NO: 97)50% GC
|
M074AGAndrogenL29496TATGAAGCAGGGATGACTCTGG
50 bp, e3-4, 50% GC;
receptorAGCCCGGAAGCTGAAGAAACTT![text missing or illegible when filed]()
GTAA
(SEQ ID NO: 98)
|
M075SBPplasma sexX05792AGGGACTCAGGCAGAATTCAAT
50 bp, 50% GC; will
steroid-TCCGAGACATTCCCCAGCCTCAT
also detect SHGB,
bindingCAGSHGB-2
protein(SEQ ID NO: 99)
|
M076ESR1estrogenXM_045967TGCTACGAAGTGGGAATGATGA
50 bp, e3-4, 48% GC;
receptor 1AGGTGGGATACGAAAAGACCGA![text missing or illegible when filed]()
GAGG
(SEQ ID NO: 100)
|
M077ESRRB o
estrogenAB006590TTACGAAGTGGGAATGGTGAAG
50 bp, e3-4, 53% GC;
ESR2receptorGTGGCTCCCGGAGAGAGAGATG![text missing or illegible when filed]()
betaGGGT
(SEQ ID NO: 101)
|
M078ESRRAestrogen-NM_004451ATCAGCTGGGCCAAGAGCATCC
50 bp, e3-4, 58% GC;
relatedAGGCTTCTCATCGCTGTCGCTGT![text missing or illegible when filed]()
receptorTGA
alpha(SEQ ID NO: 102)
|
M079estrogenL25275GACTCTGTTGGATCAGAAGGTCA
50 bp, e4-5, 50% GC;
sulfotrans-GGTGGTCTATGTTGCCCGAAAC
may also detect phen![text missing or illegible when filed]()
feraseAAand aryl
(SEQ ID NO: 103)sulphotransferase
|
M080REArepressor ofNM_007273GAGCAGCCCAGAATATCTCCAA
50 bp, e6-7, 50% GC
estrogenACGATCGCCACATCACAGAATC![text missing or illegible when filed]()
receptorATC
activity(SEQ ID NO: 104)
|
M081glucocorticoidX03225TGAAATGGGCAAAGGCAATAC
50 bp, e5-6, 46% GC;
receptorM10901GGTTTCAGGAACTTACACCTGGA
detects both alpha and
X03348 M11GAGbeta receptors
(SEQ ID NO: 105)
|
M082alpha-X03225GACGATGAGTATTGAATTCCCC
50 bp, e10, 42% GC;
glucocorticoidM10901GATGTTAGCTGAAATCATCACCA
detects only alpha
receptorTCreceptor = NR3C1
(SEQ ID NO: 106)
|
M083LOC1432similar toXM_089709ACAAAGCAGGGAAGAGAAACTT
50 bp, e2-3, 42% GC
glucocorticoidAGGTGGGAGCATGTGTCAGTCTT![text missing or illegible when filed]()
receptorCCC
(SEQ ID NO: 107)
|
M084MRmineralocorticoidM16801CTTCAAGCTGGAATGAATTTAG
50 bp, e4-5, 40% GC;
receptorGCACGAAAGTCAAAGAAGTTG
detects full-length =
AAANR3C2
(SEQ ID NO: 108)
|
M085mineralocorticoidAJ315514CTTCAAGCTGGAATGAATTTAG
50 bp, e4-?, 44% GC;
receptor deltaGAGAGAAGATGCATCAGTCTGC
should detect delta
ATGisoform
(SEQ ID NO: 109)
|
M086BZRPbenzodiazapineNM_000714TTCTTTGGTGCCCGACAAATGG
50 bp, e2-3, 58% GC;
receptorTGGGCCTTGGTGGATCTCCTGCT![text missing or illegible when filed]()
GT
(SEQ ID NO: 110)
|
M087NR1H2nuclearNM_007121CCTCCTGAAGGCATCCACTATC
50 bp, e7-8, 56% GC;
receptorGATCATGCTGCTAGAGACAGCC![text missing or illegible when filed]()
subfamily 1,GGC
group H(SEQ ID NO: 111)
member 2
|
M088NR1I3nuclearNM_005122GTGAGGGCTGCAAGGGTTTCTT
50 bp, e3-4, 56% GC;
receptorGGAGAACAGTCAGCAAAAGCAT![text missing or illegible when filed]()
subfamily 1,GGT
group I,(SEQ ID NO: 112)
member
|
M089NR2C1nuclearNM_003297TGATCTGTCTGCACAACACCTG
50 bp, e2-3, 48% GC;
receptorGCTCCTAACAGATAATTCTCCA![text missing or illegible when filed]()
subfamily 2,CC
group C(SEQ ID NO: 113)
member 1
|
M090NR2C2nuclearNM_003298TTCAGACACACACGTCACATTTA
50 bp, e10-11 46% G![text missing or illegible when filed]()
receptorGCTAACAATGCCCAGTCCAATG
may detect some
subfamily 2,AGorphan receptors
group C,(SEQ ID NO: 114)
member 2
|
M091NR2F2nuclearNM_021005AAGGCCATAGTCCTGTTCACCT
50 bp, e2-3, 52% GC;
receptorGATGCCTGTGGTCTCTCTGATGT![text missing or illegible when filed]()
subfamily 2,GC
group F,(SEQ ID NO: 115)
member 2
|
M092NR4A1nuclearNM_002135TGGCGGTGGGCATGGTGAAGGA
47 bp, e3-4, 57% GC;
receptorGTTGTCCGAACAGACAGCCTGA![text missing or illegible when filed]()
subfamily 4,G
group A,(SEQ ID NO: 116)
member 1
|
M093NR0B1nuclearNM_000475CGCTTCTGTACCGCTGCTGCTTT
44 bp, e1, 60% GC;
receptorGCGGTGAAGACCACCCGCAGCA![text missing or illegible when filed]()
subfamily 0,(SEQ ID NO: 117)
group B,
member 1
|
M094NR2F1nuclearNM_005654TCAAAGTGGGCATGAGGCGGGA
47 bp, e1-2, 57% GC;
receptorGCGGTTCAGCGAGGAAGAATG
has homology to orphan
subfamily 2,Treceptor (COUP-TFI)
group F,(SEQ ID NO: 118)
member 1
|
M095NR1H4nuclearNM_005123GCACTGACCTGTGAGGGGTGTA
50 bp, e4-5, 48% GC
receptorAGGTTTCTTCAGGAGAAGCATTA
farnesol receptor
subfamily 1,CAA
group H,(SEQ ID NO: 119)
member 4
|
M096NR2E1nuclearAF411525TGAGCAAGCCAGCCGGATCAAC
50 bp, e1-2, 50% GC
receptorAGCCGCATTTTAGATATCCCCTG![text missing or illegible when filed]()
subfamily 2AAA
group E(SEQ ID NO: 120)
member 1
|
M097NR4A2nuclearNM_006186TGTITTGTCCTTCGATTAGCATAC
50 bp, e6-7, 48% GC;
receptorGGTCCAACCCAGTGGAGGGTAA
almost the same as
subfamily 4,CTCNGFI-B/nur77 (acc
group A,(SEQ ID NO: 121)S77154)-has several
member 2exons deleted
|
M098NR4A3nuclearNM_006981CTCAGTGTTGGAATGGTAAAAG
50 bp, e6-7, 42% GC
receptorAGTTGTCCGTACAGATAGTCTGA
neuron derived orphan
subfamily 4,AGGreceptor (NOR-1,
group A,(SEQ ID NO: 122)#D78579)
member 3
|
M099NR5A1nuclearNM_004959TGCTCACGTGTGAGAGCTGCAA
56 bp, e1-2, 58% GC =
receptorGGCTTCTTCAAGCGCACGGTGCA
steroidogenic factor
subfamily 5,(SEQ ID NO: 123)1(#U76388)
group A,
member 1
|
M100AAGTTCATCATCCTCTTCAGCCT
50 bp, e5-6, 40% GC
GATTTGAAGTTCCTGAATAACCA![text missing or illegible when filed]()
AT
(SEQ ID NO: 124)
|
M101NR6A1nuclearNM_033334CGCCCTCCGATGAAGAACTACA
50 bp, e5-6, 50% GC =
receptorAGATTTAGTGATGAAGGGATGG
gem cell nuclear
subfamily 6,GGTGreceptor, GCNF
group A,(SEQ ID NO: 125)(S83309)
member 1
|
M102PGRprogesteroneNM_000926CTTCTTTAAGAGGGCAATGGAA
50 bp, e2-3, 44% GC
receptorGGCAGCACAACTACTTATGTGCT![text missing or illegible when filed]()
GAA
(SEQ ID NO: 126)
|
M103DeltaGCTGTCAGGCTGGCATGGTCCTT
50 bp, e2-3, 46% GC
isoformGAGGTTTTCGAAACTTACATATT![text missing or illegible when filed]()
AT
(SEQ ID NO: 127)
|
M104PGRMC1progesteroneNM_006667AGTGACTGGGAGTCTCAGTTCA![text missing or illegible when filed]()
receptorTTCAAGTATCATCACGTGGGCAA![text missing or illegible when filed]()
membraneCT
component 1(SEQ ID NO: 128)
|
M105PGRMC2progesteroneNM_006320CGAGAATGGGAAATGCAGTTTA
50 bp, e2-3, 36% GC
receptorAGAAAAATATGATTATGTAGGC![text missing or illegible when filed]()
membraneGACT
component 2(SEQ ID NO: 129)
|
M106RARAretinoic acidNM_000964TTTGAAGTGGGCATGTCCAAGGA
50 bp, e4-5, 46% GC
receptor,GTCTGTGAGAAACGACCGAAAC![text missing or illegible when filed]()
alphaAGAA
(SEQ ID NO: 130)
|
M107RARB v1retinoic acidNM_000965GGTCAGCGCCTGTGAGGGATGT
50 bp, e2-3, 52% GC;
(NR1B2)receptor,AGGGCTTTTTCCGCAGAAGTATT
detects both v1 and
beta, v
AGAv
isoforms
(SEQ ID NO: 131)
|
M108RARGretinoic acidNM_00096ACCTCCGGGGCATCAGCACTAA
49 bp, e6-7, 55% GC
receptor,GGAGCTGAAAGGGCCATTACTC![text missing or illegible when filed]()
gammaGAA
(SEQ ID NO: 132)
|
M109RXRAretinoid XNM_002957ATCTGCGGGGACCGCTCCTCAG
46 bp, e3-4, 58% GC
receptor,AAGCACTATGGAGTGTACAGCT![text missing or illegible when filed]()
alpha(SEQ ID NO: 133)
|
M110RXRBretinoid XNM_021976CAATCTGCGGGGACAGAAGCTC
48 bp, e1-2, 50% GC
receptor,GGCAAACACTACGGGGTTTACA![text missing or illegible when filed]()
betaCT
(SEQ ID NO: 134)
|
M111AKR1D1aldo-ketoNM_005989TGGTACCTACTCAGAACCTAAAT
50 bp, e1-2, 52% GC
reductaseGACCCCTAAGGGAGCCTGTGCA![text missing or illegible when filed]()
family 1CAT
member D1(SEQ ID NO: 135)
|
M112CYP11Acytochrome P45
NM_000781TCCAGAAGTATGGCCCGATTTA
48 bp, e1-2, 54% GC
subfamily X1AGGGAGAAGCTCGGCAACGTGGA
P450 scc
T
(SEQ ID NO: 136)
|
M113CYP11B1cytochrome P4
NM_000497AAATGTGGCGTGTTCTTGCTGAA
50 bp, e2-3, 50% GC
subfamily X1BGGGCCTGAATGGCGCTTCAACC
(steroid 11-beta-
polypeptide 1ATThydroxylase) will also
(SEQ ID NO: 137)detect CYP11B2
|
M114CYP17cytochrome P4
NM_000102ACTTCTCTGGGCGGCCTCAAAT
48 bp, e2-3, 54% GC
subfamily XVI
CAACTCTAGACATCGCGTCCAA
Steroid 17-alpha-
(SEQ ID NO: 138)hydroxylase
|
M115CYP19cytochrome P4
NM_000103GCTCTTCTTGAGGATCCCTTTGG
50 bp, e5-6, 46% GC
subfamily XIXCGAAAGTGCTATCGTGGTTAAA
aromatization of
CCandrogens
(SEQ ID NO: 139)
|
M116CYP21A2cytochrome P4
NM_000500TGTGGACGTGATTCCCTTTCTCA
50 bp, e5-6, 54% GC
subfamily XXI
GTTCTTCCCCAATCCAGGTCTCC
Steroid 21-hydroxylase
GA
(SEQ ID NO: 140)
|
M117CYP24cytochrome P4
XM_030593CTCAAGAAACAGCACGACACCC
50 bp, e1-2, 50% GC
subfamily XXI
GGTGGAGTACCACAAGAAGTAT
vitamin D 24-
GCAAhydroxylase
(SEQ ID NO: 141)
|
M118CYP27A1
cytochrome P4
NM_000784GGTTGGAATGCCATCTTTTCCTT
50 bp, e4-5, 44% GC
subfamilyGGGAAGAAGCTGATTGATGAGA
Steroid 27-hydroxylase
XXVIIAGCT
(SEQ ID NO: 142)
|
M119CYP2C9cytochrome P4
NM_000771CTGCTGAAGCACCCAGAGGTCA
48 bp, e6-7, 50% GC
subfamily IICAGCTAAAGTCCAGGAAGAGATT
Mephenytoin 4-
AAhydroxylase; will also
(SEQ ID NO: 143)detect CYP2C8, 17,
19
|
M120CYP3A4cytochrome P4
NM_017460AGTCGCCTCGAAGATACACAAA
50 bp, e6-7, 48% GC
subfamily IIIAGCACCGAGTGGATTTCCTTCAG
niphedipine oxidase
GATwill detect other CYP![text missing or illegible when filed]()
(SEQ ID NO: 144)genes
|
M121HSD17B117beta-AF037438AGTGTGGCTGCCTTCGAGGGTCA
= ERAB (U96132)
hydroxysteroidGTTGGACAAGCTGCATACTCTG![text missing or illegible when filed]()
dehydrogenaseT
type 10(SEQ ID NO: 145)
|
M122HSD17B3hydroxysteroidNM_000197CCTGAACGCACCGGATGAAATC
50 bp, e5-6, 50% GC
(17-beta)AGAGCCTCATCCATTGTAACAT![text missing or illegible when filed]()
dehydrogenaseCCT
(SEQ ID NO: 146)
|
M123HSD17B8hydroxysteroidNM_014234AACATCAGTAGCATCGTAGGAA
50 bp, e4-5, 51% GC
(17-beta)GGTGGGGAACGTGGGGCAGACA![text missing or illegible when filed]()
dehydrogenaseACT
(SEQ ID NO: 147)
|
M124adrenalineE07358TTCGTGCTCTGCTGGTITCCCCTT
50 bp, 50% GC
alpha2CIITCTTCAGCTACAGCCTGTACGG![text missing or illegible when filed]()
receptorT
(SEQ ID NO: 148)
|
M125adrenalineE14946AGGCTTTGCCAACGGCTCGACG
50 bp, e1-2, 57% GC
beta receptorGGCTTCTTGGGGAGTTTCTTAG![text missing or illegible when filed]()
(SEQ ID NO: 149)
|
M126PNMTphenylethanola
NM_002686AACATGCCTGCCTCATTGAGGG
46 bp, e2-3, 54% GC
ne N-methylAGGGGGAATGCTGGCAGGATAA![text missing or illegible when filed]()
transferase(SEQ ID NO: 150)
|
M127SLC6A2solute carrierNM_001043TTCTACCGCTTGAAAGAGGCCA
50 bp, e5-6, 50% GC
family 6GTATGGATTGATGCCGCAACTCA
neurotransmitter
ATtransporter,
(SEQ ID NO: 151)noradrenalin
|
M128ADMadrenomedullinNM_001124TGTCGCGTCGGAGTTTCGAAAGA
50 bp, e2-3, 52% GC
GTGGAATAAGTGGGCTCTGAGT![text missing or illegible when filed]()
GTG
(SEQ ID NO: 152)
|
M129ADMRadrenomedullinNM_007264TCCCAAGGGAAACTCAGGCGTG
46 bp, e1-2, 55% GC
receptorGCTGGTCCCAATGTCAGTGAAA![text missing or illegible when filed]()
(SEQ ID NO: 153)
|
M130ANGPT1angiopoietin 1NM_001146CAACCTTGTCAATCTTTGCACTA
50 bp, e4-5, 38% GC
AGAAGGTGTTTTACTAAAGGGA![text missing or illegible when filed]()
GAA
(SEQ IDNO: 154)
|
M131ANGPT2angiopoietin 2XM_034835ATCCCAGTCCACCTGAGGA50 bp, e9, 46% GC
ACTGTCTCGAACTATTTTCAAA![text missing or illegible when filed]()
CTTAAGC
(SEQ ID NO: 155)
|
M132ANGPT4angiopoietin 4NM_015985AAGAAAGGGCTAACGCCTCGG
47 bp, e4-5, 59% GC;
CCGGCCTTCATAATGGCAGGTGA
angiopoetin-3
(SEQ ID NO: 156)
|
M133CDT6angiopoietin-NM_021146AGACGGTCACTCAGACCTCCGC
47 bp, e1-2, 57% GC
like factGATGCCATCTACGACTGCTCTT![text missing or illegible when filed]()
(SEQ ID NO: 157)
|
M134LOC1643similar toXM_092738AACTGGATCTGAGCGCAAAAAG
50 bp, only 1 exon
Angiopoietin 1AAGACACAGACGGTCAAAAAC
50% GC
receptorCCCC
precursor(SEQ ID NO: 158)
|
M135TEKTEK tyrosineXM_005480TGTGGAGTCAGCTTGCTCCTTTC
50 bp, e1-2, 50% GC
kinaseGGAACTGTGGAAGGTGCCATGG![text missing or illegible when filed]()
CTT
(SEQ ID NO: 159)
|
M136BDKRB1bradykininNM_000710CTGCTGCACAGAGTGCTGCCAA
50 bp, e2, 52% GC
receptor B1TTTATCATCTCCATCTGTTTCTT![text missing or illegible when filed]()
G
(SEQ ID NO: 160)
|
M137BDKRB2bradykininXM_040854TCCGTGCCCACCACGGCCTCTTT
46 bp, e1-2, 60% GC
receptor B2AGCGCCGACATGCTCAATGTCA![text missing or illegible when filed]()
(SEQ ID NO: 161)
|
M138PTGISprostaglandinNM_000961TGATGAAAAGGCCAGGATGAAA
50 bp, e3-4, 50% GC
I2 (prosta-TGACTCTTCTCCACAGAGAGCT![text missing or illegible when filed]()
cyclin)AGG
synthase(SEQ ID NO: 162)
|
M139CTCalcitoninX00356 J001TCATGTTAGCATGCCCCAGAAT
50 bp, e3, 48% GC
CAACTAAACTCCTCCCTTTTCCTT![text missing or illegible when filed]()
CT
(SEQ ID NO: 163)
|
M140CALCACalcitoninM64486ATCATTGCCCAGAAGAGAGCCT
49 bp, e3, 54% G
with differentGACACTGCCACCTGTGTGACTCA
Detected in medullar
C-termCthyroid carcinoma
(SEQ ID NO: 164)
|
M141CALCBcalcitonin-XM_113645TCAAGCCTGAGCAGATGAATGA
50 bp, e8-9, 50% G
relatedTCCAGGAAGAAGGTTATCATGA![text missing or illegible when filed]()
polypeptide,ACTG
beta(SEQ ID NO: 165)
|
M142CALCRcalcitoninNM_001742AGGGCCGTGTACTTCAATGACA![text missing or illegible when filed]()
receptorTGCTGGCTGAGTGTGGAAACCCA![text missing or illegible when filed]()
TT
(SEQ ID NO: 166)
|
M143ECE2endothelinNM_014693AGCCACTGAGAGACCTCATTGA
49 bp, e5-6, 49% GC
convertingAAGATTGGTGGTTGGAACATTA![text missing or illegible when filed]()
enzyme 2GG
(SEQ ID NO: 167)
|
M144ECE2Variants AAF428263GGCTGCCTTGTGGCCCTAGGGGT
47 bp, e3-9, 55% GC
AF428264TATGGGATGGATTATTFGCAGCA![text missing or illegible when filed]()
(SEQ ID NO: 168)
|
M145ECE1endothelinNM_001397CTCTCATCAACACCACCGACAG
50 bp, e9-10, 50% G
convertingGCCTGCTCAACAACTACATGAT![text missing or illegible when filed]()
enzyme 1GG
(SEQ ID NO: 169)
|
M146EDN1endotbelin 1XM_165812ACATCATTTGGGTCAACACTCCT
50 bp, e2-3, 50% GC
AGCACGTTGTTCCGTATGGACTT![text missing or illegible when filed]()
GA
(SEQ ID NO: 170)
|
M147EDN2endothelin 2NM_001956ACATCATCTGGGTGAACACTCCT
50 bp, e2-3, 54% GC
AACAGACAGCTCCTTACGGCCT![text missing or illegible when filed]()
GA
(SEQ ID NO: 171)
|
M148EDN3endothelin 3XM_030725ACATCATTTGGATCAACACTCC
49 bp, e2-3, 53% GC
AACAGACGGTGCCCTATGGACT![text missing or illegible when filed]()
C
(SEQ ID NO: 172)
|
M149EDNRAendothelinNM_001957TGATCTCCCTATCAATGTATTTA
50 bp, e2-3, 50% GC
receptorGCTGCTGGCTGGGCGCTGGCCTT![text missing or illegible when filed]()
type ATG
(SEQ ID NO: 173)
|
M150EDNRBendothelinXM_007108TGACATCCCTATCAATGTCTACA
50 bp, e1-2, 50% GC
receptorGCTGCTGGCAGAGGACTGGCCA
very similar to M149
type BTG
(SEQ ID NO: 174)
|
M151GTCTATGTGCTCTGAGTATTGA
50 bp, e2-3, 50% GC
GATATCGAGCTGTTGCTTCTTGG
sure only EDNRB
GT
(SEQ ID NO: 175)
|
M152CCKcholecystokininNM_000729AGATACATCCAGCAGGCCCGGA
50 bp, e2-3, 54% GC
AGCTCCTTCTGGACGAATGTCCA![text missing or illegible when filed]()
CGT
(SEQ ID NO: 176)
|
M153CCKBRcholecystokininNM_000731TGCAAGGCGGTTTCCTACCTCAT
47 bp, e2-3, 57% GC;
receptorGGGGTGTCTGTGAGTGTGTCCA
will also detect gastric
(SEQ ID NO: 177)receptor
|
M154GASgastrinNM_000805CCCACACCTCGTGGCAGACCCGT
41 bp, e1-2, 63% GC
CAAGAAGCAGGGACCAT
(SEQ ID NO: 178)
|
M155CGACTATGTGTGTATGTGCTGAT
49 bp, e1, 53% GC
TTTGCACTGGCTCTGGCCGCCTT![text missing or illegible when filed]()
T
(SEQ ID NO: 179)
|
M156GRPgastrin-NM_002091AAAGATGTAGGTTCAAAAGGCA
50 bp, e2-3, 44% GC
releasingAGTTGGTAGACTCTCTGCTCCA![text missing or illegible when filed]()
peptideTTC
(SEQ ID NO: 180)
|
M157GRPRgastrin-NM_005314AGGGAATATACATGTCAAGAAG
50 bp, e1-2, 46% GC
releasingAGATTGAATCCCGGAAGCGACT![text missing or illegible when filed]()
peptideGCCA
receptor(SEQ ID NO: 181)
|
M158LEPleptinNM_000230CAGGATCAATGACATTTCACACA
50 bp, e1-2, 46% GC
GCAGTCAGTCTCCTCCAAACAGA![text missing or illegible when filed]()
AG
(SEQ ID NO: 182)
|
M159LEPRLeptinNM_002303ACCTTTTCATGGCCTATGAGCAA
50 bp, e15-16, 46% G![text missing or illegible when filed]()
GTAAATATCGTGCAGTCACTCA![text missing or illegible when filed]()
GC
(SEQ ID NO: 183)
|
M160MCH-R2melanin-AF399937TCATGACTGTAATGAGTGTGGA
50 bp, e2-3, 46% GC
concentratingGGTACTTTGCCCTCGTCCAACCA![text missing or illegible when filed]()
hormoneTT
receptor(SEQ ID NO: 184)
|
M161PMCHpro-melanin-XM_006590CGAAGAGGAAAATAAAGTTTCA
50 bp, e1-2, 34% GC
concentratingAGAACACAGGCTCCAAACATAA![text missing or illegible when filed]()
hormoneTTCT
(SEQ ID NO: 185)
|
M162CATGCTCAGATGTATGCTGGGAA
50 bp, e3, 50% GC
AGTCTACCGACCTTGTTGGCAA![text missing or illegible when filed]()
CT
(SEQ ID NO: 186)
|
M163SomethingGTAGCGTTAAGATAGATCAGTA
50 bp, 36% GC
sim
fromCCAAAATCATAGGCTTTTTCTGT![text missing or illegible when filed]()
chromosome 5CAT
(SEQ ID NO: 187)
|
M164CABP1calciumNM_031205GGAACTGCGAGATGCTTTCCGA
50 bp, e5-6, 50% GC
bindingAGTTTGACACCAATGGTGATGG![text missing or illegible when filed]()
protein 1 v1GAAA
(SEQ ID NO: 188)
|
M165Variant 2TCCACTGAGAAATCTCTCAAGGA
50 bp, e1-3, 46% GC
GGATAGATCACTGCGACCAGAG![text missing or illegible when filed]()
AAA
(SEQ ID NO: 189)
|
M166CABP2calciumNM_016366GCAGCATAAAGGACTCAAGGA
47 bp, e7, 55% GC
protein 2 v1ACAGCCTCTGCCCACCAGCATGT![text missing or illegible when filed]()
(SEQ ID NO: 190)
|
M167CABP3calciumNM_016367CTCAAGAAATGCTTCCCGCAGCT
50 bp, e1-2, 50% GC
bindingTTCAATCTCATCTTGTCCCAGTG![text missing or illegible when filed]()
protein 3TC
(SEQ ID NO: 191)
|
M168CABP5calciumNM_019855CACTGGGACAAGATGAGATTGA
50 bp, e1-2, 48% GC
bindingGAGCTGCGGGAAGCATTTCTTGA![text missing or illegible when filed]()
protein 5TTC
(SEQ ID NO: 192)
|
M169CALM1calmodulin 1NM_006888AACTGTCATGAGGTCACTGGGT
50 bp, e2, 50% GC
GAACCCAACAGAAGCTGAATTG
will also detect
AGGcalmodulin 2
(SEQ ID NO: 193)
|
M170CALM2calmodulin 2?D45887AGAAGCATTCCGTGTGTTTGATA
50 bp, e3-4, 48% GC
GGATGGCAATGGCTATATTAGT![text missing or illegible when filed]()
TG
(SEQ ID NO: 194)
|
M171CALM3calmodulin 3NM_005184ATATGATCAATGAGGTGGATGC
50 bp, e3-4, 48% GC
GATGACCTTCCAGGGAACGGGA![text missing or illegible when filed]()
CATTGA
(SEQ ID NO: 195)
|
M172CALN1calneuron 1NM_031468CACGATAGACAGCATATTCTGG
50 bp, e3-4, 44% GC
GTTTGACATGCAAAGGATAACT![text missing or illegible when filed]()
GG
(SEQ ID NO: 196)
|
M173CAMKK2calcium/calmo
XM006592CACGTCTCCATCACGGGTATGCA
49 bp, e2-3, 51% GC
n-dependentGACTGTGTGCAGCTGAATCAGTA![text missing or illegible when filed]()
protein kinaseA
kinase 2(SEQ ID NO: 197)
|
M174PDE1Aphosphodiester
NM_005019GAAACAGTTTGCAGCAGCCTGA
50 bp, e10-11, 50% G![text missing or illegible when filed]()
1A, calmodulinGGGATTGACAGAGCCAAAACCA![text missing or illegible when filed]()
dependentGTCC
(SEQ ID NO: 198)
|
M175MLNmotilinNM_002418CTATGGCGAACTCCAGAGGATG
50 bp, e2-3, 50% GC
AGGAAAAGGAACGGAATAAAG![text missing or illegible when filed]()
CAAA
(SEQ ID NO: 199)
|
M176NPPBnatriureticNM_002521ACTTGGAAACGTCCGGGTTACA
46 bp, e2, 56% GC;
peptideGAGCAGCGCAACCATTTGCAGG![text missing or illegible when filed]()
precursor B(SEQ ID NO: 200)
|
M177NPPCnatriureticNM_024409CAAATACAAAGGAGCCAACAA
48 bp, e1-2, 52% GC
peptideAGGGCTTGTCCAAGGGCTGCTT![text missing or illegible when filed]()
precursor C(SEQ ID NO: 201)
|
M178NPR1natriureticNM_000906CGGATGTGGAACCGAAGCTTTC
50 bp, e3-4, 52% GC
peptideAGGTGTGACAGGATACCTGAAA![text missing or illegible when filed]()
receptor ATTGA
(SEQ ID NO: 202)
|
M179GGATCCCGAGAATGGTGCCTTC
50 bp, e5-6, 50% GC
GGTTGTACTGAACTACAATGGG![text missing or illegible when filed]()
TT
(SEQ ID NO: 203)
|
M180NPR2natriureticNM_003995AAAGATGCAGGGACGAAGATAT
50 bp, e4-5, 50% GC
peptideACGGTGTAACTGGGCTGGTTGT![text missing or illegible when filed]()
receptor BTGG
(SEQ ID NO: 204)
|
M181TTGGACGACCCATCCTGTGATAA
50 bp, e6-7, 46% GC
ACTCCACTTTCAACCCTGGCAAT![text missing or illegible when filed]()
GT
(SEQ ID NO: 205)
|
M182NPR3natriureticNM_000CAATATCCAGGCCAGTGAGAGA
48 bp, e1-2, 52% GC
peptideTGGTGATCATGTGTGCGAGCAG![text missing or illegible when filed]()
receptor CA
(SEQ ID NO: 206)
|
M183KIAA097netrin G1fNM_014917CCCTCCTGAGACGTTCTGTGCAA
50 bp, e2-3, 50% GC
GGGCAATCCCTACATGTGCAATA![text missing or illegible when filed]()
TG
(SEQ ID NO: 207)
|
M184KIAA185netrin G2NM_032536CCCTGAGAGGTTCTGCTCCCAT
48 bp, e1-2, 54% GC
GAATCCCTACCTATGCAGCAAC![text missing or illegible when filed]()
(SEQ ID NO: 208)
|
M185NTN1Netrin 1NM_004822CAGCAGCGTGGAGGAGCCTGAA
45 bp, e3-4, 59% GC
ACTGCGATTCCTACTGCAAGG
(SEQ ID NO: 209)
|
M186NTN4Netrin 4NM_02122TTCTCAGCTCCAGATGCTTGCAA
49 bp, e1-2, 51% GC
CCGTGTTCCTGCCATCCAGTAG![text missing or illegible when filed]()
T
(SEQ ID NO: 210)
|
M187iNOSnitric oxideAF051164CAGGATGACCCTAAGAGTCACA
50 bp, 48% GC
synthaseGCATCAAAATGGTTTCCCCCAGT
will also detect NOS![text missing or illegible when filed]()
CCT
(SEQ ID NO: 211)
|
M188NOS1nitric oxideNM_000620CAACTCTGTGCAGGAAGAAAGG
50 bp, e15-16, 50% G![text missing or illegible when filed]()
synthase 1AGAGCTACAAGGTCCGATTCAA![text missing or illegible when filed]()
AGCG
(SEQ ID NO: 212)
|
M189NOS2nitric oxideTGACACAGGATGACCTTCAGTA
50 bp, 48% GC in one
synthase 2ACAACCTCAGCAAGCAGCAGAA
exon will also detect
GAGiNOS
(SEQ ID NO: 213)
|
M190NOS3nitric oxideCACAGGAAATGTTCACCTACAT
50 bp, 46% GC
synthase 3GCAACCACATCAAGTATGCCAC![text missing or illegible when filed]()
AAC
(SEQ ID NO: 214)
|
M191PEDFpigmentM76979GCCTCCCGGATCGTCTTTGAGA
A50 bp, e4-5, 50% GC
epithelium-AAGCTGCGCATAAAATCCAGCT![text missing or illegible when filed]()
differenti-GT
ation factor(SEQ ID NO: 215)
|
M192NPY5RneuropeptideNM_006174GCTACTGTCTGGACACTAGGTTT
50 bp, single exon,
Y
receptor Y5GCCATCTGTTCTCCCCTTCCAGT
50% GC
TT
(SEQ ID NO: 216)
|
M193neuropeptideU42389AATGGGTCCAATAGGTGCAGAG
50 bp, single exon,
y/peptide YYCTGATGAGAACCAGACAGTGGA
50% GC
receptor type 2GAAA
(SEQ ID NO: 217)
|
M194PPY2pancreaticNM_021092TTGGAGCCATTGTACCGAGGGG
44 bp, 54% GC
polypeptide 2AATACCACACCGGAGCAGAT
(SEQ ID NO: 218)
|
M195PPYR1pancreaticNM_005972TACACCATCATGGACTACTGGAT
50 bp, single exon,
polypeptideTTTGGAGAGACCCTCTGCAAGAT
48% GC
receptor 1TC
(SEQ ID NO: 219)
|
M196PYYpeptide YYNM_004160ACTACCTCAACCTGGTCACCCG
41 bp, e2-3, 54% GC
AGCGGTATGGGAAAAGA
(SEQ ID NO: 220)
|
M197PYY2peptide YY, 2NM_021093TACGCCTATCCTCGCCAGTACCT
46 bp, single exon,
ATCCTGGTCACTCAGCCGTCGT54% GC
(SEQ ID NO: 221)
|
M198VIPvasoactiveNM_003381TTACAGGGCACCTTCTGCTCT
50 bp, e1-2, 50% GC
intestinalGGTTGGGTGACAGAATACCCTTT![text missing or illegible when filed]()
peptideAG
(SEQ ID NO: 222)
|
M199AGTCTCTTATGGGAAAACGTGTT
50 bp, e3-4, 42% GC
GCAGTAACATCTCAGAAGACCC![text missing or illegible when filed]()
GTA
(SEQ ID NO: 223)
|
M200PTHparathyroidNM_000315AAATCGGATGGGAAATCTGTTA
50 bp, e2-3, 38% GC
hormonGAAGAGATCTGTGAGTGAAATA![text missing or illegible when filed]()
AGCT
(SEQ ID NO: 224)
|
M201PTHR1parathyroidNM_000316GGTGCCCATCCTGGCCTCCATT
50 bp, e10-11, 50% G![text missing or illegible when filed]()
hormoneGCTCAACTTTCATGCTCTTCATCA![text missing or illegible when filed]()
receptor 1TA
(SEQ ID NO: 225)
|
M202CATATACTGTTTCTGCAATGGC
50 bp, e14-15, 40% G![text missing or illegible when filed]()
GGTACAAGCTGAGATCAAGAA![text missing or illegible when filed]()
CTT
(SEQ ID NO: 226)
|
M203PTHR2parathyroidNM_005048GGCATGACACAAGGAAGCAATA
50 bp, e10-11, 50% G![text missing or illegible when filed]()
hormoneAGGAAACTGGCCAAATCGACA![text missing or illegible when filed]()
receptor 2GGTC
(SEQ ID NO: 227)
|
M204GGCAACTTCTGTGGACAAATCA
50 bp, e6-7, 44% GC
ATATATCGGGTGCAAGATTGCT![text missing or illegible when filed]()
TG
(SEQ ID NO: 228)
|
M205CYP4F8cytochrome P4
NM_007253GTCCGATCTGTCATCAATACCT
50 bp, e2-3, 44% GC
subfamily IVF,GATGCCATTACAGACAAGGACA![text missing or illegible when filed]()
polypeptide 8AGT
(SEQ ID NO: 229)
|
M206PTGDRprostaglandinXM_051711CACTATGTGTTCTCTGCCCGTAA
50 bp, e1-2, 42% GC
D
receptorTTATCGCGCTTACTATGGAGCAT![text missing or illegible when filed]()
TA
(SEQ ID NO: 230)
|
M207CYP4F11cytochrome P4
NM_021187GCCTATCACCAGTGCCTCAGCT
47 bp, e1-2, 53% GC
subfamily IVF,TGTCGCACCCAAGGATATGATTT![text missing or illegible when filed]()
polypeptide 11(SEQ ID NO: 231)
|
M208CYP4F12cytochrome P4
NM_023944AACAAGAGTGCAAACATCATGC
50 bp, e4-5, 50% GC
isoform 4F12TGACAAGTGGCAGCACCTGGCC![text missing or illegible when filed]()
AGA
(SEQ ID NO: 232)
|
M209CYP4F2cytochrome P4NM_001082ATCCGGTCTGTCATCAACGCCT
50 bp, e3-4, 52% GC
subfamily IVF,GCTGCCATTGCACCAAAGGACA![text missing or illegible when filed]()
polypeptide 2GTT
(SEQ ID NO: 233)
|
M210CYP4F3cytochrome P4XM_029072CATTGATGTACTCCTGCTGAGCA
50 bp, e6-7, 48% GC
subfamily IVF,GGATGAAGATGGGAAGAAGTT![text missing or illegible when filed]()
polypeptide 3CCG
(SEQ ID NO: 234)
|
M211PTGER1prostaglandin ENM_000955CGTGCATCTGCTGGAGCCCAAT
40 bp, e2-3, 62% GC
receptor 1TGGTGTTGGTGGCGCT
(SEQ ID NO: 235)
|
M212PTGER2prostaglandin ENM_000956CGCCGTCTGCTCCTTGCCTTTCA
50 bp, e1-2, 44% GC
receptor 2GATTTTTGCATATATGAATGAAA![text missing or illegible when filed]()
CT
(SEQ ID NO: 236)
|
M213PTGER3prostaglandin ENM_000957AGGACTTGGTGCAGTTCTCATGA
50 bp, e1-2, 48% GC
receptor 3AGAGAACCCTGCAGTGTCCAGC![text missing or illegible when filed]()
AAG
(SEQ ID NO: 237)
|
M214PTGER4prostaglandin ENM_000958TCATCTGCTCCATCCCGCTCGTG
48 bp, e2-3, 52% GC
receptor 4TGCGAGTATTCGTCAACCAGTTA![text missing or illegible when filed]()
(SEQ ID NO: 238)
|
M215PTGFRprostaglandin FNM_000959TCCTGTATTTGTTGGAGCCCATT
50 bp, e2-3, 42% GC
receptorCTGGTTACAATGGCCAACATTG![text missing or illegible when filed]()
AT
(SEQ ID NO: 239)
|
M216PTGIRprostaglandinNM_000960TGTGCTCCCTGCCTCTCACGATC
37 bp, e2-3, 62% GC
I2 (prosta-GCTGCTTCACCCA
cyclin)(SEQ ID NO: 240)
receptor
|
M217PTGS2prostaglandin-NM_000963TTCTATGGAGAAAACTGCTCAA
50 bp, e2-3, 32% GC
endoperoxideCCGGAATTTTTGACAAGAATAA![text missing or illegible when filed]()
synthase 2ATT
(SEQ ID NO: 241)
|
M218CAGACAAGCAGGCTAATACTGA
50 bp, e7-8, 38% GC
AGGAGAGACTATTAAGATTGTG![text missing or illegible when filed]()
TTGA
(SEQ ID NO: 242)
|
M219TBXA2Rthromboxane ANM_001060TCTCTGTCGCTTCATGGGCGTCG
44 bp, 54% GC
receptorCATGATCTTCTTCGGCCTGT
(SEQ ID NO: 243)
|
M220TBXAS1thromboxane ANM_001061TTTCAGTCCTGAAAAGCTGAAC
50 bp, e4-6, 33% GC
synthase 1GATGGTTCCCCTCATCAGCCAA![text missing or illegible when filed]()
CT
(SEQ ID NO: 244)
|
M221GGTAGACGTTTTTAAGGAGAAA
49 bp, e9-10, 51% GC
ACATGGCCCCTGAGTTCTGCAG![text missing or illegible when filed]()
TC
(SEQ ID NO: 245)
|
M222AGTR1angiotensinXM_051470TGTACGCTAGTGTGTTTCTACTC
50 bp, 46% GC
receptor 1CGTGTCTCAGCATTGATCGATA![text missing or illegible when filed]()
TG
(SEQ ID NO: 246)
|
M223AGTR2angiotensinXM_030897ATTTACTCCTTTTGGCTACTCTT
50 bp, 36% GC
receptor 2TCTATGGGCAACCTATTATTCTT![text missing or illegible when filed]()
T
(SEQ ID NO: 247)
|
M224ACEangiotensin IXM_044372CTTCTACAACAGGAAAGACTTCA
50 bp, e6-7, 50% GC
convertingGATCAAGCAGTGCACACGGGTC![text missing or illegible when filed]()
enzymeCGA
(SEQ ID NO: 248)
|
M225AGTangiotensinogeNM_000029TTCAACACCTACGTCCACTTCCA
50 bp, e2-3, 52% GC
GGGAAGATGAAGGGCTTCTCCC![text missing or illegible when filed]()
GCT
(SEQ ID NO: 249)
|
M226RENreninNM_000537CGACAGACACCACCACCTTTAAA
50 bp, e1-2, 50% GC
GGATCTTCCTCAAGAGAATGCC![text missing or illegible when filed]()
CA
(SEQ ID NO: 250)
|
M227GGAGCCAAGAAGAGGCTGTTTG
49 bp, e7-8, 51% GC
TTATGTCGTGAAGTGTAACGAG![text missing or illegible when filed]()
CC
(SEQ ID NO: 251)
|
M228RENBPrenin bindingNM_002910AAGTATGTGTGGCTGCAGGGGA
49 bp, e3-4, 53% GC
proteinGCAGGTATGGATGTATTGTCGC![text missing or illegible when filed]()
GT
(SEQ ID NO: 252)
|
M229ACE2ACE-relatedAF291820AGAACTGAAGTTGAAAAGGCCA
50 bp, e16-17, 48% G![text missing or illegible when filed]()
carboxypeptidaseCAGGATGTCCCGGAGCCGTATC![text missing or illegible when filed]()
ATGA
(SEQ ID NO: 253)
|
M230SCTsecretinNM_021920CTGGTGGGGAAGCGCAGCGAG
47 bp, e2-3, 65% GC
GGACGCAGAGAACA![text missing or illegible when filed]()
(SEQ ID NO: 254)
|
M231SCTRSecretinNM_002980GGATGCTCACCAGCAGAAATGG
49 bp, e3-4, 51% GC
receptorTCCTTGTTCCGAAACTGCACACA![text missing or illegible when filed]()
GA
(SEQ ID NO: 255)
|
M232UTS2Urotensin 2NM_021995ATGCTGGGTGCAGAAAGAGGG
50 bp, 48% GC
TATTCTCAGGAAAGCAGACTCA![text missing or illegible when filed]()
GTAC
(SEQ ID NO: 256)
|
M233AQP4aquaporin 4NM_001650CAGTTATCATGGGAAATTGGGA
50 bp, e3-4, 44% GC
AACCATTGGATATATTGGGTTG![text missing or illegible when filed]()
CCC
(SEQ ID NO: 257)
|
M234AVPR1AarginineXM_006934ACAGAACATTGTCTTACTTGAT
50 bp, e1-2, 42% GC
vasopressinTCCCGATGACCTCAACAACAGG![text missing or illegible when filed]()
receptor 1AAAG
(SEQ ID NO: 258)
|
M235AGATTTCAAGTCCAGCATCTCAA
50 bp, e2-3, 44% GC
GCGACAACCTTGGTAACTCTGCA![text missing or illegible when filed]()
GA
(SEQ ID NO: 259)
|
M236AVPR1BarginineNM_000707CGGTGACCATGCTCACGGCCTG
41 bp, e2-3, 61% GC
vasopressinACAGCCTCATCTGCCAT
receptor 1B(SEQ ID NO: 260)
|
M237CCACCAATGTGGCTTTCACCAT
50 bp, e3, 50% GC
CTAGCTTTTGGGCAACCTCAA![text missing or illegible when filed]()
GC
(SEQ ID NO: 261)
|
M238AVPR2arginineNM_000054ATGCTCATGGCGTCCACCACTT
40 bp, e1-2, 62% GC
vasopressinGCTGTGCCTGGGCATC
receptor 2(SEQ ID NO: 262)
|
M239OXTRoxytocinNM_000916ATGCCAACGCGCCCAAGGAAG
43 bp, e1-2, 58% GC
receptorTCGGCCTTCATCATCGTCAT
(SEQ ID NO: 263)
|
M240OXToxytocinNM_000915AAAGGCCGCTGCTTCGGGCCCA
39 bp, e2, 61% GC
ATCTGCTGCGCGGAA
(SEQ ID NO: 264)
|
M241oxytocinaseU62769CACCGCTTTATCAAATATGCCTA
50 bp, e3-4, 40% GC
GAAGTCATCAGTCGTTCTAGAT![text missing or illegible when filed]()
TG
(SEQ ID NO: 265)
|
M242RLN1relaxin 1NM_006911CCTCAGACACCTAGACCAGTGG
50 bp, e1-2, 46% GC
AGAAATTGTACCATCCTTCATCA
will also detect
CAArelaxin 2
(SEQ ID NO: 266)
|
M243CTATCTGAGAGGCAACCATCATT
50 bp, e2, 48% GC
CCAGAGCTACAGCAGTATGTAC
specific for
GCrelaxin 1
(SEQ ID NO: 267)
|
M244RLN2relaxin 2NM_006911GAGAGTTCCTTGGTGCCCTTTC
50 bp, e2-3, 46% GC
AATTGTGCCATCCTTCATCAACA![text missing or illegible when filed]()
AG
(SEQ ID NO: 268)
|
M245RLN3relaxin 3NM_080864ATCCTGGCCCACGAGGCTATGG
45 bp, e1-2, 57% GC
AGATACCTTCCCGGATGCAGAT![text missing or illegible when filed]()
(SEQ ID NO: 269)
|
M246vasopressinAF031476ATGTCCGACCTGGAGCTGAGAC
36 bp, e1-2, 63% GC
precursorGTGCCTCCCCTGC
(SEQ ID NO: 270)
|
M247TTTGCTGCAACGACGAGAGCTG
34 bp, e2-3, 61% GC
TGACCGAGCC
(SEQ ID NO: 271)
|
M248CHRNA1cholinergicNM_000079GACAACCAATGTGCGTCTGAAA
50 bp, e3-4, 42% GC
receptor,AGCAATGGGTGGATTACAACCT![text missing or illegible when filed]()
nicotinic,AAAT
alpha poly-(SEQ ID NO: 272)
peptide 1
(muscle)
|
M249TATTCTACCTGCCCACAGACTCA
50 bp, e6-7, 42% GC
GGGAGAAGATGACTCTGAGCAT![text missing or illegible when filed]()
TCT
(SEQ ID NO: 273)
|
M250CHRNA2cholinergicNM_000742ACCACCAACGTCTGGCTAAAAC
49 bp, e4-5, 53% GC
receptor,GGAGTGGAGCGACTACAAACTG![text missing or illegible when filed]()
nicotinic,GCT
alpha poly-(SEQ ID NO: 274)
peptide 2
(neuronal)
|
M251CHRNA4cholinergicNM_000743TCATGGAGACCAACCTGTGGCT
50 bp, e3-4, 48% GC
receptor,AGCAAATCTGGAATGACTACAA![text missing or illegible when filed]()
nicotinic,CTG
alpha poly-(SEQ ID NO: 275)
peptide 3
|
M252CHRNA4cholinergicNM_000744GTCCATCGCTCAGCTCATTGAC
50 bp, e2-3, 50% GC
receptor,GGATGAGAAGAACCAGATGAT![text missing or illegible when filed]()
nicotinic,CCA
alpha poly-(SEQ ID NO: 276)
peptide 4
|
M253CHRNA5cholinergicXM_007577CACCAGACATCGTTTTGTTTGAT
50 bp, e4-5, 44% GC
receptor,ATGCAGATGGACGTTTTGAAGG![text missing or illegible when filed]()
nicotinic,ACC
alpha poly-(SEQ ID NO: 277)
peptide 5
|
M254CHRNA6cholinergicCHRNA6GGAAACCAATTTGTGGCTGCGT
50 bp, e2-3, 42% GC
receptor,CATCTGGAATGATTATAAATTG![text missing or illegible when filed]()
nicotinic,CT
alpha poly-(SEQ ID NO: 278)
peptide 6
|
M255CHRNA7cholinergicNM_000746GAGCCTCCTGCAGATCATGGAC
50 bp, e1-2, 48% GC
receptor,GGATGAGAAGAACCAAGTTTTA![text missing or illegible when filed]()
nicotinic,CCA
alpha poly-(SEQ ID NO: 279)
peptide 7
|
M256CHRNB1cholinergicNM_000747ATCCTGGCGCAACTCATCAGCCT
49 bp, e2-3, 51% GC
receptor,AACGAGAAGGATGAAGAGATGA![text missing or illegible when filed]()
nicotinic,CA
beta poly-(SEQ ID NO: 280)
peptide 1
(muscle)
|
M257CHRNB2cholinergicNM_000748AGCAGATCATGACCACCAATGT
50 bp, e3-4, 50% GC
receptor,GGCTGACCCAGGAGTGGGAAGA![text missing or illegible when filed]()
nicotinic,TAT
beta poly-(SEQ ID NO: 281)
peptide 2
(neuronal)
|
M258CHRNB3cholinergicNM_000749TTCCTGACATAGTTCTCTTTGAA
50 bp, e1-2, 48% GC
receptor,ATGCTGACGGCCGCTTCGAAGG![text missing or illegible when filed]()
nicotinic,CC
beta poly-(SEQ ID NO: 282)
peptide 3
|
M259CHRNB4CholinergicXM_039151AGAATGACGATGAAGACCAGA
50 bp, e1-2, 50% GC
receptor,GTCGTTGAGGACTGGAAGTACG![text missing or illegible when filed]()
nicotinic,GGCT
beta poly-(SEQ ID NO: 283)
peptide 4
|
M260DRD1dopamineXM_003966AGACTTTGCCCTGCGACGAATAA
50 bp, 44% GC
receptorGCCATAGAGACGGTGAGTATCA![text missing or illegible when filed]()
D1TAA
(SEQ ID NO: 284)
|
M261DRD2dopamineNM_000795CTCCTCTTCGGACTCAATAACG
50 bp, e5-6, 50% GC
receptorGACCAGAACGAGTGCATCATTG![text missing or illegible when filed]()
D2CAA
(SEQ ID NO: 285)
|
M262DRD3dopamineXM_113416TTCTGTTTGGCTTTAATACCACA
49 bp, e4-5, 51% GC
receptorGGGACCCCACTGTCTGCTCCAT![text missing or illegible when filed]()
D3C
(SEQ ID NO: 286)
|
M263DRD4dopamineXM_006145TGGTGCTGCCGCTCTTCGTCTA
36 bp, e1-2, 63% GC
receptorCCGAGGTCCAGG
D4(SEQ ID NO: 287)
|
M264AANATarylalkylamineNM_001088CTTTGAGATCGAGCGTGAAGCC
44 bp, e2-3, 54% GC
acetyl-CATCTCCGTCTTGGGCGTCT
transferase(SEQ ID NO: 288)
|
M265ACAAGGAGAGACTCATGCAGGA
39 bp, e2-3, 53% GC
TCACTGACGCTGCACA![text missing or illegible when filed]()
(SEQ ID NO: 289)
|
M266TPHTryptophanX52836GATCTGAACTAGATGCAGACCA
50 bp, e4-5, 46% GC
hydroxylaseCTGGCTTCAAAGACAATGTCTA![text missing or illegible when filed]()
GT
(SEQ ID NO: 290)
|
M267ATAAAAGCCCTGAAAATCTTTCA
49 bp, e1-3, 46% GC
GTATGGAAACTGTTCCTTGGTTT
might detect deletion
Cexon 2 (regulatory
(SEQ ID NO: 291)domain)
|
M268CAGATCCCTTCTATACCCCAGA
50 bp, e6-7, 50% GC
CAGATACCTGCCATGAACTCTTA![text missing or illegible when filed]()
GT
(SEQ ID NO: 292)
|
M269HIOMTacetylserotoninNM_004043AAGAACAGATTGACTTCCAGGA
50 bp, e7-8, 46% GC
methyl-GGGGATTTCTTCAAAGACCCTCT![text missing or illegible when filed]()
transferaseCCG
(SEQ ID NO: 293)
|
M270ABAT4-aminobutyrat
NM_000663GGAAGTCCCAGGGCCTAGATCT
50 bp, e2-3, 44% GC
amino-AGGAGTTAATGAAACAGCTGAA![text missing or illegible when filed]()
transferaseATAA
(SEQ ID NO: 294)
|
M271AOX1aldehydeNM_001159GCCAGAATTTGAGGAAGGAAGT
50 bp, e6-7, 44% GC
oxidase 1AGACAAGTCCAAAACTCTTCGC![text missing or illegible when filed]()
GAAG
(SEQ ID NO: 295)
|
M272DBHdopamineNM_000787TACCACAACCCACTGGTGATAGA
48 bp, e5-6, 52% GC
beta-AGGACGAAACGACTCCTCAGG![text missing or illegible when filed]()
hydroxylaseTC
(SEQ ID NO: 296)
|
M273CHAT vNcholineNM_020549CGTCATCGTAGCCTGCTGCAAT
50 bp, e6-7, 44% GC
acetyl-GTTCTTTGTCTTGGATGTTGTCA
detects all variants
transferaseA
(SEQ ID NO: 297)
|
M274Variant N1TGAGGCTTTGAGAAAGGAGTAG
50 bp, e1, 50% GC
AGCCTAGCATTCCGGCAGAGGA![text missing or illegible when filed]()
GAAA
(SEQ ID NO: 298)
|
M275COMTcatechol-O-NM_000754AGAGGGCTGGAGCCTGCTCAGA
42 bp, e1-2, 59% GC
methyl-GTGCTTTGAAGATGCCGGAwill detect only MB
transferase(SEQ ID NO: 299)isoform
|
M276CATGAACGTGGGCGACAAGAAA
46 bp, e3-4, 54% GC
GCAAGATCGTGGACGCCGTGAT
will detect all
(SEQ ID NO: 300)isoform
|
M277DDCdopaXM_033775AAAGGACTGCAGGCTTATATCC
49 bp, e9-10, 51% GC![text missing or illegible when filed]()
decarboxylaseAAGCATGTCCAGCTGTCCCATGA![text missing or illegible when filed]()
T
(SEQ ID NO: 301)
|
M278GAD2glutamateNM_000818CTCTGCTCTCCTGGTTAGAGAA
50 bp, e12-13, 48% G![text missing or illegible when filed]()
decarboxylaseGGGATTGATGCAGAATTGCAAC![text missing or illegible when filed]()
2AAA
(SEQ ID NO: 302)
|
M279GAD2glutamateNM_013445GACTTCTCTAATCTGTTTGCTAG
50 bp, e3-4, 46% GC
decarboxylaseGATCTGCTTCCGGCTAAGAACG
Detects both 25 and
GAisoforms
(SEQ ID NO: 303)
|
M280glutamineY00387GACAGTGAGCCCAAGTGTGTGG
50 bp, e3-4, 52% GC;
synthetaseAGAGTTGCCTGAGTGGAATTTC
should detect also so![text missing or illegible when filed]()
TGGgene on chr 11
(SEQ ID NO: 304)
|
M281CATGCGGGAGGAGAATGGTCTG
50 bp, e7-8, 52% GC;
AGTACATCGAGGAGGCCATTGA
should detect also so![text missing or illegible when filed]()
AAACgenes on chr 2, 9
(SEQ ID NO: 305)
|
M282HNMThistamineNM_006895AAGATGCTCATTATTGTTGTGT
50 bp, e5-6, 48% GC
N-methylGGAAGCAGTGGCTGGGACAAG![text missing or illegible when filed]()
transferaseGTG
(SEQ ID NO: 306)
|
M283MAOAmonoamineNM_000240CTGGGTACAAGAACCTGAATCA
50 bp, e13-14, 50% G![text missing or illegible when filed]()
oxidase AAGGACGTTCCAGCGGTAGAAAT![text missing or illegible when filed]()
ACCC
(SEQ ID NO: 307)
|
M284MAOBmonoamineNM_000898GGGAGGCAGGACTTACACTCTT
50 bp, e2-3, 46% GC
oxidase BGGAACCAAAAGGTTAAATATGT![text missing or illegible when filed]()
GACC
(SEQ ID NO: 308)
|
M285HRH1histamineXM_052382CCGAGAGGACAAGTGTGAGACA
50 bp, 50% GC
receptor H1ACTTCTATGATGTCACCTGGTTC![text missing or illegible when filed]()
AGG
(SEQ ID NO: 309)
|
M286HRH2histamineNM_022304AAGGGCAATCATACCACCTCTA
50 bp, 44% GC
receptor H2GTGCAAAGTCCAGGTCAATGAA![text missing or illegible when filed]()
TGTA
(SEQ ID NO: 310)
|
M287HRH3histamineAF321910TCAACCTCGCCATCTCCGACTT
43 bp, e1-2, 60% GC
receptor H3TCGTCGGCGCCTTCTGCAT
(SEQ ID NO: 311)
|
M288HRH4histamineNM_021624GGCCATCTCTGACTTCTTTGTGG
50 bp, e1-2, 48% GC
receptor H4TGTGATCTCCATTCCTTTGTACA![text missing or illegible when filed]()
C
(SEQ ID NO: 312)
|
M289MTNR1AmelatoninNM_005958GTATCGGAACAAGAAGCTCAGG
50 bp, e1-2, 48% GC
receptor 1AACGCAGGAAACATCTTTGTGGT![text missing or illegible when filed]()
GCT
(SEQ ID NO: 313)
|
M290MTNR1BmelatoninNM_005959AGGAACCGCAAGCTCCGGAACG
48 bp, e1-2, 52% GC
receptor 1BAGGTAATTTGTTCTTGGTGAGT![text missing or illegible when filed]()
G
(SEQ ID NO: 314)
|
M291NTSneurotensinNM_006183TTCAGCTCCTGGAGTCTGTGCT
50 bp, e1-2, 44% GC
GATTCAGAAGAGGAAATGAAA![text missing or illegible when filed]()
ATT
(SEQ ID NO: 315)
|
M292NTSR1neurotensinNM_002531CATCTCGGATGAGCAGTGGACT
50 bp, e2-3, 50% GC
receptor 1GTTCCTCTATGACTTCTACCACT![text missing or illegible when filed]()
(highCT
affinity)(SEQ ID NO: 316)
|
M293NTSR2neurotensinNM_012344ACCGCGCTCCAAGTCTTTATCCA
47 bp, e1-2, 53% GC
receptor 2GTGAATGTGCTGGTGTCCTTCGT![text missing or illegible when filed]()
(SEQ ID NO: 317)
|
M294ADRA1Aadrenergic,NM_033303TTTTCTTAGTCATGCCCATTGGG
50 bp, e1-2, 44% GC
alphaCTTTCTTCCCTGATTTCAAGCCC![text missing or illegible when filed]()
1A-, receptorT
(SEQ ID NO: 318)
|
M295ADRA1Badrenergic,NM_000679TACCCTTCTTCATCGCTCTACCG
48 bp, e1-2,
alphaTGGCTCCTTGTTCTCCACCCTGA
54% GC = adral c?
1B-, receptor(SEQ ID NO: 319)
|
M296ADRA1Dadrenergic,NM_000678TGCTGGTTCCCTTTCTTCTTTGT
45 bp, e1-2, 55% GC
alphaTGCCGCTCGGCTCCTTGTTC
1D-, receptor(SEQ ID NO: 320)
|
M297ADRA2Aadrenergic,NM_000681TCTCCCTACTCTCTCCCGCCGCT
50 bp, 5′UTR, 44% G![text missing or illegible when filed]()
alphaGAAATAAAACTTGGCTGTATTA![text missing or illegible when filed]()
2A-, receptorA
(SEQ ID NO: 321)
|
M298ADRA2Badrenergic,NM_000682TTCCTCATTCTCTTTACCATCTT
50 bp, 50% GC
alphaGCAACGCTCTGGTCATCCTGGCT![text missing or illegible when filed]()
2B-, receptorT
(SEQ ID NO: 322)
|
M299ADRA2Cadrenergic,NM_000683CAACAGCTCGCTCAACCCGGTCA
50 bp, 50% GC; may
alphaCTACACGGTCTTCAACCAGGATT
also detect ADRA 2A
2C-, receptor(SEQ ID NO: 323)and 2B
c
|
M300ADRB1adrenergic,NM_000684TAAGACCGATAGCAGGTGAACT
50 bp, 3′UTR, 48% G![text missing or illegible when filed]()
betaGAAGCCCACAATCCTCGTCTGA![text missing or illegible when filed]()
1-, receptorCAT
(SEQ ID NO: 324)
|
M301ADRB2adrenergic,NM_000024GAGACCTGCTGTGACTTCTTCA
49 bp, 51% GC
betaAACCAAGCCTATGCCATTGCCT![text missing or illegible when filed]()
2-, receptorT
(SEQ ID NO: 325)
|
M302ADRB3adrenergic,NM_000025CCTGAAGGACAAGAAGCAACAA
50 bp, 3′UTR, 46% G![text missing or illegible when filed]()
betaTCTGTTGATCAGAACCTGTGGAA![text missing or illegible when filed]()
3-, receptorACC
(SEQ ID NO: 326)
|
M303HTR1AserotoninXM_003692AATTGGCTGGGCTACTCCAACT
50 bp, 48% GC
receptorCTGCTTAACCCCGTCATTTACG![text missing or illegible when filed]()
1ATA
(SEQ ID NO: 327)
|
M304HTR1BserotoninXM_004117TGGAAAAGAAGAAACTCATGG
49 bp, 51% GC
receptorGCTAGGGAGCGCAAAGCCACCA
similarity to 1 D?
1B(SEQ ID NO: 328)
|
M305HTR1DserotoninXM_001542CCAAATCTTGTGTGACATCTGG
49 bp, 51% GC
receptorGTCCTCTGACATCACGTGCTGCA![text missing or illegible when filed]()
1DA
(SEQ ID NO: 329)
|
M306HTR1EserotoninXM_004134GGAAACATGAACATCACAAACT
50 bp, 46% GC
receptorTACCACAGAGGCCAGCATGGCT![text missing or illegible when filed]()
1ETAAG
(SEQ ID NO: 330)
|
M307HTR1FserotoninXM_003092ATTGTGTATATTGTGAGAGAGA
50 bp, 44% GC
receptorTGGATTATGGGGCAAGTGGTCT![text missing or illegible when filed]()
1FGA
(SEQ ID NO: 331)
|
M308HTR2AserotoninXM_007123CATGTTAACCATCCTGTATGGGT
45 bp, e1-255% GC
receptorCCGGTGGCCTCTGCCGAGCAA![text missing or illegible when filed]()
2A(SEQ ID NO: 332)
|
M309HTR2CserotoninXM_013121CTGTCTCTCCTGGCAATCCTTTA
50 bp, e2-3, 44% GC
receptorGATTATGTCTGGCCACTACCTA![text missing or illegible when filed]()
2CTA
(SEQ ID NO: 333)
|
M310HTR3AserotoninXM_006444TCCCGGACATTCTCATCAATGA
50 bp, e4-5, 48% GC
receptorTCGTGGATGTGGGGAAGTCTCCA![text missing or illegible when filed]()
3AAT
(SEQ ID NO: 334)
|
M311HTR3BserotoninXM_006445ACCTTCAAGAGCATTCTGCATA
50 bp, e5-6, 48% GC
receptorGTGGAAGACGTAGACCTGGCCT![text missing or illegible when filed]()
3BCT
(SEQ ID NO: 335)
|
M312HTR4serotoninNM_000870TTCCTGTAATGGACAAACTTGAT
50 bp, e5-6, 42% GC
receptorCTAATGTGAGTTCTGAGGAGGG![text missing or illegible when filed]()
4TC
(SEQ ID NO: 336)
|
M313HTR5AserotoninXM_017055ACCCATATCCGAAGCTGTGGAG
44 bp, e5-6, 53% GC
receptorGAAGGACTCTGCCAAACAG
5A(SEQ ID NO: 337)
|
M314HTR6serotoninXM_001435TTTGTGGCCAACATAGTCCAGG
40 bp, e2-3, 55% GC
receptorGTGTGCGACTGCATCT
6(SEQ ID NO: 338)
|
M315EGFepidermalNM_001963AGAGAGATGGGAAAACATGTA
50 bp, e7-8, 48% GC
growthGGTTGTTCCTCACCCGATAATG![text missing or illegible when filed]()
factorGGA
(SEQ ID NO: 339)
|
M316EGFRepidermalNM_005228AAGTGCGAAGGGCCTTGCCGCA
50 bp, e7-8, 48% GC
growthAGTGTGTAACGGAATAGGTATT![text missing or illegible when filed]()
factorGTGA
receptor(SEQ ID NO: 340)
|
M317ATACGCGGCAGGACCAAGCAA
49 bp, e10-11, 51% G![text missing or illegible when filed]()
TGGTCAGTTTTCTCTTGCAGTC![text missing or illegible when filed]()
CA
(SEQ ID NO: 341)
|
M318ERBB2v-erb-b2NM_004448TGAACTGGTGTATGCAGATTGC
49 bp, e20-21, 51% G![text missing or illegible when filed]()
erytbroblasticAGGGGATGAGCTACCTGGAGGA![text missing or illegible when filed]()
leukemia viralGT
oncogene(SEQ ID NO: 342)
homolog 2
|
M319FGF1fibroblastNM_000800CACCGACGGGCTTTTATACGGCT
50 bp, e3-4, 48% GC
growthACAGACACCAAATGAGGAATGT![text missing or illegible when filed]()
factor 1TGT
(SEQ ID NO: 343)
|
M320FGF2fibroblastNM_002006GTCCGGGAGAAGAGCGACCCT
50 bp, e1-2, 52% GC
growthCATCAAGCTACAACTTCAAGCA![text missing or illegible when filed]()
factor 2AAGA
(SEQ ID NO: 344)
|
M321FGF3fibroblastNM_005247TGGCCATGAACAAGAGGGGAC
46 bp, e1-2, 54% GC
growthCTCTATGCTTCGGAGCACTACA![text missing or illegible when filed]()
factor 3(SEQ ID NO: 345)
|
M322FGF4fibroblastNM_002007GGCAAGCTCTATGGCTCGCCCTT
45 bp, e2-3, 57% GC
growthTTCACCGATGAGTGCACGTTC
factor 4(SEQ ID NO: 346)
|
M323FGFSfibroblastNM_004464GATCCCACGAAGCCAATATGTTA
50 bp, e1-2, 38% GC
growthGTGTTTTGGAAATATTTGCTGTG![text missing or illegible when filed]()
factor 5CT
(SEQ ID NO: 347)
|
M324FGF6fibroblastNM_020996CAGTAAAGGAAGATTGTACGCA
50 bp, e2-3, 46% GC
growthCGCCCAGCTTCCAAGAAGAATG![text missing or illegible when filed]()
factor 6AAGT
(SEQ ID NO: 348)
|
M325FGF7fibroblastNM_002009ACCCAAGAGATGAAGAATAATT
50 bp, e1-2, 38% GC
growthCAATATCATGGAAATCAGGACA![text missing or illegible when filed]()
factor 7TGGC
(SEQ ID NO: 349)
|
M326FGF8fibroblastNM_033163AGAAGGGGAAGCTGATCGCCAA
45 bp, e1-2, 55% GC
growthAGCAACGGCAAAGGCAAGGACT
will detect longer and
factor 8(SEQ ID NO: 350)shorter isoforms
|
M327FGF10fibroblastNM_004465AGAAGGGGAAACTCTATGGCTC
50 bp, e2-3, 38% GC
growthAAAGAATTTAACAATGACTGTA![text missing or illegible when filed]()
factor 10GCTG
(SEQ ID NO: 351)
|
M328FGF11fibroblastNM_004112ATGCTGAGGGACTGCTCTACAG
48 bp, e,3-4, 54% GC
growthCGCCGCATTTCACAGCTGAGTGT
homol to fgf-3?
factor 11(SEQ ID NO: 352)
|
M329FGF12fibroblastNM_021032ACCAAGGACGAAAACAGCGACT
50 bp, e2-3, 48% GC
growthCACTCTCTTCAATCTAATTCCCG![text missing or illegible when filed]()
factor 12GGG
(SEQ ID NO: 353)
|
M330FGF13fibroblastNM_004114AAGAAGAGGCGCAGAAGAAGA
50 bp, e1-2, 48% GC
growthAGAGCCTCAGCTTAAGGGTATA![text missing or illegible when filed]()
factor 13TAC
(SEQ ID NO: 354)
|
M331FGF14fibroblastNM_004115ACCAAGGATGACAGCACTAATT
50 bp, e2-3, 48% GC
growthACACTCTTCAACCTCATACCAGT![text missing or illegible when filed]()
factor 14GG
(SEQ ID NO: 355)
|
M332FGF16fibroblastNM_003868ACCTAGGAATGAATGAGCGAG
50 bp, 48% GC
growthGAACTCTATGGGTCGAAGAAAC![text missing or illegible when filed]()
factor 16CACA
(SEQ ID NO: 356)
|
M333FGF17fibroblastNM_003867TTCTCTGCTGTCAAACTCAGGG
50 bp, e2-3, 48% GC
growthAGAATCACCCGTCTCCTAATTTT![text missing or illegible when filed]()
factor 17AC
(SEQ ID NO: 357)
|
M334FGF18fibroblastNM_033649CCTCCGCCTGCACTTGCCTGTGT
46 bp, e1-2, 56% GC
growthTACACTTCCTGCTGCTGTGCTT
factor 18(SEQ ID NO: 358)
|
M335FGF19fibroblastNM_005117GACGGCAAGATGCAGGGGCTG
45 bp, e2-3, 57% GC
growthTCAGTACTCGGAGGAAGACTGT![text missing or illegible when filed]()
factor 19(SEQ ID NO: 359)
|
M336FGF20fibroblastNM_019851GAATGACAAAGGAGAAGTCTAT
50 bp, e2-3, 40% GC
growthGATCAGAGAAACTTACTTCCGAA![text missing or illegible when filed]()
factor 20GCA
(SEQ ID NO: 360)
|
M337FGF21fibroblastNM_019113TGCTGACCAGAGCCCCGAAAGT
45 bp, e1-2, 55% GC
growthCCTGCAGCTGAAAGGCTTGAA
factor 21(SEQ ID NO: 361)
|
M338FGF22fibroblastNM_020637CCACGGCCAGGACAGCATCCTG
40 bp, e1-2, 62% GC
growthAGATCCGCTCTGTACAC
factor 22(SEQ ID NO: 362)
|
M339FGF23fibroblastNM_020638TTTCAGAGGCAACATTTTTGGAT
50 bp, e2-3, 44% GC
growthACACTATTTCGACCCGGAGAAC![text missing or illegible when filed]()
factor 23CA
(SEQ ID NO: 363)
|
M340FGFR1fibroblastNM_000604CGACTACTATAAAAAGACAACC
50 bp, e13-14, 50% G![text missing or illegible when filed]()
growthACGGCCGACTGCCTGTGAAGTG![text missing or illegible when filed]()
factorATGG
receptor
(SEQ ID NO: 364)
|
M341FGFR2fibroblastNM_000141TTCTTGGAGCCTGCACACAGGAT
50 bp, e13-14, 48% G![text missing or illegible when filed]()
growthGGCCTCTCTATGTCATAGTTGA
detects almost all
factorATvariants (tyrosine
receptor
(SEQ ID NO: 365)kinase domains)
|
M342FGFR3fibroblastXM_044120ACCGTAGCCGTGAAGATGCTGA
49 bp, e10-11, 53% G![text missing or illegible when filed]()
growthAGACGATGCCACTGACAAGGA![text missing or illegible when filed]()
factorTGT
receptor
(SEQ ID NO: 366)
|
M343FGFR4fibroblastNM_002011ACTGTGGCCGTCAAGATGCTCAA
48 bp, e11-12, 54% G![text missing or illegible when filed]()
growthGACAACGCCTCTGACAAGGACC![text missing or illegible when filed]()
factorG
receptor
(SEQ ID NO: 367)
|
M344FIBPfibroblastNM_004214CACTACTCATCGAGAGGTACTAT
50 bp, 50% GC
growthCCTTTGATGAGGCCTITTGTTCGG![text missing or illegible when filed]()
factor (acidic)AG
intracellular(SEQ ID NO: 368)
binding protein
|
M345SPRY1sprouty homologXM_036349CTGTTCACAATCACACTGCTGCT
50 bp, 48% GC
1, antagonistTAGATACCTGTGTATGGGAGCCA![text missing or illegible when filed]()
of FGFGT
signaling(SEQ ID NO: 369)
|
M346SPRY2sprouty homologNM_005842CCCAGAACGTGATTGACTATGG
50 bp, 48% GC
2, antagonistACTTGTGTATGCTGTGTGAAAG![text missing or illegible when filed]()
of FGFCTC
signaling(SEQ ID NO: 370)
|
M347IGF1Rinsulin-likeNM_000875TACCGGCACAATTACTGCTCCAA
50 bp, e9-10, 46% GC![text missing or illegible when filed]()
growth factorGACAAAATCCCCATCAGGAAGT![text missing or illegible when filed]()
1 receptorTGC
(SEQ ID NO: 371)
|
M348IGF2insulin-likeNM_000612TCGACCCCTCCGACCGTGCTTC
41 bp, e3-4, 61% GC
growth factorGACAACTTCCCCAGATA
2(SEQ ID NO: 372)
|
M349IGF1insulin-likeX00173GACATGCCCAAGACCCAGAAGG
50 bp, e3-4, 48% GC
growth factorAGTACATTTGAAGAACGCAAGT![text missing or illegible when filed]()
1GAGG
(SEQ ID NO: 373)
|
M350IGFBP1insulin-likeNM_000596GAATGGATTTTATCACAGCAGA
50 bp, e2-3, 47% GC
growth factorGTGTGAGACATCCATGGATGGA![text missing or illegible when filed]()
binding proteinAGGC
(SEQ ID NO: 374)
|
M351IGFBP2insulin-likeNM_000597AAGCATGGCCTGTACAACCTCA
50 bp, e3-4, 50% GC
growth factorACAGTGCAAGATGTCTCTGAAC![text missing or illegible when filed]()
binding proteinGGCA
(SEQ ID NO: 375)
|
M352IGFBP3insulin-likeNM_000598AAGCGGGAGACAGAATATGG50 bp, e2-3, 50% GC
growth factorTCCCTGCCGTAGAGAAATGGAA![text missing or illegible when filed]()
binding proteinACACACT
(SEQ ID NO: 376)
|
M353IGFBP4insulin-likeNM_001552AACGGCAACTTCCACCCCAAGC
42 bp, e2-3, 57% GC
growth factorGTGTCACCCAGCTCTGGAT
binding protein(SEQ ID NO: 377)
|
M354IGFBP5insulin-likeU20271CAAAGGATTCTACAAGAGAAAG
49 bp, e3-4, 51% GC
growth factorAGTGCAAACCTTCCCGTGGCG![text missing or illegible when filed]()
binding proteinAG
(SEQ ID NO: 378)
|
M355IGFBP6insulin-likeNM_002178GCGCGCCTGCTGTTGCAGAGGA
42 bp, e1-2, 54% GC
growth factorAATCCTAAGGAGAGTAAAC
binding protein(SEQ ID NO: 379)
|
M356IMP-1IGF-II mRNA-AF117106ATGGTACAGTAGAGAACTGTGA
50 bp, e2-3, 50% GC
binding proteinCAAGTGAACACCGAGAGTGAGA![text missing or illegible when filed]()
GGCA
(SEQ ID NO: 380)
|
M357IMP-2IGF-II mRNA-NM_006548GGACAGTGGAGAATGTGGAACA
50 bp, e4-5, 50% GC
binding proteinGTCAACACAGACACAGAAACCG![text missing or illegible when filed]()
CGTT
(SEQ ID NO: 381)
|
M358IMP-3IGF-II mRNA-AF117108TATCCCGCCTCATTTACAGTGG
50 bp, e2-3, 48% GC
binding proteinGGTGCTGGATAGTTTACTAGTC![text missing or illegible when filed]()
GT
(SEQ ID NO: 382)
|
M359NGFBnerve growthNM_002506GTTCTACACTCTGATCACAGCTT
50 bp, 50% GC
factor, betaTCTGATCGGCATACAGGCGGAA![text missing or illegible when filed]()
polypeptideCAC
(SEQ ID NO: 383)
|
M360NGF-2X53655CAAGCTCTCCAAGCAGATGGTG
50 bp, 50% GC
ACGTTAAGGAAAATTACCAGAG![text missing or illegible when filed]()
ACCC
(SEQ ID NO: 384)
|
M361NGFRnerve growthNM_002507TTGTGGCCTACATAGCCTTCAA
50 bp, e4-5, 50% GC
factorGGTGGAACAGCTGCAAGCAGAA![text missing or illegible when filed]()
receptorAAG
(SEQ ID NO: 385)
|
M362TDGF1teratocarcinomaNM_003212TCTTTGAACTGGGATTAGTTGC
44 bp, e2-3, 50% GC
derived growthGGCTGGGCCATCAGGAATTT
factor 1(SEQ ID NO: 386)
|
M363PDGFAplatelet-NM_002607AGATAGACTCCGTAGGGAGTGA
48 bp, e3, 52% GC
derived growthGATTCTTTGGACACCAGCCTGA![text missing or illegible when filed]()
factor alphaG
polypeptide(SEQ ID NO: 387)
|
M364PDGFBplatelet-NM_002608GACCTGTCCAGGTGAGAAAGAT
47 bp, e4-5, 51% GC
derived growthGAGATTGTGCGGAAGAAGCCAA![text missing or illegible when filed]()
b polypeptideC
(SEQ ID NO: 388)
|
M365PDGFCplatelet-NM_016205TTTCCAGCAACAAGGAACAGAA
50 bp, e1-2, 46% GC
derived growthGGAGTACAAGATCCTCAGCATG![text missing or illegible when filed]()
factor CGAGA
(SEQ ID NO: 389)
|
M366PDGFDplatelet-AF336376TCATACCATGACCGGAAGTCAA
50 bp, e5-6, 44% GC
derived growthAGTTGACCTGGATAGGCTCAAT![text missing or illegible when filed]()
factor DTGA
(SEQ ID NO: 390)
|
M367PDGFRAplatelet-NM_006206TCAATGGACTTACCCTGGAGAA
50 bp, e5-6, 48% GC
derived growthGAAAGGCAAAGGCATCACAAT![text missing or illegible when filed]()
factor receptor,TGG
alpha poly-(SEQ ID NO: 391)
peptide
|
M368PDGFRBplatelet-NM_002609TGCCTACTATGTCTACAGACTC
50 bp, e4-5, 48% GC
derived growthGGTGTCATCCATCAACGTCTCT![text missing or illegible when filed]()
factor receptor,GA
beta polypeptide(SEQ ID NO: 392)
|
M369VEGFvascularNM_003376TGAGGAGTCCAACATCACCATG
50 bp, e3-4, 48% GC
endothelialAGATTATGCGGATCAAACCTCA![text missing or illegible when filed]()
growth factorAAG
(SEQ ID NO: 393)
|
M370VEGFBvascularNM_003377ACCAGAGGAAAGTGGTGTCATG
50 bp, 50% GC
endothelialATAGATGTGTATACTCGCGCTA![text missing or illegible when filed]()
growth factorTGC
B(SEQ ID NO: 394)
|
M371VEGFCvascularNM_005429CAGCACGAGCTACCTCAGCAAG
50 bp, e1-2, 46% GC
endothelialCGTTATTTGAAATTACAGTGCCT![text missing or illegible when filed]()
growth factorTCT
C(SEQ ID NO: 395)
|
M372VEGFDvascularNM_004469CAGTAATGAACATGGACCAGTG
50 bp, e1-2, 46% GC
endothelialAGCGATCATCTCAGTCCACATT![text missing or illegible when filed]()
growth factorAAC
D(SEQ ID NO: 396)
|
M373similar toXM_067723TTTGCAGAACTTGTGGAAAAAC
50 bp, e4-5, 34% GC
VascularGAAAATAGTGGGTTTACATACT![text missing or illegible when filed]()
endothelialAC
growth factor(SEQ ID NO: 397)
receptor
|
M374ADARadenosineNM_001111AAAGAAGGCCCTGCCCATGAA
48 bp, e4-5, 50% GC
deaminase, RNCAAGTTCCAATACTGTGTTGCA
should detect all 3
specificGvariants
(SEQ ID NO: 398)
|
M375SPSselenium donorNM_012247ATCGTAGACGACCCTTACATGAT
48 bp, e2-3, 52% GC
proteinGGCAGGATAGCGTGTGCCAATG
may also detect
CLOC158861
(SEQ ID NO: 399)
|
M376SPS2selenium donorNM_012248ATGTTACTCAGCGTCAGCCAGA
50 bp, 50% GC
protein 2ATGAGTGAGGAGGAACGCGAAA![text missing or illegible when filed]()
GGT
(SEQ ID NO: 400)
|
M377LOC1235similar toXM_063731GAACTGAAGGGCACAGGCTGCA
50 bp, e1-2, 50% GC
Selenide, waterAGAGAACCACTTCCAAGAAGAT![text missing or illegible when filed]()
dikinase 1AGCA
(SEQ ID NO: 401)
|
M378LOC1295similar toXM_065297TTAAAGATGCAGCCGAGGAAG
50 bp, e1-2, 42% GC
selenophosphat
GGAATATGTAGAGTTGACATAC![text missing or illegible when filed]()
synthetaseAAGA
(SEQ ID NO: 402)
|
M379LOC1505-//-XM_086946AAAATATGAATCCCACACCTGG
50 bp, e1-2, 42% GC
CCACCTCTTAATCTAGACAGAAA![text missing or illegible when filed]()
AGC
(SEQ ID NO: 403)
|
M380LOC1588-//-XM_005845CAGAATGTGACAATATGCTGAT
50 bp, 40% GC
TCCTTGGAGTCAGTAATAAAAT![text missing or illegible when filed]()
CC
(SEQ ID NO: 404)
|
M381LOC1670-//-XM_094245TTACAGTGCTTTTGCTGAAAAT
50 bp, e2-3, 38% GC
GAATGCAGGAACTGAGACCAT![text missing or illegible when filed]()
TTA
(SEQ ID NO: 405)
|
M382LOC1684-//-XM_095122CAGAATGTGACAATATGCTGAT
50 bp, 40% GC
TCCTTGGAGTCAGTAATAAAAT![text missing or illegible when filed]()
CC
(SEQ ID NO: 406)
|
M383LOC2020-//-XM_116312ATATCACAGGCTTTGGCATTCTA
50 bp, 46% GC
GACACTCTCAGAACCTCGTGAA![text missing or illegible when filed]()
AA
(SEQ ID NO: 407)
|
M384SCYA21smallNM_002989AAAGGAAAGGGCTCCAAAGGCT
44 bp, e3-4, 54% GC
inducibleCAAGAGGACTGAGCGGTCACA
cytokine(SEQ DI NO: 408)
subfamily A
|
M385ACVR1activin ANM_001105CCAATGTTGGAGACAGCACTTTA
50 bp, e4-5, 40% GC
receptor type ICAGATTTATTGGATCATTCGTGT![text missing or illegible when filed]()
CA
(SEQ ID NO: 409)
|
M386ACVR1Bactivin ANM_004302AGATTGCTCGAAGATGCAATTCT
50 bp, e7-8, 44% GC
receptor type IBGAGGAGTCCATGAAGAATATCA
should detect only
CTGisoform a
(SEQ ID NO: 410)
|
M387ACVR2activin ANM_001616GCTGATCACAGCATTTCATGAAA
50 bp, e4-5, 40% GC
receptor type 2GGGTTCACTATCAGACTTTCTTA![text missing or illegible when filed]()
GG
(SEQ ID NO: 411)
|
M388ACVR2Bactivin ANM_001106TGCTGGCTAGATGACTTCAACT
45 bp, e2-3, 51% GC
receptor type 2BTACGATAGGCAGGAGTGTGTG
(SEQ ID NO: 412)
|
M389INHBAinhibin, betaXM_042996ATCATCACGTTTGCCGAGTCAG
47 bp, e1-2, 53% GC;
AACAGCCAGGAAGACGCTGCACT
same as erythroid
(SEQ ID NO: 413)differentiation
protein
|
M390INHBBinhibin, betaNM_002193AATCATCAGCTTCGCCGAGACA
40 bp, e1-2, 60% GC
BATGGCCTCGCCTCCTCC
(SEQ ID NO: 414)
|
M391INHBCinhibin, betaNM_005538GAAATCATCAGCTTTGCTGAGA
49 bp, e1-2, 51% GC
CGGCCTCTCCACCATCAACCAGA![text missing or illegible when filed]()
C
(SEQ ID NO: 415)
|
M392BLCB lymphocyteAF044197ATGGTTGTCCAAGAAAAGAAAT
50 bp, e3-4, 34% GC
chemo-ATAGTCTGGAAGAAGAACAAGT![text missing or illegible when filed]()
attractantAATT
(SEQ ID NO: 416)
|
M393TNFSF13tumor necrosisNM_006573GCCGTTCAGGGTCCAGAAGAAA
50 bp, e2-3, 50% GC
factor (ligand)AGTCACTCAAGACTGCTTGCAA
AF132600, AF11645![text missing or illegible when filed]()
superfamily,GATAF186114, AF13471![text missing or illegible when filed]()
member 13b(SEQ ID NO: 417)
|
M394TNFRSF5tumor necrosisNM_001250AAACAGTCAGTGCTGTTCTTTGT
50 bp, e2-3, 50% GC
(CD40L)factor receptorCCAGCCAGGACAGAAACTGGTG![text missing or illegible when filed]()
superfamily,GTG
member 5(SEQ ID NO: 418)
|
M395CNTFciliaryNM_000614CTGACTGCTCTTACGGAATCCTA
50 bp, e1-2, 48% GC
neurotrophicGTGAAGCATCAGGGCCTGAACA![text missing or illegible when filed]()
factorGAA
(SEQ ID NO: 419)
|
M396CNTFRciliaryNM_001842ATCACCTTTGACGAGTTCACCAT
50 bp, e5-6, 44% GC
neurotrophicGTGAAGCCTGATCCTCCAGAAA![text missing or illegible when filed]()
factor receptor GT
(SEQ ID NO: 420)
|
M397CSF1colonyNM_000757ACATTTGAGTTTGTAGACCAGGA
50 bp, 44% GC =
stimulatingCAGTTGAAAGATCCAGTGTGCTA
CSF4?
factor ICT
(SEQ ID NO: 421)
|
M398CSF1RcolonyNM_005211CTTCCTCCAACACAACAACACTA
50 bp, e4-5, 50% GC
stimulatingGCTCGCAATCCCTCAACAATCT![text missing or illegible when filed]()
factor 1CT
receptor(SEQ ID NO: 422)
|
M399CSF2colonyNM_000758TGAACCTGAGTAGAGACACTGC
50 bp, e1-2, 44% GC
stimulatingGCTGAGATGAATGAAACAGTAG![text missing or illegible when filed]()
factor 2AGTC
(SEQ ID NO: 423)
|
M400CSF2RAcolonyNM_006140CTAGTCTCAATGTGAGGTTTGA
50 bp, 46% GC
stimulatingCCAGGACGATGAATTTAAGCTG![text missing or illegible when filed]()
factor 2GAC
receptor,(SEQ ID NO: 424)
alpha low-
affinity
|
M401CSF2RBcolonyNM_000395GGCAGAGAAACACATAAAGAG
49 bp, e7-8, 51% GC
stimulatingCAGTGAACATCCAGATGGCCCC![text missing or illegible when filed]()
factor 2CA
receptor,(SEQ ID NO: 425)
beta low-
affinity
|
M402CSF3colonyNM_000759AGGAGAAGCTGGTGAGTGAGT
43 bp, e2-3, 55% GC
stimulatingGCCACCTACAAGCTGTGCCA
factor 3(SEQ ID NO: 426)
|
M403CTF1cardiotrophin 1XM_096076CATGTGTACATCTCAGCCTTAT
50 bp, 48% GC
CAAGGAGGTGACACCTTCTCTC![text missing or illegible when filed]()
TG
(SEQ ID NO: 427)
|
M404CLCcardiotrophin-AY049779AAGCCTCAATGACAAACTGCGG
42 bp, 54% GC
li
cytokineTGACCCAGAACTACGAGGC
(SEQ ID NO: 428)
|
M405EMAPIIsmall inducibleNM_004757CAGGCAGAAATTCAAAATGGAG
50 bp, e2-3, 40% GC
(SCYE1)cytokineGAAGCAAATAGCATTTCCATCT![text missing or illegible when filed]()
subfamily E,TAC
member 1(SEQ ID NO: 429)
|
M406EpoerytropoetinX02157CCGAGAATATCACGACGGGCTG
49 bp, e2-3, 51% GC
GCTGAACACTGCAGCTTGAATGA![text missing or illegible when filed]()
GAA
(SEQ ID NO: 430)
|
M407CCR3CC chemokineAF247361CATGGCATGTGTAAGCTCCTCT
50 bp, 48% GC
receptor 3GGGTTTTATCACACAGGCTTGTA![text missing or illegible when filed]()
AG
(SEQ ID NO: 431)
|
M408eotaxineosinophil-D49372TGGCAAATGTCCCCAGAAAGCT
50 bp, e2-3, 50% GC
selective CCGATCTTCAAGACCAAACTGGCC![text missing or illegible when filed]()
chemokineAGG
(SEQ ID NO: 432)
|
M409osteopont
osteopontinAF052124CTAGGCATCACCTGTGCCATAC
50 bp, e2-3, 48% GC
GTTAAACAGGCTGATTCTGGAA![text missing or illegible when filed]()
TC
(SEQ ID NO: 433)
|
M410GSNgelsolinNM_000177AAGATGGGAAAATCTTTGTCTG
50 bp, e7-8, 48% GC
AAGGCAAGCAGGCAAACACGGA![text missing or illegible when filed]()
GAG
(SEQ ID NO: 434)
|
M411GZMBgranzyme BNM_004131AGAGATTAAAAAGACTTCCTTTA
50 bp, e3-4, 46% GC
GGGGGACTCTGGAGGCCCTCTT![text missing or illegible when filed]()
GT
(SEQ ID NO: 435)
|
M412CD44CD44 hyaluronicX55150GACAGGACCTCTTTCAATGACAA
50 bp, e5-6, 46% GC
receptorGCAGCAGAGTAATTCTCAGAGC![text missing or illegible when filed]()
(epithelialCT
form)(SEQ ID NO: 436)
|
M413AGCACAGACAGAATCCCTCGTA
50 bp, e4-5, 46% GC
CAATATGGACTCCAGTCATAGTA![text missing or illegible when filed]()
AAC
(SEQ ID NO: 437)
|
M414IFN-alphainterferonJ00210ATTCTGCACCGAACTCTACCAG
50 bp, 50% GC will a![text missing or illegible when filed]()
alphaGCTGAATGACTTGGAAGCCTGT
detect IFN-alpha 13, ![text missing or illegible when filed]()
GAmay detect 2, F, 6, 5, ![text missing or illegible when filed]()
(SEQ ID NO: 438)
|
M415IFN-alphainterferonX02959TGCCTGAAGGACAGACATGACT
50 bp, 46% GC; may
14alphaGAATTTCCCCAGGAGGAATTTGA
also detect IFN-alpha
GG1B, 21, 17, 5, F, 1B,
(SEQ ID NO: 439)D, 2, 21
|
M416IFN-alphainterferonX02957ACAAAGGATTCATCTGCTGCTT
50 bp, 46% GC; may
16alphaGATGAGACCCTCCTAGACAAAT
also detect IFN-alpha
TA14, F, 5, 6, 7, 8,
(SEQ ID NO: 440)
|
M417IFN-alphainterferonX02955AATACAGCCCTTGTGCCTGGGA
50 bp, 46% GC; will
4balphaTTGTCAGAGCAGAAATCATGAG
also detect IFN-alpha
TCC21, 7, 13, 14, 1, 16, 1![text missing or illegible when filed]()
(SEQ ID NO: 441)d, N, F, H, N, M1, A
|
M418IFN-alphainterferonX02956GTAACAGGAGGACTTTGATGAT
50 bp, 40% GC; may
alphaATGGCACAAATGGGAAGAATCT
also detect IFN-alpha
TCCT14, H
(SEQ ID NO: 442)
|
M419IFN-alphainterferonX02958ATGACTTCAGATTTCCCCAGGA
50 bp, 48% GC; may
alphaAGTTTGATGGCAACCAGTTCCA
also detect IFN-alpha
AG16, F
(SEQ ID NO: 443)
|
M420IFN-alphainterferonX02960AGCCTGCGTAATAGGAGGGCCT
50 bp, 50% GC; may
alphaGATACTCCTGGCACAAATGGGA
also detect IFN-alpha
GAAT21, 17, 4, A, N, F, C,
(SEQ ID NO: 444)10, 8
|
M421IFN-alphainterferonX03125GAGATGATCCAGCAGACCTTCA
50 bp, 50% GC; will
alphaCCTCTTCAGCACAAAGGACTCAT
also detect IFN-alpha
TGC1B, 201, may detect ![text missing or illegible when filed]()
(SEQ ID NO: 445)21, 5, 7, 17, 4, 16, 10
|
M422IFNAR1interferonNM_000629GACTCATTTACACCATTTCGCAA
50 bp, e3-4, 44% GC
(alphGCTCAGATTGGTCCTCCAGAAGT![text missing or illegible when filed]()
beta andCA
omega(SEQ ID NO: 446)
receptor 1
|
M423IFNAR2interferonNM_000874CACTTAATTTGGTTCTCATGGTG
50 bp, e3-4, 38% GC;
(alphATATCAGCCTCGTGTTTGGTATT
will detect both soluble
beta andCAand membrane-bound
omega(SEQ ID NO: 447)receptors
receptor 2
|
M424IFN-betafibroblastM35591GATCAAGCAACTCCAGCAATTC
50 bp, 46% GC
interferonGAAAGAAGACGCAGCTCTGACT![text missing or illegible when filed]()
TCT
(SEQ ID NO: 448)
|
M425IFN-betainterferon-X04430ATGCTTCCAATCTGGATTCAAT
50 bp, e3-4, 42% GC =
(IL6)beta-GGAGACTTGCCTGGTGAAAATC
IL6
(interleukin 6)CA
(SEQ ID NO: 449)
|
M426IFMBRinterferonA26595GACTCATTTACACCATTTCGCAA
50 bp, e3-4, 44% GC
betaGCTCAGATTGGTCCTCCAGAAGT![text missing or illegible when filed]()
receptorCA
(SEQ ID NO: 450)
|
M427IFN-gammaA25270ACCTTCTAAGTCACGTCACCAT![text missing or illegible when filed]()
antagonistNM_006083GATGCCAAGGGAGTACAATGAG![text missing or illegible when filed]()
cytokineATG
(SEQ ID NO: 451)
|
M428IFNGinterferon,NM_000619CTTAGGCATTTTGAAGAATTGGA
50 bp, e2-3, 36% GC
gammaAGAGGAGAGTGACAGAAAAATA![text missing or illegible when filed]()
TGC
(SEQ ID NO: 452)
|
M429IFNGR1interferonNM_000416GTATGTGAGAATGAACGGAAGT
50 bp, e4-5, 40% GC
gammaAGATCCAGTATAAAATACTCAC![text missing or illegible when filed]()
receptor 1AGA
(SEQ ID NO: 453)
|
M430IFNGR2interferonNM_005534TTGTCTACCGAGTGCAGTTTTAAA
50 bp, e2-3, 46% GC
gammaACACCGACAGTAAATGGTTCAC![text missing or illegible when filed]()
receptor 2GCC
(SEQ ID NO: 454)
|
M431ILI8interleukinNM_001562GATATGACTGATTCTGACTGTA
50 bp, e2-3, 40% GC
18GATAATGCACCCCGGACCATATT![text missing or illegible when filed]()
AT
(SEQ ID NO: 455)
|
M432IL1AinterleukinNM_000575GCATTACATAATCTGGATGAAG
50 bp, e4-5, 36% GC
1, alphaGTGAAATTTGACATGGGTGCTTA![text missing or illegible when filed]()
AA
(SEQ ID NO: 456)
|
M433IL1BinterleukinNM_000576CCAGTGAAATGATGGCTTATTA
50 bp, e2-3, 40% GC
1, b
GTGGCAATGAGGATGACTTGTT![text missing or illegible when filed]()
TT
(SEQ ID NO: 457)
|
M434IL1Einterleukin-1AF206696GATGGTGGAGGAAGGGCCGTCT
50 bp, e2-3, 46% GC
epsilonTCAATCAATGTGTAAACCTATTA![text missing or illegible when filed]()
TGG
(SEQ ID NO: 458)
|
M435IL1R1interleukin 1NM_000877GTAATAGAATTTATTACTCTAGA
50 bp, e4-5, 36% GC
receptor,GAAAACAAACCCACAAGGCCTG![text missing or illegible when filed]()
type I
GAT
(SEQ ID NO: 459)
|
M436IL1R2interleukin 1NM_004633CTGGCACCTACGTCTGCACTACT
50 bp, e2-3, 44% GC
receptor,GAAATGCTTCTTACTGTGACAAA![text missing or illegible when filed]()
type I
TG
(SEQ ID NO: 460)
|
M437IL10interleukin 10NM_000572CTTCAGCAGAGTGAAGACTTTCT
50 bp, e1-2, 42% GC
TCAAATGAAGGATCAGCTGGAC![text missing or illegible when filed]()
ACT
(SEQ ID NO: 461)
|
M438IL10RAinterleukin 10NM_001558TACCTGCTATGAAGTGGCGCTC
50 bp, e2-3, 50% GC
receptor, alphaGAGGTATGGAATAGAGTCCTGG![text missing or illegible when filed]()
ACT
(SEQ ID NO: 462)
|
M439IL10RBinterleukin 10NM_000628TTCTCTTCCACAGCACCTGAAA
50 bp, e6-7, 44% GC
receptor, betaGTTTTTGGGCCATCCTCATCATA![text missing or illegible when filed]()
CA
(SEQ ID NO: 463)
|
M440IL11interleukin 11NM_000641GACATGAACTGTGTTTGCCGCCT
40 bp, e1-2, 57% GC
GTCCTGGTCGTGCTGA
(SEQ ID NO: 464)
|
M441IL10RAinterleukin 10NM_004512TATGAGAACTTCTCTTGCACTTG
49 bp, e5, 49% GC
receptor, alphaAGTCCCAGCCAGATCAGCGGTT![text missing or illegible when filed]()
C
(SEQ ID NO: 465)
|
M442IL12interleukin 12AF180562GGCCGTCAGCAACATGCTCCAG
50 bp, e2-3, 50% GC
AGGCCAGACAAACTCTAGAATT![text missing or illegible when filed]()
ACC
(SEQ ID NO: 466)
|
M443IL12RB1interleukin 12NM_005535TGACCCTGCAGCTCTACAACTCA
50 bp, e4-5, 50% GC
receptor, betaTTAAATATGAGCCTCCTCTGGGA![text missing or illegible when filed]()
1A
(SEQ ID NO: 467)
|
M444IL12RB2interleukin 12NM_00155AGTAACAGCAGGCTCTGGAATA
50 bp, e6-7, 42% GC
receptor, betaGGTTAATGTTACAAAGGCCAAA![text missing or illegible when filed]()
2GAAG
(SEQ ID NO: 468)
|
M445IL13interleukin 13NM_002188ATCACCCAGAACCAGAAGGCTC
46 bp, e1-2, 54% GC
GCTCTGCAATGGCAGCATGGTAT![text missing or illegible when filed]()
(SEQ ID NO: 469)
|
M446IL13RA1interleukin 13NM_001560CCAGAATTTGAGAGAAATGTGG
50 bp, e6-7, 42% GC
receptor, alphaGAATACATCTTGTTTCATGGTC![text missing or illegible when filed]()
TGG
(SEQ ID NO: 470)
|
M447IL13RA2interleukin 13NM_000640TGGAGTGATAAACAATGCTGGG
50 bp, e8-9, 40% GC
receptor, alphaAGGTGAAGACCTATCGAAGAAA![text missing or illegible when filed]()
CTTT
(SEQ ID NO: 471)
|
M448IL15interleukin 15NM_000585CATTCATGTCTTCATTTTGGGCT
50 bp, e4-5, 44% GC
TTCAGTGCAGGGCTUCCTAAAA![text missing or illegible when filed]()
G
(SEQ ID NO: 472)
|
M449IL15RAinterleukin 15NM_002189TTCTGGAAAAGAGCCCGCAGCT
47 bp, e3-4, 51% GC
receptor, alphaATCTCCCAGCTCAAACAACACA![text missing or illegible when filed]()
(SEQ ID NO: 473)
|
M450IL2interleukin 2NM_000586ATTTAAGTTTTACATGCCCAAGA
50 bp, e2-3, 40% GC
GGCCACAGAACTGAAACAGCTT![text missing or illegible when filed]()
AGT
(SEQ ID NO: 474)
|
M451IL2RAinterleukin 2NM_000417AACCAATGTCAATGCACAAGCT
50 bp, e2-3, 44% GC
receptor, alphaGCCACTCGGAACACAACGAAA![text missing or illegible when filed]()
AGT
(SEQ ID NO: 475)
|
M452IL2RBinterleukin 2NM_000878AACCTGATCCTCGGAGCCCCAGA
50 bp, e4-5, 50% GC
receptor, betaTCTCAGAAACTGACCACAGTTGA![text missing or illegible when filed]()
AT
(SEQ ID NO: 476)
|
M453IL2RGinterleukin 2NM_000206TGGGAATGAAGACACCACAGCT
50 bp, e1-2, 50% GC
receptor, gammaATTTCTTCCTGACCACTATGCCC![text missing or illegible when filed]()
CTG
(SEQ ID NO: 477)
|
M454IL3interleukin 3NM_000588ATCAGCAATTGAGAGCATTCTTA
50 bp, e3-4, 46% GC
AAATCTCCTGCCATGTCTGCCC![text missing or illegible when filed]()
GG
(SEQ ID NO: 478)
|
M455IL3RAinterleukin 3NM_002183TTGCCAACAGGCGTCAACAGTA
50 bp, 48% GC
receptor, alphaGAGTGTCTTCACTACAAAACGG![text missing or illegible when filed]()
GCT
(SEQ ID NO: 479)
|
M456IL4interleukin 4NM_000589TAACAGACATCTTTGCTGCCTC
50 bp, e2-3, 44% GC
AGAACACAACTGAGAAGGAAA![text missing or illegible when filed]()
TTC
(SEQ ID NO: 480)
|
M457IL4Rinterleukin 4NM_000418TTGGAGTGAAAACGACCCGGCA
50 bp, e5-6, 46% GC
receptorATTTCAGAATCTATAACGTGAC![text missing or illegible when filed]()
ACC
(SEQ ID NO: 481)
|
M458IL5interleukin 5NM_000879TCGAACTCTGCTGATAGCCAAT
50 bp, e1-2, 48% GC
GACTCTGAGGATTCCTGTTCCTG![text missing or illegible when filed]()
AC
(SEQ ID NO: 482)
|
M459IL5RAinterleukin 5NM_000564ACACGCAGTATTTTCTCTACTAT
50 bp, e7-8, 42% GC
receptor, alphaGGTATGGCTCTTGGACTGAAGAA![text missing or illegible when filed]()
GC
(SEQ ID NO: 483)
M460IFNB1interferon,NM_002176AGTGTCTCCTCCAAATTGCTCTC
50 bp, 48% GC
beta fibroblastTGTTGTGCTTCTCCACTACAGCT![text missing or illegible when filed]()
TT
(SEQ ID NO: 484)
|
M461IL6Rinterleukin 6NM_000565TCAAAGACATTCACAACATGGA
50 bp, e5-6, 46% GC
receptorGGTCAAGGACCTCCAGCATCAC![text missing or illegible when filed]()
TGT
(SEQ ID NO: 485)
|
M462IL7interleukin 7NM_000880TAATGGTCAGCATCGATCAATTA
50 bp, e2-3, 38% GC
TGGACAGCATGAAAGAAATTGG![text missing or illegible when filed]()
AGC
(SEQ ID NO: 486)
|
M463IL7Rinterleukin 7NM_002185GGAGAAAGTGGCTATGCTCAAA
50 bp, e1-2, 46% GC
receptorTGGAGACTTGGAAGATGCAGAA![text missing or illegible when filed]()
TGGA
(SEQ ID NO: 487)
|
M464IL8interleukin 8NM_000584CTGATTTCTGCAGCTCTGTGTGA
50 bp, e1-2, 48% GC
GGTGCAGTTTTGCCAAGGAGTG![text missing or illegible when filed]()
AA
(SEQ ID NO: 488)
|
M465IL8RAinterleukin 8NM_000634CTTGGTCAAGTTTGTTTGTCTTG
50 bp, 46% GC
receptor, alphaCTGCTGGGGACTGTCTATGAAT![text missing or illegible when filed]()
GT
(SEQ ID NO: 489)
|
M466IL8RBinterleukin 8NM_001557GGAAGATTTTAACATGGAGAGT
50 bp, 40% GC
receptor, betaACAGCTTTGAAGATTTCTGGAAA![text missing or illegible when filed]()
GTG
(SEQ ID NO: 490)
|
M467IL9interleukin 9NM_000590ACTAAAGAACAACAAGTGTCCA
50 bp, e4-5, 40% GC
ATTTTTCCTGTGAACAGCCATG![text missing or illegible when filed]()
ACC
(SEQ ID NO: 491)
|
M468IL9Rinterleukin 9NM_002186TGTTCAAGCTGTCGCCCAGGGT
46 bp, e8-9, 50% GC
receptorAGAGAATCTTCTAGCAGAACGT![text missing or illegible when filed]()
(SEQ ID NO: 492)
|
M469LIFleukemiaNM_002309TGCCAATGCCCTCTTTATTCTCT
48 bp, e2-3, 53% GC
inhibitoryTACACAGCCCAGGGGGAGCCGT![text missing or illegible when filed]()
factor(SEQ ID NO: 493)
receptor
|
M470LIFRleukemiaNM_002310GGAGCCCTGTGAAGAACATTTCT
50 bp, e6-7, 44% GC
inhibitoryGGATACCTGATTCTCAGACTAA![text missing or illegible when filed]()
factorTT
receptor(SEQ ID NO: 494)
|
M471BLT1leukotriene B4AB008193TCACTAGGTGTAGAGTTCATCT
50 bp, 48% GC
receptorCTGCTGGCTATCATCCTGCTGTC![text missing or illegible when filed]()
GT
(SEQ ID NO: 495)
|
M472BLT2leukotriene B4AB008193TTGGCCTTCTTCAGTTCTAGCGT
44 bp, 52% GC
receptorAACCCGGTGCTCTACGTCTT
(SEQ ID NO: 496)
|
M473CYSLT1cysteinylNM_006639CAGGAAATCTGACAGTATCTTCT
50 bp, 44% GC
leukotrieneCCACATGCCATGACACTATTGAT![text missing or illegible when filed]()
receptor 1AC
(SEQ ID NO: 497)
|
M474LTA4Hleukotriene A4NM_000895TGTGAAATTAACCTATACTGCA
50 bp, e4-5, 44% GC
hydrolaseGGTGTCTGTCCCTAAAGAACTG![text missing or illegible when filed]()
GG
(SEQ ID NO: 498)
|
M475LTC4Sleukotriene C4NM_000897GTCTACCGAGCCCAGGTGAACT
36 bp, e2-3, 58% GC
synthaseAGCGAGTACTTC
(SEQ ID NO: 499)
|
M476LTB4DHNADP depende
XM_088569ATGATGGGGCAGGAAGTGGCCA
50 bp, e4-5, 46% GC
leukotriene b4
AGTTGTGGAAAGTAAAAATGTA![text missing or illegible when filed]()
hydroxydehydro-CCCT
genase(SEQ ID NO: 500)
|
M477SELLselectin LNM_000655TCATCTCCAGAACCAACCTGTCA
50 bp, e5-6, 46% GC
GTGATTCAGTGTGAGCCTCTAT![text missing or illegible when filed]()
GC
(SEQ ID NO: 501)
|
M478SCYC1lymphotactinNM_002995TCTCTCACTGCATACATTGTGGA
50 bp, e1-2, 44% GC
GGTGTAGGGAGTGAAGTCTCAG
also detect SCYC2 =
TAASCYC1?
(SEQ ID NO: 502)
|
M479CCXCR1chemokine (CNM_005283CAAACTCCTCAATATGATCTTCT
50 bp, 44% GC
motif) XCCATCAGCCTCTACAGCAGCATCT![text missing or illegible when filed]()
receptor 1CT
(SEQ ID NO: 503)
|
M480SCYA22 =small inducibleNM_002990TTCAAGCAACTGAGGCAGGCCC
42 bp, e1-2, 58% GC
MDC?cytokineACGGCGCCAACATGGAA
subfamily A(SEQ ID NO: 504)
(C![text missing or illegible when filed]()
Cys),
member 2
|
M481CCR2chemokine (C-
NM_000648AGTGCTTGACTGACATTTACCT
50 bp, 48% GC shoul![text missing or illegible when filed]()
motif) receptorTCAACCTGGCCATCTCTGATCT
detect both isoforms
TTmay also detect CCR
(SEQ ID NO: 505)
|
M482SCYA3small inducibleNM_002983AAGCCCGGTGTCATCTTCCTAA
41 bp, e2-3, 58% GC
cytokine A3AAGCGAAGCCGGCAGGT![text missing or illegible when filed]()
(SEQ ID NO: 506)
|
M483SCYA4small inducibleNM_002984GCTCCCAGCCAGCTGTGGTATT
50 bp, e2-3, 50% GC
cytokine A4AAACCAAAAGAAGCAAGCAAGT![text missing or illegible when filed]()
TGT
(SEQ ID NO: 507)
|
M484AMHanti-MullerianNM_000479AGCCCCGCGGAGAGGACTCCCG
30 bp, e3-4, 70% GC
hormoneCTGAGTA
(SEQ ID NO: 508)
|
M485AMHR2anti-MullerianNM_020547ATGAGGAGCGCTGGCAGAATG
48 bp, e7-8, 52% GC
hormone receptorCAATATAAACCAGGTATTGCCCA![text missing or illegible when filed]()
typeIIC
(SEQ ID NO: 509)
|
M486SCYD1neurotactinNM_002996TGCGGCAAACGCGCAATCATCT
47 bp, e2-3, 55% GC
GAGACGAGACAGCACAGGCTGT![text missing or illegible when filed]()
(SEQ ID NO: 510)
|
M487NRTNneurturinNM_004558TCAGTGCTCTGCAGCTCCGTGCT
40 bp, e1, 57% GC
TCCATCTGGATGTGTC
(SEQ ID NO: 511)
|
M488BMP-8bone morpho-NM_001720AGGTGGTCCAGGAGCAGTCCAA
50 bp, e2-3, 50% GC
geneticAGGGAGTCTGACTTGTTCTTTTT![text missing or illegible when filed]()
protein 8GAT
(SEQ ID NO: 512)
|
M489FAAHfatty acidNM_001441TGCTCTTCACCTATGTGGGAAA
49 bp, e2-3, 51% GC
amide hydrolaseCCTGGGAAGTGAACAAAGGGA![text missing or illegible when filed]()
AA
(SEQ ID NO: 513)
|
M490OSMoncostatin MNM_020530ATCTCATGCAGGACACCAGCAG
50 bp, e2-3, 50% GC
CTCCTGGACCCCTATATACGTAT![text missing or illegible when filed]()
CAA
(SEQ ID NO: 514)
|
M491OSMRoncostatin MNM_003999TCCTTGAGGACTTACCAGAGTGA
50 bp, e2-3, 46% GC
receptorGTCTTGGCTGAACGTTTACCATT![text missing or illegible when filed]()
AC
(SEQ ID NO: 515)
|
M492SCYA5RANTESNM_002985AAGTGCTCCAACCCAGCAGTCG
44 bp, e2-3, 54% GC
TTTGTCACCCGAAAGAACCG
(SEQ ID NO: 516)
|
M493RANTESL10918TGTACTCCTTGGTATTTGTCATT
50 bp, 46% GC
ReceptorGCCTGGTTGGAAACATCCTGGT![text missing or illegible when filed]()
TC
(SEQ ID NO: 517)
|
M494relaxin H1X00949CCTCAGACACCTAGACCAGTGG
50 bp, e1-2, 46% GC
AGAAATTGTACCATCCTTCATCA
should detect also
CAArelaxin H2 (1 bp
(SEQ ID NO: 518)different)
|
M495SDF1stromal cell-XM_165565CTCCAAACTGTGCCCTTCAGATT
50 bp, e2-3, 50% GC
derived factorTAGCCCGGCTGAAGAACAACAA![text missing or illegible when filed]()
1AGA
(SEQ ID NO: 519)
|
M496SDF2stromal cell-NM_006923CTTCACCTCTTTCTGGAAACCA
50 bp, e2-3, 48% GC
derived factorAAGTGAGTGCTTTTGGTGAGGA![text missing or illegible when filed]()
GGT
(SEQ ID NO: 520)
|
M497SDFR1stromal cellXM_015963AGAATGCCAGCAACATGGAGTA
50 bp, e3-4, 48% GC
derived factorAGGATCAATAAGCCGAGAGCTG![text missing or illegible when filed]()
receptor 1GGAT
(SEQ ID NO: 521)
|
M498TGF-alphatransformingM31172TTTTTGGTGCACGAGGACAAGC
48 bp, e2-3, 52% GC
growth factor-GCATGTGTCTGCCATTC TGGGTA![text missing or illegible when filed]()
alpha(SEQ ID NO: 522)
|
M499TGFB1transformingNM_000660GTGCTAATGGTGGAAACCCACA
50 bp, e1-2, 44% GC
growth factor,CGAAATCTATGACAAGTTCAAG![text missing or illegible when filed]()
beta 1AGAG
(SEQ ID NO: 523)
|
M500TGFB2transformingM19154GAAGAACTAGAAGCAAGATTTG
50 bp, e3-4, 42% GC
growth factor,M22045AGGTATTGATGGCACCTCCACAT![text missing or illegible when filed]()
beta 2M22046TAG
(SEQ ID NO: 524)
|
M501TGFB3transformingJ03241GAGGTGATGGAAATCAAATTCA
50 bp, e4-5, 46% GC
growth factor,AGGCGTGGACAATGAGGATGA![text missing or illegible when filed]()
beta 3ATGG
(SEQ ID NO: 525)
|
M502TGFBR1transformingNM_004612ATGACAACGTCAGGTTCTGGCT
50 bp, e3-4, 46% GC
growth factor,GGTTTACCATTGCTTGTTCAGAG![text missing or illegible when filed]()
beta receptorAC
1(SEQ ID NO: 526)
|
M503TGFBR2transformingNM_003242CACAGGAAGTCTGTGTGGCTGTA
50 bp, e2-3, 44% GC
growth factor,GGAGAAAGAATGACGAGAACAT![text missing or illegible when filed]()
beta receptorACA
2(SEQ ID NO: 527)
|
M504TGFBR3transformingNM_003243TGGGGTCTCCAGACTGTTTTTGG
50 bp, e3-4, 50% GC
growth factor,GTCTGAGGGTTCTGTGGTCCAGT![text missing or illegible when filed]()
beta receptorTT
3(SEQ ID NO: 528)
|
M505THPOthrombopoietinNM_000460TTTAGCTTGGGAGAATGGAAAA
50 bp, e3-4, 50% GC
CCAGATGGAGGAGACCAAGGCA![text missing or illegible when filed]()
AGGA
(SEQ ID NO: 529)
|
M506TNFtumor necrosisNM_000594CGAGTGACAAGGCTGTAGCCCA
46 bp, e2-3, 52% GC
TNFSF2factorGTTGTAGCAAACCCTCAAGCTGA![text missing or illegible when filed]()
(SEQ ID NO: 530)
|
M507TNFSF1lymphotoxinNM_000595AAACCTGCTGCTCACCTCATTG
45 bp, e3-4, 53% GC
(LTA)alphaGACCCCAGCAAGCAGAACTCA
(SEQ ID NO: 531)
|
M508TNFSF3lymphotoxinNM_002341CTTAGTGCCCCAGGATCAGGGA
39 bp, e1-2, 59% GC
(LTB)be
GACTGGTAACGGAGAC
(SEQ ID NO: 532)
|
M509TNFSF4tumor necrosisNM_003326TGCCTGCACTTCTCTGCTCTTCA
50 bp, e1-2, 48% GC
factor (ligand)GTATCACATCGGTATCCTCGAAT![text missing or illegible when filed]()
superfamily,CA
member 4(SEQ ID NO: 533)
|
M510TNFSF5tumor necrosisNM_000074GAGGCCAGCAGTAAAACAACAT
50 bp, e2-3, 50% GC
factor (ligand)TGTGTTACAGTGGGCTGAAAAA![text missing or illegible when filed]()
superfamily,GATA
member 5(SEQ ID NO: 534)
|
M511TNFSF6tumor necrosisNM_000639GAGCTGAGGAAAGTGGCCCATT
50 bp, e3-4, 50% GC
factor (ligand)AACAGGCAAGTCCAACTCAAGG![text missing or illegible when filed]()
superfamily,CCAT
member 6(SEQ ID NO: 535)
|
M512TNFSF7tumor necrosisNM_001252TGCAGCTGAATCACACAGGACC
43 bp, e2-3, 55% GC =
factor (ligand)AGCAGGACCCCAGGCTATACD27?
superfamily,(SEQ ID NO: 536)
member 7
|
M513TNFSF8tumor necrosisNM_001244ATTATGGTGTTGGTCGTTCAGA
50 bp, e1-2, 50% GC
factor (ligand)ACGGACTCCATTCCCAACTCAC![text missing or illegible when filed]()
superfamily,GA
member 8(SEQ ID NO: 537)
|
M514TNFSF9tumor necrosisNM_003811AGGGCATGTTTGCGCAGCTGGT
50 bp, e2-3, 50% GC
factor (ligand)CCCAAAATGTTCTGCTGAT
superfamily,(SEQ ID NO: 538)
member 9
|
M515TNFSF10tumor necrosisNM_003810GTACTTTACCAACGAGCTGAAG
50 bp, e1-2, 46% GC
factor (ligand)GATGCAGGACAAGTACTCCAAA![text missing or illegible when filed]()
superfamily,GTG
member 10(SEQ ID NO: 539)
|
M516TNFSF11tumor necrosisNM_003701GCCTTTCAAGGAGCTGTGCAAA
50 bp, e2-3, 42% GC
factor (ligand)GGAATTACAACATATCGTTGGAT![text missing or illegible when filed]()
superfamily,ACA
member 11(SEQ ID NO: 540)
|
M517TNFSF12tumor necrosisNM_003809CTCTACTACCTGTACTGTCAGGT
47 bp, e6-7, 51% GC
factor (ligand)CACTTTGATGAGGGGAAGGCTG![text missing or illegible when filed]()
superfamily,(SEQ ID NO: 541)
member 12
|
M518TNFSF13tumor necrosisNM_003808TGGAGTTTATCTGCTGTATAGC
50 bp, e4-5, 44% GC
factor (ligand)GGTCCTGTTTCAAGACGTGACTT![text missing or illegible when filed]()
superfamily,CA
member 13(SEQ ID NO: 542)
|
M519TNFSF14tumor necrosisNM_003807AGCTGATACAAGAGCGAAGGT
42 bp, e2-3, 54% GC
factor (ligand)CACGAGGTCAACCCAGCAG
superfamily,(SEQ ID NO: 543)
member 14
|
M520TNFSF15tumor necrosisNM_005118TCACCAAGAACCGAATGAACTA
50 bp, 44% GC
factor (ligand)ACCAACAAATTCCTGCTGATCC
may also detect
superfamily,GAGtransmembrane LIGH![text missing or illegible when filed]()
member 15(SEQ ID NO: 544)mRNA (AY028261)
|
M521TNFSF18tumor necrosisNM_005092AAGGAGCCCTGTATGGCTAAGT
50 bp, e2-3, 44% GC
factor (ligand)GGACCATTACCCTCAAAATGGCA![text missing or illegible when filed]()
superfamily,AAT
member 18(SEQ ID NO: 545)
|
M522TNFRSF10Btumor necrosisNM_003842TTTTCTGCTTGCGCTGCACCAGG
50 bp, e2-3, 50% GC
factor receptorGTGATTCAGGTGAAGTGGAGCT![text missing or illegible when filed]()
superfamily,AGT
member 10B(SEQ ID NO: 546)
|
M523TNFRSF11Atumor necrosisXM_036978ACAAATGCAGACCCTGGACCAA
50 bp, e4-5, 50% GC
factor receptorTGTACCTTCCTTGGAAAGAGAGT![text missing or illegible when filed]()
superfamily,GAA
member 11A(SEQ ID NO: 547)
|
M524TNFRSF11Btumor necrosisNM_002546TGGATTTGGAGTGGTGCAAGCT
50 bp, e2-3, 50% GC
factor receptorAACCCCAGAGCGAAATACAGTT![text missing or illegible when filed]()
superfamily,GCA
member 11B(SEQ ID NO: 548)
|
M525TNFRSF12tumor necrosisNM_003790CACACACGGCTACTCTGTTCCC
45 bp, e4-5, 53% GC
factor receptorAGAGATACTGACTGTGGGA
superfamily,(SEQ ID NO: 549)
member 12
|
M526TNFRSF14tumor necrosisNM_003820GTGAAAAGAAGAAAGCCAAGG
50 bp, e6-7, 48% GC
factor receptorTGATGTAGTCAAGGTGATCGTCT![text missing or illegible when filed]()
superfamily,CGT
member 14(SEQ ID NO: 550)
|
M527TNFRSF17tumor necrosisNM_001192CATGTCAGCGTTATTGTAATGCA
50 bp, e1-2, 42% GC
factor receptorGTGTGACCAATTCAGTGAAAGG![text missing or illegible when filed]()
superfamily,ACG
member 17(SEQ ID NO: 551)
|
M528TNFRSF18tumor necrosisNM_004195ACTGCAAACCTTGGACAGACTG
49 bp, e3-4, 51% GC
factor receptorACCCAGTTCGGGTTTCTCACTGT![text missing or illegible when filed]()
superfamily,TT
member 18(SEQ ID NO: 552)
|
M529TNFRSF19tumor necrosisNM_018647GTATTACTAGGCTATTTGTCATG50 bp, e2-3, 38% GC
factor receptorTAAAGTGACTTGTGAATCAGGAG
superfamily,ACTG
member 19(SEQ ID NO: 553)
|
M530TNFRSF21tumor necrosisNM_014452ACTTATGTTCCCAAAGGCATGAA50 bp, e2-3, 44% GC
factor receptorCTCAACAGAATCCAACTCTTCTG
superfamily,CCTC
member 21(SEQ ID NO: 554)
|
M531TNFRSF3tumor necrosisNM_002342ACTGAAGCCGAGCTCAAAGATG50 bp, e4-5, 50% GC
factor receptorAAGTTGGGAAGGGTAACAACCA
superfamily,CTGCGT
member 3(SEQ ID NO: 555)
|
M532TNFRSF4tumor necrosisNM_003327TGCACGTGGTGTAACCTCAGAAG41 bp, e2-3, 56% GC
factor receptorTGGGAGTGAGCGGAAGCA
superfamily,(SEQ ID NO: 556)
member 4
|
M533TNFRSF6tumor necrosisNM_000043AGATTGTGTGATGAAGGACATGG50 bp, e3-4, 44% GC =
factor receptorCTTAGAAGTGGAAATAAACTGCAApo1 antigen?
superfamily,CCCG
member 6(SEQ ID NO: 557)
|
M534TNFRSF6Btumor necrosisNM_003823TCAGCACCAGGGTACCAGGAGC38 bp, e2-3, 60% GC
factor receptorTGAGGAGTGTGAGCGT
superfamily,(SEQ ID NO: 558)
member 6B
|
M535TNFRSF7tumor necrosisNM_001242CATCAACGAAGGAAATATAGAT50 bp, e5-6, 42% GC
factor receptorCAAACAAAGGAGAAAGTCCTGT
superfamily,GGAGCC
member 7(SEQ ID NO: 559)
|
M536TNFRSF8tumor necrosisNM_001243CACGGAGCACACCAATAACAAG50 bp, e9-10,
factor receptorATTGAGAAAATCTACATCATGAA42% GC
superfamily,GGCTG
member 8(SEQ ID NO: 560)
|
M537TNFRSF9tumor necrosisNM_001561TGTGACATATGCAGGCAGTGTAA50 bp, e3-4, 48% GC
factor receptorAGGTGTTTTCAGGACCAGGAAGG
superfamily,AGTG
member 9(SEQ ID NO: 561)
|
M538GAPDglyceraldehyde-NM_002046CCCTTCATTGACCTCAACTACAT50 bp, e2-3, 40% GC
3-phosphateGGTTTACATGTTCCAATATGATT
dehydrogenaseCCAC
(SEQ ID NO: 562)
|
M539CATTGACCTCAACTACATGGTTT40 bp, e2-3, 35% GC
ACATGTTCCAATATGAT
(SEQ ID NO: 563)
|
M540ACCTCAACTACATGGTTTACATGTTCC30 bp, e2-3, 32% GC
AAT
(SEQ ID NO: 564)
|
M541AGTATGACAACAGCCTCAAGATCATC50 bp, e5-6, 50% GC
AGCATGCCTCCTGCACCACCAAC
(SEQ ID NO: 565)
|
M542GACAACAGCCTCAAGATCATCAGCAA40 bp, e5-6, 52% GC
TGCCTCCTGCACCA
(SEQ ID NO: 566)
|
M543CAGCCTCAAGATCATCAGCAAT30 bp, e5-6, 53% GC
GCCTCCTG
(SEQ ID NO: 567)
|
M544AACTTTGGTATCGTGGAAGGACT50 bp, e6-7, 50% GC
CATGACGACAGTCCATGCCATC
ACTGC
(SEQ ID NO: 568)
|
M545ACTBactin, betaNM_001101AGATCACTGCCCTGGCACCCAG50 bp, e4-5, 50% GC
CAATGAAGATCAAGATCATTGC
CT
(SEQ ID NO: 569)
|
M546GCCCTGGCACCCAGCACAATGA40 bp, e4-5, 52% GC
GATCAAGATCATTGCTC
(SEQ ID NO: 570)
|
M547TGGCACCCAGCACAATGAAGAT
30 bp, e2-3, 46% GC
AAGATCA
(SEQ ID NO: 571)
|
M548NegativeNegativeNM_002046ATGACAACAGCCTCAAGATCAT
50 bp, 44% GC
controlcontrolNM_001101AGGAAGATCAAGATCATTGCTC
e5 of GAPD + e5
CCTofACTB
(SEQ ID NO: 572)
|
M549NegativeNegativeNM_002046AACAGCCTCAAGATCATCAGGA
40 bp, 42% GC
controlcontrolNM_001101GATCAAGATCATTGCTCe5 of GAPD + e5
(SEQ ID NO: 573)ofACTB
|
M550NegativeNegativeNM_002046CCTCAAGATCATCAGGAAGATC
30 bp, 40% GC
controlcontrolNM_001101AGATCATe5 of GAPD + e5
(SEQ ID NO: 574)ofACTB
|
M551PTGDSprostaglandinNM_000954AACCTGACCTCCACCTTCCTCAG
50 bp, e2-3, 52% GC
D synthaseAAAAACCAGTGTGAGACCCGAA![text missing or illegible when filed]()
CAT
(SEQ ID NO: 575)
|
M552PTGESprostaglandinNM_004878ACGTGGAACGCTGCCTCAGGGC
42 bp, e2-3, 64% GC
E synthaseCACCGGAACGACATGGAGA
(SEQ ID NO. 576)
|
M553LYSTChediak-Higas
U84744CCTGTCCAAGAAGAAAAGGCAA
50 bp, e4-5, 46% GC
syndrome proteinAGATTTTAACCTACCGCTCTCAG![text missing or illegible when filed]()
short isoAGA
(SEQ ID NO: 577)
|
M554MITFmicrophthalmia
NM_000248AATGCTAGAATATAATCACTAT
50 bp, e1-2, 44% GC
associatedGGTGCAGACCCACCTCGAAAAC![text missing or illegible when filed]()
transcriptionCCA
factor(SEQ ID NO: 578)
|
M555OCA2oculocutaneousNM_000275GTTTGCCTTTGTGGTGCTGTGTT
50 bp, e3-4, 44% GC
albinism IIATTTTGTTCAGCCTATATCCGGA![text missing or illegible when filed]()
C
(SEQ ID NO: 579)
|
M556OMPolfactory marke
NM_006189TGGCCAAGATCCGCAAGGTCAT
46 bp, 54% GC
proteinACTTCCTCGTCACCTTTGGCGA
(SEQ ID NO: 580)
|
M557TRP-2tyrosinase-AJ000503TCTTCCACCGGACCTGCAAGTG
50 bp, e1-2, 50% GC
relatedNM_001922CAGGAAACTTTGCCGGCTATAA![text missing or illegible when filed]()
protein 2GT
(dopachrome(SEQ ID NO: 581)
tautomerase)
|
M558TATTCTGTTAGAGATACATTATT
50 bp, e2-3, 46% GC
GGACCAGGACGCCCCTACAGGG![text missing or illegible when filed]()
CAT
(SEQ ID NO: 582)
|
M559TYRtyrosinaseNM_000372AGCATCATTCTTCTCCTCTTGGC
50 bp, e1-2, 48% GC
GATTGTCTGTAGCCGATTGGAG![text missing or illegible when filed]()
GT
(SEQ ID NO: 583)
|
M560TYRP1tyrosinase-NM_000550GCCTGTGACCAGAGGGTTCTCAT
50 bp, e2-3, 46% GC
relatedGTCAGGAGAAATCTTCTGGACTT![text missing or illegible when filed]()
protein 1AG
(SEQ ID NO: 584)
|
M561PNMTphenylethanola
NM_002686TGCCTCATTTGAGGGCAAGGGGG
41 bp, e2-3, 56% GC
ne N-methyl-ATGCTGGCAGGATAAGGA
transferase(SEQ ID NO: 585)
|
M562HGFhepatocyteD14012GCAGTGCACACAGGAAGTGGTG
50 bp, e4-5, 46% GC
growthGCCACAACTCACAACTACGAC
factor(SEQ ID NO: 586)
|
M563METhepatocyteNM_000245GATCTGTCTGCCTGCAATCTACA
50 bp, e5-6, 46% GC
growthGGTTTTCCCAAATAGTGCACCC![text missing or illegible when filed]()
factorTG
receptor(SEQ ID NO: 587)
|
M564NPYneuropeptideNM_000905ACATCAACCTCATCACCAGGCA
50 bp, e1-2, 50% GC
YAGATATGGAAAACGATCCAGCC![text missing or illegible when filed]()
AGAG
(SEQ ID NO: 588)
|
M565NPY2RneuropeptideNM_000910GCAAAAACGCGAGGTCCAGGT
49 bp, e1-2, 53% GC
Y receptor Y2GTTGTAGACTCTTGTGCTGGTTG![text missing or illegible when filed]()
AG
(SEQ ID NO: 589)
|
M566neuropeptideM84755ATTTATTTGCTACTTCAAGATAT
50 bp, e1-2, 28% GC
y receptorTATACGCCTAAAAAGGAGAAA![text missing or illegible when filed]()
ACA
(SEQ ID NO: 590)
|
M567BDNFbrain-derivedNM_001709TGATAGAAGAGCTGTTGGATGA
50 bp, 44% GC
neurotrophicGACCATAAAGTTCGGCCCAATG![text missing or illegible when filed]()
factorAGAA
(SEQ ID NO: 591)
|
M568NTF3neurotrophin 3NM_002527TTGCCAGAAGACTCGCTCAATT
50 bp, 46% GC
CTCATTATTAAGCTGATCCAGG![text missing or illegible when filed]()
GA
(SEQ ID NO: 592)
|
M569NTF5neurotrophin 5NM_006179TCCGCCAGTACTTCTTTGAAAC
50 bp, e4-5, 46% GC
GCTGCAAGGCTGATAACGGTGA![text missing or illegible when filed]()
GAA
(SEQ ID NO: 593)
|
M570OGFRopioid growthNM_007346TTGAGGAGAATCACTCCTACAT
50 bp, e4-5, 50% GC
factor receptorAGTGGCTGTTTCCTCTGCGAGAA![text missing or illegible when filed]()
CA
(SEQ ID NO: 594)
|
M571OPRD1opioid receptorNM_000911CTTGTCATGTTCGGCATCGTCCG
50 bp, e1-2, 52% GC
delta 1TACACTAAGATGAAGACGGCCA![text missing or illegible when filed]()
CAA
(SEQ ID NO: 595)
|
M572OPRK1opioid receptorNM_000912CGCTGGTCATGTTCGTGATCAT
50 bp, e1-2, 46% GC
kappa 1GATACAGAAAGATGAAGACAG![text missing or illegible when filed]()
ACC
(SEQ ID NO: 596)
|
M573OPRM1opioid receptorNM_000914TCCTGGTCATGTATGTGATTGTC
50 bp, e1-2, 46% GC
mu 1GATACACCAAGATGAAGACTGC![text missing or illegible when filed]()
ACC
(SEQ ID NO: 597)
|
M574VIPR1vasoactiveNM_004624ATGACAAGGCAGCGAGTTTGGA
50 bp, e3-4, 50% GC
intestinalGAGCAGCAGACCATGTITCTACG![text missing or illegible when filed]()
peptideTCT
receptor 1(SEQ ID NO: 598)
|
M575VIPR2vasoactiveXM_036413CAGCGACCCGGAGGATGAGAG
50 bp, e4-5, 50% GC
intestinalAGATCACGTTTTATATTCTGGTG![text missing or illegible when filed]()
peptideAGG
receptor 2(SEQ ID NO: 599)
|
M576AKR1C2aldo-ketoXM_048859ATTTGGCACCTATGCGCCTGCA
50 bp, e1-2, 48% GC
reductaseGGTTCCTAAAAGTAAAGCTCTA
may also detect
family 1,GGAKR1C1, DD1
member C2(SEQ ID NO: 600)
|
M577AKR1C3aldo-ketoNM_003739TCATTCTCCAATGTCTCTAAAG
50 bp, e3-4, 44% GC
reductaseAGGTGAGGAACTTTCACCAACA![text missing or illegible when filed]()
family 1,ATG
member C3(SEQ ID NO: 601)
|
M578CYP8B1cytochrome P4
XM_046266ATGTTTGAATTTCTGAAGCGCAT
50 bp, 46% GC
subfamily VIIII
AGGACCAAGGATGGGGATGTGT![text missing or illegible when filed]()
GAG
(SEQ ID NO: 602)
|
M579EBRPemopamilNM_032565CCATAGTCAAAGAAAAATATTA
50 bp, e3-4, 44% GC
bindingCGGCATTTCCTGCAGATCACCCT![text missing or illegible when filed]()
relatedTGC
protein(SEQ ID NO: 603)
|
M580HSD3Aoxidative 3U89281GGAAGCCTTTTCAGATATTCTGA
50 bp, e1-2, 44% GC
alpha hydroxy-GCGTGAGATTCAACATTTTGGG![text missing or illegible when filed]()
steroidGA
dehydrogenase(SEQ ID NO: 604)
|
M581HSD3B3 Beta-X53321TCTATCATGAATGTCAATGTGAA
50 bp, e2-3, 46% GC
hydroxysteroidGGTACCCAGCTCCTGTTAGAGG![text missing or illegible when filed]()
dehydrogenaseTG
(SEQ ID NO: 605)
|
M582RDHLretinolNM_005771GTGAAGAACCAAGTTGGGGAGA
50 bp, e1-2, 48% GC
dehydrogenaseAGGTCTCTGGGGTCTGATCAATA
will also detect
homologTGChydroxysteroid
(SEQ ID NO: 606)epimerase
(NM_003725)
|
M583sterol/retinolAF057034TGAAGGAGTGCGTGAGAGACAA
50 bp, e1-2; 52% GC
dehydrogenaseGGACTCTGGGGGCTGGTGAATA![text missing or illegible when filed]()
GCT
(SEQ ID NO: 607)
|
M584TAC1tachykinin,NM_003182GGATTAATGGGCAAACGGGATG
50 bp, e3-4, 44% GC
precursor 1TGATTCCTCAATTGAAAAACAA![text missing or illegible when filed]()
GGC
(SEQ ID NO: 608)
|
M585TACR1tachykininNM_001058GAGCAAGTCTCTGCCAAGCGCA
50 bp, e3-4, 50% GC
receptor 1GGTGGTCAAAATGATGATTGTC
will detect both
GGTisoforms
(SEQ ID NO: 609)
|
M586TACR2tachykininNM_001057ATCTACTGCTGTCTCAACCACA
50 bp, e4-5, 54% GC
receptor 2TTTCGCTCTGGGTTCCGGCTTGC![text missing or illegible when filed]()
TT
(SEQ ID NO: 610)
|
M587TACR3TachykininNM_001059TCATCTACTGCTGTCTGAATAAA
50 bp, e4-5, 42% GC
receptor 3GATTTCGAGCTGGCTTCAAGAGA![text missing or illegible when filed]()
CA
(SEQ ID NO: 611)
|
M588TBGthyroxine-M14091GAGGACAATGGTCTGAAACTTT
50 bp, e4-5, 50% GC =
bindingAATGCTGCCCATAAGGCTGTGCT
serine (or cysteine)
globulinCAproteinase inhibitor
(SEQ ID NO: 612)
|
M589TPOthyroidNM_000547CCGCCATGTACGCCACGATGCA
50 bp, e2-3, 50% GC
peroxidaseAGAAACCTCAAGAAAAGAGGAA![text missing or illegible when filed]()
CCTT
(SEQ ID NO: 613)
|
M590CALB2bcalbindin 2NM_007087GCTCCAGGAATACACCCAAACC
50 bp, e5-6, 46% GC
TACTACGGATGTTTGACTTGAA![text missing or illegible when filed]()
GGG
(SEQ ID NO: 614)
|
M591CALB3calbindin 3NM_004057GCTGAATTCCCCAGTTTACTCAA
50 bp, e2-3, 44% GC
GGTCCAAACACCCTAGATGATCT![text missing or illegible when filed]()
TT
(SEQ ID NO: 615)
|
M592NCOA2nuclearNM_006540AAAAACCTGCTGCCAAAGTCTAGG
50 bp, e6-7, 46% GC
receptorGTAAATGGGGGATCTTGGTCTGGAA![text missing or illegible when filed]()
coactivator 2GA
(SEQ ID NO: 616)
|
M593VDRvitamin DNM_000376GTGGACATCGGCATGATGAAGG
50 bp, e3-4, 48% GC
receptorGTTCATTCTGACAGATGAGGAA![text missing or illegible when filed]()
GCA
(SEQ ID NO: 617)
|
M594VDBPvitamin DNM_000583CTCTGAAGATTGCATGGCCAAA
50 bp, e7-8, 46% GC
bindingAGCTGCCTGAACACACAGTAAA![text missing or illegible when filed]()
proteinCTCT
(SEQ ID NO: 618)
|
M595BMP1boneNM_006128TCGTAAGTCCTCCATCAAAGCT
50 bp, e2-3, 50% GC
morphogeneticAGTTCCAGGAAACACTTCTACC![text missing or illegible when filed]()
protein 1CA
(SEQ ID NO: 619)
|
M596BMP10boneNM_014482CATCATTAGGAGTTTCAAGAAT
50 bp, e1-2, 42% GC
morphogeneticAGATCTGTTTTCCCAGCCGGTCA
detects almost all
protein 10TTsplicing variants
(SEQ ID NO: 620)
|
M597BMP11boneAF100907GTCATTAGCATGGCCCAGGAGA
45 bp, e1-2, 55% GC
morphogeneticGGACCCAGCAGTACAGACAGAT![text missing or illegible when filed]()
protein 11(SEQ ID NO: 621)
|
M598BMP15boneNM_005448ACCAGTGTGGCAAGGCCTCACA
47 bp, e1-2, 53% GC
morphogeneticAGGTACCTGGCATATACAGATC![text missing or illegible when filed]()
protein 15(SEQ ID NO: 622)
|
M599BMP2boneNM_00120ACTGTGCGCAGCTTCCACCATGA
50 bp, e2-3, 46% GC
morphogeneticGAATCTTTGGAAGAACTACCAG![text missing or illegible when filed]()
protein 2AAC
(SEQ ID NO: 623)
|
M600BMP3boneNM_001201CAGCTTTCGGGCGGCAGCAGCA
50 bp, e1-2, 48% GC
morphogeneticAAACTCTTGAAAGAAAAGGACT![text missing or illegible when filed]()
protein 3TATA
(SEQ ID NO: 624)
|
M601BMP4boneNM_001202AGCTTCCACCACGAAGAACATC
50 bp, e3-4, 50% GC
morphogeneticGAGAACATCCCAGGGACCAGTG![text missing or illegible when filed]()
protein 4AAA
(SEQ ID NO: 625)
|
M602BMP5BoneNM_021073CAGCTCTGTGCAGAAACAGGGG
50 bp, e1-2, 48% GC
morphogeneticTGGACGCAGTATCAACGTAAAA![text missing or illegible when filed]()
protein 5GTGC
(SEQ ID NO: 626)
|
M603BMP6boneNM_001718ACATGGTCATGAGCTTTGTGAA
50 bp, e1-2, 50% GC
morphogeneticTGGTGGAGTACGACAAGGAGTT![text missing or illegible when filed]()
protein 6TCC
(SEQ ID NO: 627)
|
M604BMP7boneNM_001719ATGGTCATGAGCTTGGTCAACCT
50 bp, e1-2, 46% GC =
morphogeneticGTGGAACATGACAAGGAATTCT
TGF beta?
protein 7CA
(SEQ ID NO: 628)
|
M605BMP8boneNM_001720AGGTGGTCCAGGAGCAGTCCAA
50 bp, e3-4, 50% GC
morphogeneticAGGGAGTCTGACTTGTTCTTTTT![text missing or illegible when filed]()
protein 8GAT
(SEQ ID NO: 629)
|
M606BMP9boneAF188285ATTGTGCGGAGCTFCAGCATGGA
50 bp, e1-2, 50% GC
morphogeneticGATGCCATCTCCATAACTGCCA![text missing or illegible when filed]()
protein 9GA
(SEQ ID NO: 630)
|
M607BMPR1AboneNM_004329AGTGGGTCTGGACTACCTTTATT
50 bp, e8-9, 44% GC
morphogeneticGTTCAGCGAACTATTGCCAAACA![text missing or illegible when filed]()
proteinAT
receptor(SEQ ID NO: 631)
type IA
|
M608BMPR1BboneNM_001203GAAGGCTCAGATTTTCAGTGTC
50 bp, e5-6, 48% GC
morphogeneticGACACTCCCATTCCTCATCAAA![text missing or illegible when filed]()
proteinAG
receptor(SEQ ID NO: 632)
type IB
|
M609BMPR2boneNM_001204TGCTTTGGATACAGAATGTTGA
50 bp, e4-5, 44% GC
morphogeneticGGAGACCGTAAACAAGGTCTTC![text missing or illegible when filed]()
proteinCAG
receptor(SEQ ID NO: 633)
type 2
|
M610GDF1growthNM_001492TCTTCTTTGACAACAGCGACAA
49 bp, e2, 51% GC
differentiationTGGTGCTGCGGCAGTATGAGGA![text missing or illegible when filed]()
factor 1AT
(SEQ ID NO: 634)
|
M611GDF1growthNM_004962CATGTGAGTTCCCCATGCCTAA
48 bp, e3-4, 52% GC
differentiationTCGTTCGTCCATCCAACCATGC![text missing or illegible when filed]()
factor 10(SEQ ID NO: 635)
|
M612GDF3GrowthNM_020634GGAATGTACTTCGCTTTCTCCCA
50 bp, e1-2, 48% GC
differentiationACCAAGGTTTCTTTCTTTACCCA![text missing or illegible when filed]()
factor 3AG
(SEQ ID NO: 636)
|
M613GDF7GrowthNM_000557ACCAGCTTTATTGACAAAGGGC
50 bp, e1-2, 52% GC
differentiationAGATGACCGAGGTCCCGTGGTC![text missing or illegible when filed]()
factor 7GGAA
(SEQ ID NO: 637)
|
M614GDF8GrowthNM_005259CAGGACCAGGAGAAGATGGGCT
50 bp, e2-3, 48% GC
differentiationAATCCGTTTTTAGAGGTCAAGGT![text missing or illegible when filed]()
factor 8ACA
(SEQ ID NO: 638)
|
M615GDF9GrowthNM_005260AAGCAGGCTCCTGGAGACCAGG
48 bp, e1-2, 52% GC
differentiationAACAGGAATCCTTCCATCAGTG![text missing or illegible when filed]()
factor 9A
(SEQ ID NO: 639)
|
M616AQP1aquaporin 1NM_000385TGTAGCCCTTGGACACCTCCTG
50 bp, e2-3, 52% GC
TATTGACTACACTGGCTGTGGGA![text missing or illegible when filed]()
TA
(SEQ ID NO: 640)
|
M617AQP10aquaporin 10NM_080429GGAGCCACCTATGTTCTCTACCA
50 bp, e3-4, 50% GC
GATGCCCTACAGAACTATACAG![text missing or illegible when filed]()
GG
(SEQ ID NO: 641)
|
M618AQP2aquaporin 2NM_000486TGTCGTCACTGGCAAATTTGAT
48 bp, e3-4, 52% GC
CCACTGGGTCTTCTGGATCGGA![text missing or illegible when filed]()
(SEQ ID NO:642)
|
M619AQP3aquaporin 3NM_004925CTGGAATAGTTTTTGGGCTGTAT
50 bp, e3-4, 44% GC
ATGATGCAATCTGGCACTTTGC![text missing or illegible when filed]()
AC
(SEQ ID NO: 643)
|
M620AQP4aquaporin 4NM_001650CAGTTATCATGGGAAATTGGGA
50 bp, e4-5, 48% GC
AACCAUGGATATATTGGGTTG![text missing or illegible when filed]()
CCC
(SEQ ID NO: 644)
|
M621AQP5aquaporin 5NM_001651ACCCTGGGCCACCTTGTCGGAAT
47 bp, e4-5, 55% GC
TACTTCACTGGCTGCTCCATGAA![text missing or illegible when filed]()
(SEQ ID NO: 645)
|
M622AQP6aquaporin 6XM_113241ATCCGAGAGACCCTTGGGATCA
48 bp, e1-2, 54% GC
CGTGGTCCGGAACAGTGTCTCAA![text missing or illegible when filed]()
T
(SEQ ID NO: 646)
|
M623AQP7aquaporin 7NM_001170AGTTCATGAGCACATATGTCAT
50 bp, e3-4, 50% GC
TGGTATTCGGCCTTGGTTCCGTT![text missing or illegible when filed]()
CC
(SEQ ID NO: 647)
|
M624AQP8aquaporin 8NM_001169GCCATCTGATCCTGATGTCTGGA
50 bp, e1-2, 48% GC
AGATAGCCATGTGTGAGCCTGA![text missing or illegible when filed]()
TT
(SEQ ID NO: 648)
|
M625AQP9aquaporin 9NM_020980CGTTCATCTTGATTGTCCTTGGA
50 bp, e1-2, 48% GC
GTGGCTGTGTTGCCCAAGCTATT![text missing or illegible when filed]()
TC
(SEQ ID NO: 649)
|
M626SLC6A1neurotransmitterNM_003042TACCTGTACAACTCCTTCACCA
50 bp, e4-5, 52% GC
transporter,ACACTGCCGTGGAAACAGTGCG![text missing or illegible when filed]()
GABACAA
(SEQ ID NO: 650)
|
M627SLC6A11neurotransmitterNM_014229GGAGGAAAGTTTGCCCTTTATTT
50 bp, e2-3, 46% GC
transporter,AAGGCATTGGCTATGCAACACA![text missing or illegible when filed]()
GABAGTG
(SEQ ID NO: 651)
|
M628SLC6A9neurotransmitterTGGAGGATCAGCCCCATGTTCAA
50 bp, e3-4, 52% GC
transporter 9GGAGTGGGCTATGGTATGATGG![text missing or illegible when filed]()
GGT
(SEQ ID NO: 652)
|
M629SLC6A13neurotransmitterNM_016615TATCTCTGCTACAAAAATGGGG
50 bp, e1-2, 50% GC
transporter,GGTGCCTTCTTCATCCCCTACCT
may detect also
GABAGTSLC6A12
(SEQ ID NO: 653)
|
M630SLC6A14neurotransmitterNM_007231GTTTCTTCAAGTGCAGGGAGAA
50 bp, e1-2, 46% GC
transporterGAGAAAGTGTCGGCTTCATCAG![text missing or illegible when filed]()
GAAT
(SEQ ID NO: 654)
|
M631SLC6A2neurotransmitterNM_001043TGGAAAATCTGCCCATTCTTCAA
50 bp, e2-3, 48% GC
transporter,GGCGTTGGCTATGCTGTCATCCT![text missing or illegible when filed]()
noradrenalinAT
(SEQ ID NO: 655)
|
M632SLC6A3neurotransmitterNM_001044AACAAGTTCACCAACAACTGCTA
50 bp, e7-8, 50% GC
transporter,AGGGACGCGATTGTCACCACCT![text missing or illegible when filed]()
dotamineAT
(SEQ ID NO: 656)
|
M633SLC6A4neurotransmitterNM_001045ACAACAAGTTCAACAACAACTG
50 bp, e6-7, 50% GC
transporter,TACCAAGATGCCCTGGTGACCA![text missing or illegible when filed]()
serotoninGTG
(SEQ ID NO: 657)
|
M634SLC6A5neurotransmitterNM_004211AGACTTCAGGAAAAGTGGTGTA
50 bp, e7-8, 50% GC
transporter,TTCACGGCCACGTTCCCGTATGT![text missing or illegible when filed]()
glycineGTA
(SEQ ID NO: 658)
|
M635SLC6A6neurotransmitterNM_003043ACAAGTACAAGTATAACTCGTA
50 bp, e3-4, 48% GC
transporter,AGGGACTGTATGCTGCTGGGAT![text missing or illegible when filed]()
taurineCTG
(SEQ ID NO: 659)
|
M636SLC6A7neurotransmitterNM_014228CCACCACTTGTTGTCTTCCAAGG
50 bp, e6-7, 48% GC
transporter, L-GTGGATTGAAGCTGCTCTTCAGA![text missing or illegible when filed]()
prolineCT
(SEQ ID NO: 660)
|
M637SLC6A8neurotransmitterNM_005629CGCTTCAACAACAACTGCTACAA
50 bp, e6-7, 50% GC
transporter,GACGCCATCATCCTGGCTCTCAT![text missing or illegible when filed]()
creatineAA
(SEQ ID NO: 661)
|
M638GABBR1gamma-NM_001470CAATACCCGCAGCATTTCCAACA
50 bp, e9-10, 46% GC
aminobutyric a
GACATCCCAGGAATTTGTGGAG![text missing or illegible when filed]()
B receptor, 1AAC
(SEQ ID NO: 662)
|
M639GABRA1gamma-NM_000806TTCTGAGCACACTGACTGGAAGA
50 bp, e2-3, 46% GC
aminobutyric a
AGCTATGGACAGCCGTCATTACA![text missing or illegible when filed]()
A receptor,GAT
alpha 1(SEQ ID NO: 663)
|
M640GABRA2gamma-NM_000807GATAATCGGCTTAGACCAGGAC
50 bp, e3-4, 46% GC
aminobutyric a
GGGAGACAGTATTACTGAAGTC![text missing or illegible when filed]()
A receptor,GAG
alpha 2(SEQ ID NO: 664)
|
M641GABRA3gamma-NM_000808CTGCGACCTGGGCTTGGAGATG
50 bp, e3-4, 52% GC
aminobutyric a
GTGACTGAAGTGAAGACTGACA![text missing or illegible when filed]()
A receptor,CTA
alpha 3(SEQ ID NO: 665)
|
M642GABRA4gamma-NM_000809AGGCTGCGTCCTGGATTTGGGG
50 bp, e2-3, 50% GC
aminobutyric a
CCTGTTACAGAAGTGAAAACTG![text missing or illegible when filed]()
A receptor,CAT
alpha 4(SEQ ID NO: 666)
|
M643GABRA5gamma-NM_000810ACTGAGAACATCAGCACCAGCA
50 bp, e1-2, 48% GC
aminobutyric a
AGGCGAATACACAATCATGACA![text missing or illegible when filed]()
A receptor,CTCA
alpha 5(SEQ ID NO: 667)
|
M644GABRA6gamma-NM_000811ATGGAACCATTTTATACACCAT
50 bp, e4-5, 46% GC
aminobutyric a
GGCTTACCATCAATGGTGACTGT![text missing or illegible when filed]()
A receptor,CC
alpha 6(SEQ ID NO: 668)
|
M645GABRB1gamma-NM_000812TGATGGAACAGTTCTCTATGGA
50 bp, e4-5, 46% GC
aminobutyric a
CCGAATCACAACCACAGCTGCA![text missing or illegible when filed]()
A receptor,GTA
beta(SEQ ID NO: 669)
|
M646GABRB2gamma-XM_011222ACCAAGAAGGTTGTTTTTTCCA
50 bp, e1-2, 48% GC
aminobutyric a
GGTTCCTATCCCAGGTTATCCCT![text missing or illegible when filed]()
A receptor,AG
beta(SEQ ID NO: 670)
|
M647GABRB3gamma-XM_007751GAACTGCACTCTGGAAATTGAA
50 bp, e4-5, 46% GC
aminobutyric a
GCTATGGCTACACCACGGATGA![text missing or illegible when filed]()
A receptor,ATTG
beta(SEQ ID NO: 671)
|
M648GABRDgamma-NM_000815AGCATCGACCACATCTCAGAGG
50 bp, e2-3, 52% GC
aminobutyric a
CAACATGGAGTACACCATGACG![text missing or illegible when filed]()
A receptor,TGTT
delta(SEQ ID NO: 672)
|
M649GABREgamma-NM_004961GGATGGCAAGGTGTTGTACACA
50 bp, e4-5, 48% GC
aminobutyric a
TTAGGATGACCATTGATGCCGGA![text missing or illegible when filed]()
A receptor,GCT
epsilon(SEQ ID NO: 673)
|
M650GABRG2gamma-NM_000816TGGTCGAGTGCTCTACTCCCTAA
50 bp, e4-5, 48% GC
aminobutyric a
GTTGACAATTGATGCTGAGTGC![text missing or illegible when filed]()
A receptor,AT
gamma 2(SEQ ID NO: 674)
|
M651GABRG3gamma-NM_033223AAAAGATGCTACGCCAGCAAGA
50 bp, e6-7, 50% GC
aminobutyric a
CAGCATTAGGCATCACCACGGT![text missing or illegible when filed]()
A receptor,TGA
gamma 3(SEQ ID NO: 675)
|
M652GABRPgamma-XM_003708AATTTCTCAGGCCCAATTTTGGT
50 bp, e3-4, 48% GC
aminobutyric a
GAGAACCCGTACAGATAGCGCT![text missing or illegible when filed]()
A receptor, piACT
(SEQ ID NO: 676)
|
M653GABRR1gamma-NM_002042ATGAAGATGCCCACAAGCAAGT
50 bp, e2-3, 50% GC
aminobutyric a
AGCCCAATTCTGAGACGAAGTC![text missing or illegible when filed]()
A receptor, rhoGAC
(SEQ ID NO: 677)
|
M654GABR2gamma-NM_002043CAGACCTGTTCTTTGGAGCTGGA
50 bp, e1-2, 48% GC
aminobutyric a
AGCTATGCCTATACAGATGAAG![text missing or illegible when filed]()
A receptor, rhoCT
(SEQ ID NO: 678)
|
M655CRH-R1GGGCCCCATGATCCTGGTCCTG
50 bp, e10-11, 48% G![text missing or illegible when filed]()
GATCAATTTCATCTTCCTTTTCAA![text missing or illegible when filed]()
A
(SEQ ID NO: 679)
|
M656CCATGATCCTGGTCCTGCTGAT
40 bp, e1-2, 42% GC
ATTTCATCTTCCTTTT
(SEQ ID NO: 680)
|
M657ATCCTGGTCCTGCTGATCAATTT
30 bp, e1-2, 42% GC
ATCTTC
(SEQ ID NO: 681)
|
M658InsulinAGCTGGAGAACTACTGCAACTA
40 bp
ACGCAGCCCGCAGGCAG
(SEQ ID NO: 682)
|
M659InsulinCACCACTTCTTCTGACATGTGGT
45 bp
receptorCTTTGGCGTGGTCCTTTGGGA
(SEQ ID NO: 683)
|
M660InsulinTGTCACAAGCACCAGCCTTGCCA
45 bp
degradi
AACCTGAAGTGATTCAGAACA
enzyme(SEQ ID NO: 684)
|
M661ProenkephalinGCCGACATCAACTTCCTGGCTT
45 bp
GTAATGGAATGTGAAGGTAAA
(SEQ ID NO: 685)
|
M662PituitaryGGATCAGGCCAGAGGAAGAGG
40 bp
adenylate cycla
TACGGCGAGGACGGAAA
activating(SEQ ID NO: 686)
peptide
|
M663PituitaryGCAACCACTGCTTCATCTCCACT
45 bp Detects recepto![text missing or illegible when filed]()
adenylate cycla
TGGAATGTAAGGCCGTCATGGA, B, B2, C
activating(SEQ ID NO: 687)
peptide
recetor A
|
M664PC1PC1 (NEC1M90753AGAAGATGGTGGATCCAGGGGA
45 bp
GAGCAGCCCACACAAGAGAAC![text missing or illegible when filed]()
(SEQ ID NO: 688)
|
M665PC2proproteinNM_002594AGGAAAAGGAACCCCGAGGCC![text missing or illegible when filed]()
convertaseTGTGGCAACCACAGATTTGTAC
subtilisin/kexin(SEQ ID NO: 689)
type 2
|
M666polypeptide 7BY00757GAAGGGAGGAGAGAGACGAAA![text missing or illegible when filed]()
CGGAGGAGTGTCAATCCATATC![text missing or illegible when filed]()
(SEQ ID NO: 690)
|
M667COL14Acollagen, typeXM_044622CAGTGTTTATACAAAGCTCCAG
50 bp, 42% GC
XIV, alpha 1GATTGAAGGACCTAGTGTGAGC![text missing or illegible when filed]()
TAA
(SEQ ID NO: 691)
|
M668COL1A1collagen, typeNM_000088ATGCCATCAAAGTCTTCTGCAA
50 bp, 50% GC
I alpha 1TGGAGACTGGTGAGACCTGCGT![text missing or illegible when filed]()
AC
(SEQ ID NO: 692)
|
M669COL1A2collagen, typeNM_000089TGAACTTGTTGCTGAGGGCAACA
50 bp, 46% GC
I alpha 2CAGGTTCACTTACACTGTTCTTG![text missing or illegible when filed]()
AG
(SEQ ID NO: 693)
|
M670COL3A1collagen, typeNM_000090GTAGATATTGCACCCTATGACAT
50 bp, 42% GC; dete![text missing or illegible when filed]()
I alpha 1GGTGGTCCTGATCAAGAATTTG
also COL5A2
GT
(SEQ ID NO: 694)
|
M671COL5A1collagen, type
NM_000093GGACATCATGTTCAATGACTTC
50 bp, 42% GC
alpha 1TGAAGCGTCACAGAAATTTGGA![text missing or illegible when filed]()
TG
(SEQ ID NO: 695)
|
M672COL7A1collagen, typeNM_000094AGTATTCTGTGGAGGAGTACCA
50 bp, 50% GC
VII, alpha 1GACCCTGAAGCTCCTTGGGATA![text missing or illegible when filed]()
GAT
(SEQ ID NO: 696)
|
M673FN1fibronectin 1NM_002026TGAGTGCTTCATGCCTTTAGATG![text missing or illegible when filed]()
ACAGGCTGACAGAGAAGATTCC![text missing or illegible when filed]()
GAG
(SEQ ID NO: 697)
|
M674LAMA2laminin,NM_000426ATCAGATCCCTGAAGCTCACCAA![text missing or illegible when filed]()
alpha 2GGCACAGCAAGCCACTGGAGGT![text missing or illegible when filed]()
(merosin)AAT
(SEQ ID NO: 698)
|
M675LAMB2laminin,NM_002292GACCAGCATCTTGACTTGCTCAA![text missing or illegible when filed]()
beta 2CATTCAAACTTCCTGGGTGCCTA![text missing or illegible when filed]()
GA
(SEQ ID NO: 699)
|
M676LAMB3laminin,NM_000228GATTGGGTTGGAATGCTTTCCAT![text missing or illegible when filed]()
beta 3TCCAGGAGACTTTCATGCAGCCT![text missing or illegible when filed]()
AA
(SEQ ID NO: 700)
|
M677LAMC2laminin,NM_018891TTACAATCCAAGACACACTCAA![text missing or illegible when filed]()
gammaCATTAGACGGCCTCCTGCATCT![text missing or illegible when filed]()
TG
(SEQ ID NO: 701)
|
M678LOXlysylNM_002317GACTATACCAACAATGTTGTGC![text missing or illegible when filed]()
oxidaseTGTGACATTCGCTACACAGGACA![text missing or illegible when filed]()
CA
(SEQ ID NO: 702)
|
M679MMP1interstitialNM_002421ATCTACAGCTCCTTTGGCTTCCC![text missing or illegible when filed]()
collagenaseAGAACTGTGAAGCATATCGATG![text missing or illegible when filed]()
GC
(SEQ ID NO: 703)
|
M680MMP10stromelysin 2NM_002425TCAGTGGATCATCACAGTTTGA![text missing or illegible when filed]()
TTGACCCCAATGCCAGGATGGT![text missing or illegible when filed]()
CA
(SEQ ID NO: 704)
|
M681MMP11stromelysin 3NM_005940CCTCTACTGGAAGTTTGACCCT![text missing or illegible when filed]()
GAAGGTGAAGGCTCTGGAAGG![text missing or illegible when filed]()
T
(SEQ ID NO: 705)
|
M682MMP3stromelysin 1NM_002422AGGAAATCAATTCTGGGCCATC![text missing or illegible when filed]()
GAGGAAATGAGGTACGAGCTG![text missing or illegible when filed]()
TACC
(SEQ ID NO: 706)
|
M683MMP9gelatinase BNM_004994AGTGAGTTGAACCAGGTGGACC![text missing or illegible when filed]()
AGTGGGCTACGTGACCTATGAC![text missing or illegible when filed]()
(SEQ ID NO: 707)
|
M684PLODlysineNM_000302AGAACGTGCCGACTATTGACAT![text missing or illegible when filed]()
hydroxylaseACATGAACCAGATCGGCTTTGA![text missing or illegible when filed]()
(SEQ ID NO: 708)
|
M685prolyl 4-X05130AGGAGCCAGACATGGAGGAAGA![text missing or illegible when filed]()
hydoxylaseGATGACCAGAAAGCTGTGAAAG![text missing or illegible when filed]()
beta subunitTGAA
(SEQ ID NO: 709)
|
M686prolyl 4-U12762GTCTTCACTGAGGCCAAGTCTA![text missing or illegible when filed]()
hydroxylaseATTCTGCCCACCAAGAATGATG![text missing or illegible when filed]()
alphaCT
subunit(SEQ ID NO: 710)
|
M687TNXBtenascin XBNM_019105ACTATGCCCATGGTTTTGGGAA![text missing or illegible when filed]()
TCTCTGGAGAGTTCTGGCTGGG![text missing or illegible when filed]()
AT
(SEQ ID NO: 711)
|
M688VTNvitronectinNM_000638CTTCTTCTTCTCTGGAGACAAGT![text missing or illegible when filed]()
CTACCGAGTCAATCTTCGCACA![text missing or illegible when filed]()
GC
(SEQ ID NO: 712)
|
M689FLGfilaggrinXM_048104ATCATCCCATGAACAGGCAAGA![text missing or illegible when filed]()
CAAGTGCAGGAGAGAGACATG![text missing or illegible when filed]()
TCCC
(SEQ ID NO: 713)
|
M690IVLinvolucrinNM_005547AGAGCAGCAGGTAGGACAGCCA![text missing or illegible when filed]()
AGCACCTGGAACAGCAGGAAA![text missing or illegible when filed]()
CA
(SEQ ID NO: 714)
|
M691KRT1keratin 1NM_006121CAGTTCCAGCGTGAGGTTTGTTT![text missing or illegible when filed]()
TACCACTTATTCCGGAGTAACCA![text missing or illegible when filed]()
AT
(SEQ ID NO: 715)
|
M692KRT10keratin 10NM_000421CTGAAACCGAGTGCCAGAATAC![text missing or illegible when filed]()
GAATACCAACAACTCACGGATA![text missing or illegible when filed]()
AAG
(SEQ ID NO: 716)
|
M693KRT14keratin 14NM_000526TGACCAGTATGAGAAGATGGCA![text missing or illegible when filed]()
AGAAGAACCGCAAGGATGCCGA![text missing or illegible when filed]()
GAAT
(SEQ ID NO: 717)
|
M694KRT17keratin 17NM_000422GAGATGCGTGACCAGTATGAGA![text missing or illegible when filed]()
GATGGCAGAGAAGAACCGCAA![text missing or illegible when filed]()
ATG
(SEQ ID NO: 718)
|
M695KRT19keratin 19NM_002276TGCTCGAGGGACAGGAAGATCA![text missing or illegible when filed]()
TACAACAATTTGTCTGCCTCCAA![text missing or illegible when filed]()
GTC
(SEQ ID NO: 719)
|
M696KRT5keratin 5NM_000424GAAGAGCTTCAAGAGCTAAGAA![text missing or illegible when filed]()
CTGCTGCAAGTCACTGCCTTCCA![text missing or illegible when filed]()
GTG
(SEQ ID NO: 720)
|
M697KRTHA5keratin,NM_002280TGGAGATTGAGCTGCAGGCTCA![text missing or illegible when filed]()
hair,CACAGCATGAGAGATGCTTTGG![text missing or illegible when filed]()
acidic, 5AT
(SEQ ID NO: 721)
|
M698KRTHB5keratin,NM_002283ATCACTGCACTGAATGGCATGT![text missing or illegible when filed]()
hair,ATGGAAAATGTGTGCTTGCTTC![text missing or illegible when filed]()
basic, 5GA
(SEQ ID NO: 722)
|
M699LORloricrinNM_000427TGCAAATCCTTCATGTCTTAAC![text missing or illegible when filed]()
ACCTGGAAGAAGCCATTGAGCT![text missing or illegible when filed]()
CC
(SEQ ID NO: 723)
|
M700TGMItransgluta-NM_000359ACAGTGAAACTGCACCTCTACCT![text missing or illegible when filed]()
minase 1TCAGTCACTTTCTATACTGGTGT![text missing or illegible when filed]()
AG
(SEQ ID NO: 724)
|
M701TGM2transgluta-NM_004613TCCTCTTTGCATCCTCTATGAGA![text missing or illegible when filed]()
minase 2ATACCGTGACTGCCTTACGGAGT![text missing or illegible when filed]()
CA
(SEQ ID NO: 725)
|
M702TGM3transgluta-NM_003245AAGAGGCAGAACATCCCATAAA![text missing or illegible when filed]()
minase 3ATCTCGTACGCTCAGTATGAGA![text missing or illegible when filed]()
TAG
(SEQ ID NO: 726)
|
M703THHtrichohyalinNM_007113CTTAAGTGATGTTGCCAATATCT![text missing or illegible when filed]()
GACACCTGCCAAAGCTTCCAGCA![text missing or illegible when filed]()
GG
(SEQ ID NO: 727)
|
M704TRHYtrichohyalinL09190CAATACCGCCCTTAAGTGATGTT![text missing or illegible when filed]()
CCAATATCTTGACACCTGCCAAA![text missing or illegible when filed]()
CT
(SEQ ID NO: 728)
|
M705agoutiU12770TATATAGGCTGCTCGAAGGTGT![text missing or illegible when filed]()
GGCTGTTTCTGTAAAGGTCCCGA![text missing or illegible when filed]()
AG
(SEQ ID NO: 729)
|
M706AGRPagoutiNM_001138TTCTTCAATGCCTTCTGCTACTG![text missing or illegible when filed]()
relatedGCAAGCTGGGTACTGCCATGAA![text missing or illegible when filed]()
protein(SEQ ID NO: 730)
|
M707CCScopperNM_005125CAGAATGGAGGATGAGCAGCTG![text missing or illegible when filed]()
chapero
AGGTGTGGGATGTGATTGG
for super-(SEQ ID NO: 731)
oxide
dismutase
|
M708GCH1GTPNM_000161GCTACCAGGAGACCATCTCAGA![text missing or illegible when filed]()
cyclo-GTCCTAAACGATGCTATATTTGA![text missing or illegible when filed]()
hydrolaseGAA
(SEQ ID NO: 732)
|
M709GGT1gamma-NM_005265ACAACCAGCTTCTGCCCAACGT![text missing or illegible when filed]()
glutamyl-CGACAGTGGAGAGAAACATTGA![text missing or illegible when filed]()
transferase 1CA
(SEQ ID NO: 733)
|
M710GSRglutathioneNM_000637CAGTGAAGATGGGAGCAACGAA![text missing or illegible when filed]()
reductaseGCAGACTTTGACAACACAGTCG![text missing or illegible when filed]()
ATT
(SEQ ID NO: 734)
|
M711LAMP1lysosomal-NM_005561CAAGGAATCCAGTTGAATACAA![text missing or illegible when filed]()
associatedCTTCCTGACGCCAGAGACCCTG![text missing or illegible when filed]()
membraneTT
protein 1(SEQ ID NO: 735)
|
M712Pmel17S73003GCAGGTCTGAGTACTCTCATAT![text missing or illegible when filed]()
TGCTGTGATTTTCCTGGAGTTGA![text missing or illegible when filed]()
AG
(SEQ ID NO: 736)
|
M713TXNRD1thioredoxinNM_003330TCAGAGGCTCTATGCAGGTTCCA![text missing or illegible when filed]()
reductase 1TGTCAAGTGTGACTATGAAAAT![text missing or illegible when filed]()
TC
(SEQ ID NO: 737)
|
M714TXNRD2thioredoxinNM_006440GCGAAGTTACTCAAGGATTTGCT![text missing or illegible when filed]()
reductase 2TGGGGATCAAGTGTGGGGCTTC![text missing or illegible when filed]()
AT
(SEQ ID NO: 738)
|
M715BMAL1aD89722CAACGACCAAGGATCAAGTAGT![text missing or illegible when filed]()
CCAGTAATGATGAGGCAGCAAT![text missing or illegible when filed]()
GCTG
(SEQ ID NO: 739)
|
M716CLOCKclockNM_+ AF8-ACAACAGCAACAGTCACAGACA![text missing or illegible when filed]()
homolog004898TGTCAGTAACGCAGCAGCAGCA![text missing or illegible when filed]()
CAG
(SEQ ID NO: 740)
|
M717CRY1cryptochromeNM_004075CTATCAGCAGCTTTCACGATATA![text missing or illegible when filed]()
1AGGACTAGGTCTTCTGGCATCA![text missing or illegible when filed]()
AC
(SEQ ID NO: 741)
|
M718CRY2cryptochromeXM_051030TATGGCGAGAGTTCTTCTACAC![text missing or illegible when filed]()
2CAGCTACCAACAACCCCAGGTTT![text missing or illegible when filed]()
A
(SEQ ID NO: 742)
|
M719CYP39A1cytochrome P4
NM_016593TGAATATAAACAAAGAATATGA![text missing or illegible when filed]()
subfamilyATCTGTTGGGCCTCACAAGGAC![text missing or illegible when filed]()
XXXIXGGG
(oxysterol 7(SEQ ID NO: 743)
alpha-
hydroxylase),
polypeptide 1
|
M720CYP7A1cholesterolNM_000780ATCCGGACAGCTAAGGAGGATT![text missing or illegible when filed]()
7alpha-CACTTTGCACCTTGAGGACGGTT![text missing or illegible when filed]()
monooxygenaseCTA
(SEQ ID NO: 744)
|
M721CYP7B1oxysterol 7NM_004820CCTACATGGTGACCCTGAAATCT![text missing or illegible when filed]()
alphaTGAAGCTCCAGAGGAGTTTAGA![text missing or illegible when filed]()
hydroxylaseATG
(SEQ ID NO: 745)
|
M722DHCR77-dehydro-NM_001360TGCAGGCCATCTACGTGATTGA![text missing or illegible when filed]()
cholesterolTCTTCTGGAACGAAACCTGGTA![text missing or illegible when filed]()
reductaseTG
(SEQ ID NO: 746)
|
M723PAHphenylalanineNM_000277GCCTCTCTGGGTGCACCTGATGA![text missing or illegible when filed]()
hydroxylaseTACATTGAAAAGCTCGCCACAA![text missing or illegible when filed]()
TA
(SEQ ID NO: 747)
|
M724PER1periodNM_002616CAGTCCAGCCTTACCTACAGCA![text missing or illegible when filed]()
homologAAACTGCACCAGCTAGACTCCA![text missing or illegible when filed]()
CT
(SEQ ID NO: 748)
|
M725PER2periodNM_022817CCTTCTCTGGGACTCAGCGAAGT![text missing or illegible when filed]()
homologTCGGACACCAAAGAAGACGAAA![text missing or illegible when filed]()
TGG
(SEQ ID NO: 749)
|
M726PER3periodNM_+ AF8-CTCATGGGCAAAAGGAGGAGCT![text missing or illegible when filed]()
homolog016831GCTAAGGTGTATAATTGGATTCA![text missing or illegible when filed]()
AGC
(SEQ ID NO: 750)
|
M727THtyrosineNM_000360CTACCAAGACCAGACGTACCAG![text missing or illegible when filed]()
hydroxylaseCAGTCTACTTCGTGTCTGAGAG![text missing or illegible when filed]()
TCA
(SEQ ID NO: 751)
|
M728GSTA1glutathioneNM_145740ACCAGAGCCATTCTCAACTACAT![text missing or illegible when filed]()
S-transferaseGCCAGCAAATACAACCTCTATG![text missing or illegible when filed]()
A1GAA
(SEQ ID NO: 752)
|
M729GSTA2glutathioneNM_000846TGAAAACCAGAATCAGTAACCT![text missing or illegible when filed]()
S-transferaseCCCACAGTGAAGAAGTTTCTACA![text missing or illegible when filed]()
A2CCT
(SEQ ID NO: 753)
|
M730GSTA3glutathioneNM_000847CATTGCCAGCAAATACAACCTCT![text missing or illegible when filed]()
S-transferaseCGGGAAAGACATAAAGGAGAGA![text missing or illegible when filed]()
A3CCC
(SEQ ID NO: 754)
|
M731GSTA4glutathioneNM_001512CAGACCCGAAGCATTCTCCACTA![text missing or illegible when filed]()
S-transferaseATAGCAGACAAGCACAATCTCT![text missing or illegible when filed]()
A4GG
(SEQ ID NO: 755)
|
M732GSTM1glutathioneNM_000561AGTACTTGGAGGAACTCCCTGAA![text missing or illegible when filed]()
S-transferaseAAGCTAAAGCTCTACTCAGAGTT![text missing or illegible when filed]()
M1CTG
(SEQ ID NO: 756)
|
M733GSTM3glutathioneNM_000849AGCTCTGACCACGAAAAACTGA![text missing or illegible when filed]()
S-transferaseGCCTCAGTACTTGGAAGAGCTA![text missing or illegible when filed]()
M3 (brain)TGG
(SEQ ID NO: 757)
|
M734GSTM4glutathioneNM_000850GCCAGAATACTTGGAGGAACTT![text missing or illegible when filed]()
S-transferaseTACAATGATGCAGCACTTCTCA![text missing or illegible when filed]()
M4GT
(SEQ ID NO: 758)
|
M735GSTM5glutathioneNM_000851TTTCCTTGCCTATGATGTCCTTGA![text missing or illegible when filed]()
S-transferaseATGAAGCGTATATTITGAGCCCAA![text missing or illegible when filed]()
M5T
(SEQ ID NO: 759)
|
M736GSTP1glutathioneNM_000852GCTGCTGATCCATGAGGTCCTA![text missing or illegible when filed]()
S-transferaseCCCTGGCTGCCTGGATGCGTT
pi(SEQ ID NO: 760)
|
M737GSTT1glutathioneNM_000853AAACCTCACCCTTGCACCGTCCT![text missing or illegible when filed]()
S-transferaseAGCAGTCCACAAAGCATTTTCAT![text missing or illegible when filed]()
thetaTC
(SEQ ID NO: 761)
|
M738GSTZ1glutathioneNM_145870CATATACTGTGTAGGAGACGAG![text missing or illegible when filed]()
transferaseTGACCATGGCTGATCTGTGCTT![text missing or illegible when filed]()
zetaT
(SEQ ID NO: 762)
|
M739MGST1microsomalNM_145792GGAGTTACTCTTTCCATGGCTTA![text missing or illegible when filed]()
glutathioneAGGTTGCTGAAAAGTAAATTGTA![text missing or illegible when filed]()
S-transferaseCT
1(SEQ ID NO: 763)
|
M740MGST2microsomalNM_002413CCAAGAAACTGAGGCGGCAATT![text missing or illegible when filed]()
glutathioneTAACTTTTTCTCTTCCCTTTAAT![text missing or illegible when filed]()
S-transferaseTT
2(SEQ ID NO: 764)
|
M741MGST3microsomalNM_004528AAGTACAAAGTGGAGTATCCTA![text missing or illegible when filed]()
glutathioneATGTACAGCACGGACCCTGAAA![text missing or illegible when filed]()
S-transferaseTGG
3(SEQ ID NO: 765)
|
M742AKR1A1Ido-ketoNM_153326ATCTGCATCCCCAAAAGTATCA![text missing or illegible when filed]()
reductaCCTTCTCGAATCCTTCAGAACAT![text missing or illegible when filed]()
family 1,AA
member A1(SEQ ID NO: 766)
|
M743ALDH1AaldehydeNM_000689TGGTGGATTCAAGATGTCTGGAA![text missing or illegible when filed]()
dehydrogenaseTGGAAGAGAACTGGGAGAGTA![text missing or illegible when filed]()
family,GTT
member A1(SEQ ID NO: 767)
|
M744ALDH1AaldehydeNM_170697AAGCTGGGACTGTTTGGATCAAT![text missing or illegible when filed]()
dehydrogenaseGTTACAATGCCTTAAATGCCCA![text missing or illegible when filed]()
family,GC
member A2(SEQ ID NO: 768)
|
M745ALDH1AaldehydeNM_000693CAACATGCGGATTGCCAAAGAG![text missing or illegible when filed]()
dehydrogenaseAGATTTTCGGGCCAGTGCAACCA![text missing or illegible when filed]()
family,TAC
member A3(SEQ ID NO: 769)
|
M746ALDH1BaldehydeNM_000692AGAGGTAAAGACGGTCACCATC![text missing or illegible when filed]()
dehydrogenaseAGGTTCCTCAGAAGAACTCGTAA![text missing or illegible when filed]()
family,GAGC
member B1(SEQ ID NO: 770)
|
M747ALDH2aldehydeNM_000690GTCAAAGTGCCTCAGAAGAACT![text missing or illegible when filed]()
dehydrogenaseATAAGAATCATGCAAGCTTCCT![text missing or illegible when filed]()
familyCTC
(SEQ ID NO: 771)
|
M748ALDH3AaldehydeNM_000691CCTCTACATGTTCTCCAGCAAC![text missing or illegible when filed]()
dehydrogenaseCAAGGTGATTAAGAAGATGATT![text missing or illegible when filed]()
family,CAG
member A1(SEQ ID NO: 772)
|
M749ALDH3AaldehydeNM_000382GAATGATCCTGTTCAACCTCCTA![text missing or illegible when filed]()
dehydrogenaseTGCCTCTACTGAATTATTCCTCT![text missing or illegible when filed]()
family,T
member A2(SEQ ID NO. 773)
|
M750ALDH4AaldehydeNM_003748ATGCTGCCGGCAACTTCTACAT![text missing or illegible when filed]()
dehydrogenaseACGACAAGTCCACTGGCTCGATA![text missing or illegible when filed]()
family,GTG
member A1(SEQ ID NO: 774)
|
M751ALDH5AaldehydeNM_170740ATGCTGTGCACTCATGAAGAGA![text missing or illegible when filed]()
dehydrogenaseTTCGGGCCTCTGGCACCAGTTAT![text missing or illegible when filed]()
family,AA
member A1(SEQ ID NO: 775)
|
M752ALDH6AaldehydeNM_005589AGGGCATCCAATFCTACACTCA![text missing or illegible when filed]()
dehydrogenaseTAAAGACCATTACTTCTCAGTG![text missing or illegible when filed]()
family,AA
member A1(SEQ ID NO: 776)
|
M753ALDH7AaldehydeNM_001182CTTGGACCTAAAGGATCAGACT![text missing or illegible when filed]()
dehydrogenaseGGCATTGTAAATGTCAACATTC![text missing or illegible when filed]()
family,AC
member A1(SEQ ID NO: 777)
|
M754ALDH8AaldehydeNM_022568CTGGAATAGGTAGAGAGGGAG![text missing or illegible when filed]()
dehydrogenaseAAGGACTCTTACGACTTCTTCA![text missing or illegible when filed]()
family,GAG
member A1(SEQ ID NO: 778)
|
M755ALDH9AaldehydeNM_000696TAGCTGAGCTTCAGGCTGGGAC![text missing or illegible when filed]()
dehydrogenaseGCTTCATTAACAACTATAACGT![text missing or illegible when filed]()
family,GC
member A1(SEQ ID NO: 779)
|
M756GPX1glutathioneNM_000581TACGAGGGAGGAACACCTTGAT![text missing or illegible when filed]()
peroxidase 1TTACAGAAAATACCACCTCGAG![text missing or illegible when filed]()
GGG
(SEQ ID NO: 780)
|
M757GPX2glutathioneNM_002083AATGAGGAGATCCTGAACAGTC![text missing or illegible when filed]()
peroxidase 2CAAGTATGTCCGTCCTGGGGGT![text missing or illegible when filed]()
ATA
(SEQ ID NO: 781)
|
M758GPX3glutathioneNM_002084CAACCAATTTGGAAAACAGGAA![text missing or illegible when filed]()
peroxidase 3CAGGAGAGAACTCAGAGATCCT![text missing or illegible when filed]()
CCTA
(SEQ ID NO: 782)
|
M759GPX4glutathioneNM_002085TGTAACCAGTTCGGGAAGCAGG![text missing or illegible when filed]()
peroxidase 4GCCAGGGAGTAACGAAGAGAT![text missing or illegible when filed]()
AAGA
(SEQ ID NO: 783)
|
M760GPX5glutathioneNM_001509CTGAACTAAATGCACTCCAGGA![text missing or illegible when filed]()
peroxidase 5GAGCTGAAGCCCTATGGTCTAGT![text missing or illegible when filed]()
GTG
(SEQ ID NO: 784)
|
M761GPX6glutathioneNM_015696ACCTACAGTGTCTCATTCCCCAT![text missing or illegible when filed]()
peroxidase 6TTTAGCAAGATTGCAGTCACCG![text missing or illegible when filed]()
AC
(SEQ ID NO: 785)
|
EXAMPLE 10
Analysis of Gene Expression
The molecular chip showed distinctive skin patterns of transcriptional expression of functional neuro-endocrine-immune and barrier forming pathways after ultraviolet light exposure. The full list of differentially expressed genes is presented in Table 2, classified into several major functionally-related groups: water and salt balance; prostaglandin metabolism; interleukins and growth factors; metalloproteinases; markers of keratinocyte differentiation and stress response. Genes from the same group that were similarly expressed presumably reflected a highly coordinated keratinocyte response to UV, which indicated genetic regulation. Each gene had a unique time response that was classified as early, when the maximum induction of expression had occurred by 4 h after treatment. A late response group was defined by expression maximum occurring at 24 h after irradiation.
EXAMPLE 11
Genes Involved in Water and Salt Balance
Up-regulation of gastrin, vasopressin and aquaporin genes was detected. All these genes are involved in the regulation of water and salt balance (Table 2, FIG. 2). The highest stimulation was observed at 12 to 24 h post-irradiation. Vasopressin is highly relevant to water metabolism by being involved in water resorption in the kidneys. Other genes related to water balance are those coding for aquaporin water channels (AQP). Aquaporins are a family of membrane proteins that facilitate water movement across biological membranes; they are important for osmotic water movement across cell membranes of epithelial and endothelial barriers. Aquaporins are also expressed in the skin. AQP3 knockout mice are remarkably polyuric and have dry skin (Verkman, 2002). The microarray data was verified by real-time quantitative RT-PCR, which showed 2-fold increases of aquaporin 3 mRNA (FIG. 2A, p<0.05).
The gastrin gene is related to salt balance since gastrin receptors are expressed in the kidneys on tubules and collecting ducts, where they mediate renal potassium and sodium absorption (von Schrenck et al., 2000). Gastrin has potent growth stimulatory effects on gastrointestinal tissues and human kidney cells (Stepan et al., 1999). Gastrin-releasing peptide may also accelerate wound healing in burns, injuries, chronic ulcers, and skin graft donor sites through enhancement of keratinocyte growth and spreading (Yamaguchi et al., 2002). Since the gastrin message was not previously detected in skin, this gene was amplified herein from several skin cell lines including human keratinocytes, melanocytes, fibroblasts and different melanomas (FIG. 2B). The band of correct length was detected only in normal and immortalized keratinocytes (FIG. 2B); after sequencing, the gene was showed perfectly matched with gastrin. Thus, gastrin is expressed in human keratinocytes and its expression is stimulated by UVR (Table 2).
TABLE 2
|
|
Genes differentially expressed in ultraviolet irradiated human epidermal keratinocytes
UP-REGULATED GENESDOWN-REGULATED GENES
mean ± SDmean ± SD
gene4 h12 h24 hgene4 h12 h24 h
|
Water and salt balance
Gastrin1.17 ± 0.352.06 ± 0.321.46 ± 0.17
Vasopressin precursor1.04 ± 0.491.56 ± 0.011.54 ± 0.01
Aquaporin 11.53 ± 0.241.87 ± 0.374.11 ± 0.42
Aquaporin 31.11 ± 0.101.49 ± 0.092.37 ± 0.19
Aquaporin 91.04 ± 0.281.87 ± 0.422.05 ± 0.07
Prostaglandin metabolism
CYP4F8 (cytochrome P450,1.57 ± 0.022.41 ± 0.323.15 ± 0.72
subfamily IVF, polypeptide 8)
Prostaglandin-endoperoxide1.87 ± 0.253.61 ± 0.401.20 ± 0.16
synlhase 2 (COX-2)
Interleukins and growth factors
Interferon-beta-20.94 ± 0.331.61 ± 0.120.98 ± 0.04Epidermal growth1.31 ± 0.710.50 ± 0.101.00 ± 0.3
(interleukin 6)factor receptor
Interleukin 1, beta2.14 ± 0.072.22 ± 0.480.98 ± 0.10Keratinocyte1.07 ± 0.100.49 ± 0.100.74 ± 0.1
growth factor
Interleukin 21.16 ± 0.251.13 ± 0.072.02 ± 0.10Keratinocyte0.78 ± 0.090.46 ± 0.040.59 ± 0.0
growth factor
Interleukin 82.44 ± 0.281.95 ± 0.121.70 ± 0.20Activin A recept0.58 ± 0.040.49 ± 0.070.99 ± 0.0
type I
1.76 ± 0.082.10 ± 0.101.28 ± 0.22TNFSF10 (TRAI0.51 ± 0.030.65 ± 0.030.73 ± 0.0
TNFSF9
Bone morphogenetic1.16 ± 0.061.67 ± 0.031.10 ± 0.06
protein 3
Insulin-like growth1.78 ± 0.240.98 ± 0.161.78 ± 0.42
factor binding
protein 6
Endothelin 12.30 ± 2.702.78 ± 4.102.10 ± 2.20
Vascular endothelial growth factor1.10 ± 0.092.09 ± 0.081.85 ± 0.49
Metalloproteinases
Stromelysin 1an/d2.02 ± 0.03n/d
Stromelysin 2an/d2.78 ± 0.93n/d
Markers of keratinocyte
differentiation
Filaggrin1.04 ± 0.211.57 ± 0.121.14 ± 0.04Fibronectin 10.96 ± 0.040.62 ± 0.070.41 ± 0.0
Involucrin1.05 ± 0.041.57 ± 0.081.46 ± 0.03
Keratin 11.26 ± 0.181.80 ± 0.171.57 ± 0.04
Keratin 101.18 ± 0.062.09 ± 0.430.98 ± 0.04
Keratin 190.92 ± 0.380.85 ± 0.233.17 ± 0.31
Transglutaminase 11.05 ± 0.151.18 ± 0.222.01 ± 0.23
Loricrin1.29 ± 0.211.54 ± 0.240.51 ± 0.07
Stress-related genes
CRF-R2 gamma1.10 ± 0.081.99 ± 0.451.60 ± 0.07Urotensin 21.10 ± 0.080.81 ± 0.130.62 ± 0.0
Aldo-keto reductase family 1,1.10 ± 0.081.25 ± 0.121.56 ± 0.05
member C2
|
aeffect was seen only when keratinocytes were co-cultivated with melanocytes; n/d—not done; data represents mean +/− SD (N = 4); underlined ratios (UV versus control) are significantly different from 1 (no difference), P < 0.05.
|
EXAMPLE 12
Prostaglandin Synthesis
Up-regulation of several genes involved in prostaglandin metabolism including prostaglandin-endoperoxide synthase 2 (Cyclooxygenase 2 or COX-2 gene) (Table 2, FIG. 2); and, of cytochrome P450, subfamily IVF, polypeptide 8 (CYP4F8) (Table 2) were detected. This was consistent with the increase in prostaglandin E2 in UVR-induced inflammation in the skin (Gresham et al., 1996). Real-time PCR also showed a 6-fold increase of COX-2 message (FIG. 2), which was in fact the highest up-regulation ever detected by quantitative PCR. Stimulation of COX-2 expression by UVR had been previously reported (Brecher, 2002) and when taken together with findings presented here, indicated de novo synthesis of prostaglandins. Therefore, the increases in prostaglandin levels in inflammation would be due to increased prostaglandin production coupled with enhanced arachidonate deacylation from the membrane (Gresham et al., 1996).
Another prostaglandin-related gene CYP4F8 was also up-regulated in UV-irradiated keratinocytes (Table 2). That gene, expressed both in human seminal vesicles and skin, catalyzes the 19-hydroxylation of prostaglandins H(1) and H(2) (Stark et al., 2003). CYP4F8 immunoreactivity and mRNA are prominently induced in psoriasis suggesting a pathophysiological role in skin (Stark et al., 2003).
Prostaglandins function has been investigated on melanocytes and keratinocytes. Prostaglandins can induce melanin synthesis in cutaneous melanocytes. Uveal melanocytes also demonstrate increased tyrosinase activity upon exposure to prostaglandin E1 (Fuller and Meyskens, 1981). Prostaglandin E2 receptor agonist has stimulating effects on growth, melanogenesis and dendrification of iridal melanocytes (Hu et al., 2001). In keratinocytes prostaglandins increase vascular endothelial growth factor (VEGF) expression (Trompezinski et al., 2001), the latter a well-recognized effect of UV radiation (Mildner et al., 1999).
EXAMPLE 13
Interleukins and Growth Factors
Ultraviolet B radiation generates cutaneous inflammation in part, by inducing oxidative stress and cytokine production in human keratinocytes. Expression of the cytokines interleukin (IL)-1, IL-6, IL-10, endothelin 1, VEGFB has already been reported to increase in epidermal keratinocytes upon UV radiation (Kirnbauer et al., 1991; Grewe et al., 1995; Kang et al., 1998; Petit-Frere et al., 1998; Mildner et al., 1999; Brink et al., 2000). An increase of message corresponding to these genes (Table 2) was detected. Additionally, the microarray showed stimulation of IL-2, IL-8, tumor necrosis factor superfamily member 9 (TNFSF9), bone morphogenetic protein 3 (BMP3) and insulin-like growth factor binding protein 6 (IGFBP6) (Table 2).
Decreased expression was noted for the following genes in UV-treated keratinocytes (Table 2): epidermal growth factor receptor (EGFR or erbB), keratinocyte growth factor (KGF or fibroblast growth factor 7), keratinocyte growth factor receptor (KGFR or fibroblast growth factor receptor 2), Activin A receptor type I and tumor necrosis factor superfamily member 10 (TNFSF10 or TRAIL).
The majority of the gene expression changes that were detected herein had been already reported in UV-irradiated skin cells. Therefore, real-time RT-PCR was used only to verify the novel TNFSF9, KGFR and KGF changes in gene expression. TNFSF9 increased 3-fold (FIG. 2A, p<0.05); KGFR gene expression was significantly inhibited in UV-irradiated keratinocytes and to even more significant degree in co-cultures of keratinocytes and melanocytes (FIG. 2A, p<0.05). KGF was also down-regulated (data not shown), but since original expression of this gene was low, it was technically difficult to amplify the amount of message to allow analysis of the data in a statistically meaningful manner.
The functional significance of the differential gene expression could be explained as follows. IL-8 is a neutrophil chemoattractant cytokine with proinflammatory and growth-promoting activities, and is involved in the pathogenesis of several inflammatory diseases. IL-8 is produced in response to ultraviolet B radiation (Countryman et al., 2000). Tumor necrosis factor superfamily member 9 (TNFSF9 or 4-1BBL) is also an important proinflammatory mediator binding CD137 receptors on activated CD4 and CD8 T cells. TNSF9 provides a costimulatory signal that induces a high level of IL-2 production by primary resting T cells (DeBenedette et al., 1999).
Within this context, it would be anticipated that IL-2 expression would increase after UVR, as was indeed found (Table 2). Investigation of infiltrating inflammatory cells and cytokine levels in UV-irradiated skin has shown that interferon-gamma and IL-2, together with the proinflammatory cytokine IL-8, become detectable at 6 h (Terui et al., 2001). In the present invention,-IL-2 was detected 24 h after radiation and most interestingly only after up-regulation of TNFSF9 (4, 12 h; Table 2). This might reflect autocrine stimulation of IL-2 by TNFSF9. The significance of this response is underlined by the effectiveness of interferons and IL-2 in the treatment of skin cancers that include metastatic melanomas (Garbe, 1995).
Stimulation of bone morphogenic protein 3 (BMP-3) and insulin-like growth factor binding protein 6 (IGFBP-6) was detected. Both these proteins inhibit proliferation and differentiation. Treatment of human bone marrow osteoprogenitors with BMP-3 causes dose- and time-dependent inhibition of DNA synthesis and cell proliferation. Simultaneously, BMP3 stimulates type I collagen synthesis (Amedee et al., 1994). IGFBP-6 is a negative effector of oligodendrocyte survival and differentiation (Kuhl et al., 2003), and is secreted by an immortalized human keratinocyte cell line (HaCaT) (Marinaro et al., 1999). Purified IGFBP-6 inhibits the growth of HaCaT and Balb/MK keratinocyte cell lines, as well as Mv1Lu cells (Kato et al., 1995).
EGFR overexpression is important for the expression of malignant behavior, since activation of the receptor stimulates tyrosine kinase activity, which initiates signal transduction cascade (including other kinases) leading to cell proliferation and protection from apoptosis (Lage et al., 2003). Conversely, anti-EGFR agents posses antitumor activity (Lage et al., 2003). Within this context, the known effect of EGF stimulating extracellular receptor-activated kinases (ERK) is prevented by UVR, in a dose-dependent manner. Therefore, the data presented herein on UVR-induced transient (12 hours) inhibition of EGFR expression, suggested that this effect on EGFR was the most likely explanation of the described ERK response inhibition.
Down-regulation of the tumor necrosis factor superfamily member 10 (TNFSF10 or TRAIL), which is a TNF-related apoptosis-inducing ligand was observed. Both up- and down-regulation of TRAIL and its receptors had been reported after exposure to UVB. Since TRAIL and TRAIL receptors function as important sensors in the human epidermis preserving skin integrity and preventing cell transformation, down-regulation of these molecules with sensor function increases the risk for less efficient elimination of aberrant cells. Supporting this concept is the low amount or absence of these molecules in precancerous states developing after long-term ultraviolet exposure (Bachmann et al., 2001).
Keratinocyte growth factor (KGF or fibroblast growth factor 7) is a potent mitogen for human keratinocytes, stimulating proliferation and migration of these cells and also affecting their differentiation process (Werner, 1998). Deletion of the KGF receptor (KGFR) gene results in severe functional defects of the anterior pituitary and also, in developmental abnormalities of the skin (De Moerlooze et al., 2000). IL-6, interferon-gamma, and ultraviolet B (UVB) treatment lead to substantial down-regulation of KGFR expression (Zhou et al., 1996). Down regulation of both KGF and KGFR (Table 2) was detected, confirmed by real-time PCR (FIG. 2A). The UV-induced down-regulation of KGF and KGFR synthesis might therefore represent an antiproliferative mechanism addressed at preventing cells from entering malignant transformation.
EXAMPLE 14
Genes Involved in Extracellular Matrix Rearrangement
Involvement of matrix metalloproteinases (MMPs), the enzymes responsible for extracellular matrix rearrangement, UVR-induced skin aging and promotion of skin cancer (Brenneisen et al., 2002), was also observed. This was represented by a significant stimulation of stromelysins 1 and 2 expression, but only when keratinocytes were co-cultivated with melanocytes (Table 2). Real-time quantitative RT-PCR did confirm this observation (FIG. 2A, p<0.05), suggesting that either keratinocytes express UV-induced metalloproteinases only when they are in contact with melanocytes or, that the matrix metalloproteinases are produced by melanocytes.
EXAMPLE 15
Stress Response Genes
CRH may be the primary mediator of autonomic, behavioral and neuroendocrine responses to stress. While CRH receptors type 1 were previously detected exclusively in human skin cells (Slominski et al., 2004), the CRH receptor type 2 gamma isoform, whose expression is increased in UVR-treated human keratinocytes were included in the present invention.
Aldo-keto reductase, another stress-response related gene, was observed to be up-regulated. Interestingly, the fungi S. cerevisiae that have aldo-keto reductases deleted show enhanced sensitivity to stress (Chang et al., 2003).
The following references were cited herein:
- Amedee, J., et al: Differentiation 58 (1994) 157-64.
- Bachrnann, F., et al: J Invest Dermatol 117 (2001) 59-66.
- Bilban, M., et al: Curr Issues Mol Biol 4 (2002) 57-64.
- Brecher, A. R.: J Drugs Dermatol 1 (2002) 44-7.
- Brenneisen, P., et al: Ann N Y Acad Sci 973 (2002) 31-43.
- Brink, N., et al: Inflamm Res 49 (2000) 290-6.
- Chang, Q., et al: Chem Biol Interact 143-144 (2003) 325-32.
- Countryman, N. B., et al: J Invest Dermatol 115 (2000) 267-72.
- DeBenedette, M. A., et al: J Immunol 163 (1999) 4833-41.
- De Moerlooze, L., et al: Development 127 (2000) 483-92.
- Fuller, B. B. and Meyskens, F. L., Jr.: J Natl Cancer Inst 66 (1981) 799-802.
- Garbe, C.: Recent Results Cancer Res 139 (1995) 349-69.
- Gresham, A., et al: Am J Physiol 270 (1996) C1037-50.
- Grewe, M., et al: J Invest Dermatol 104 (1995) 3-6.
- Hu, D. N., et al: Exp Eye Res 73 (2001) 93-100.
- Ichihashi, M., et al: Toxicology 189 (2003) 21-39.
- Kang, K., et al: J Invest Dermatol 111 (1998) 31-8.
- Kato, M., et al: J Biol Chem 270 (1995) 12373-9.
- Kirnbauer, R, et al: J Invest Dermatol 96 (1991) 484-9.
- Kuhl, N. M., et al: Glia 44 (2003) 91-101.
- Lage, A., et al: Ann Med 35 (2003) 327-36.
- Maeda, T., et al: J Cutan Med Surg 5 (2001) 294-8.
- Marinaro, J. A., et al: Am J Physiol 276 (1999) E536-42.
- Maziere, C., et al: Free Radic Biol Med 34 (2003) 629-36.
- Mildner, M., et al: Photochem Photobiol 70 (1999) 674-9.
- Petit-Frere, C., et al: J Invest Dermatol 111 (1998) 354-9.
- Pisarchik, A. and Slominski, A. T.: Faseb J 15 (2001) 2754-6.
- Slominski, A. and Pawelek, J.: Clin Dermatol 16 (1998) 503-15.
- Slominski, A., et al: Endocrinology 145 (2004) 941-50.
- Slominski, A. and Wortsman, J.: Endocr Rev 21 (2000) 457-87.
- Stark, K., et al: Arch Biochem Biophys 409 (2003) 188-96.
- Stepan, V. M., et al: Am J Physiol 277 (1999) R572-81.
- Terui, T., et al: Acta Derm Venereol 81 (2001) 8-13.
- Trompezinski, S., et al: Inflamm Res 50 (2001) 422-7.
- Verkmnan, A. S.: Ann Med 34 (2002) 192-200.
- von Schrenck, T., et al: Kidney Int 58 (2000) 995-1003.
- Werner, S.: Cytokine Growth Factor Rev 9 (1998) 153-65.
- Yamaguchi, Y., et al: Dermatol Surg 28 (2002) 314-9.
- Zhou, Y., et al: Exp Dermatol 5 (1996) 138-44.
Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.